

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 264 820 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

11.12.2002 Bulletin 2002/50

(51) Int Cl.7: C07C 233/75

(21) Application number: 01912338.9

(86) International application number:
PCT/JP01/01993

(22) Date of filing: 13.03.2001

(87) International publication number:
WO 01/068585 (20.09.2001 Gazette 2001/38)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 14.03.2000 JP 2000070127

05.10.2000 JP 2000305947

(71) Applicant: FUJISAWA PHARMACEUTICAL CO.,
LTD.

Osaka-shi Osaka 541-8514 (JP)

(72) Inventors:

- YAMADA, Akira,
Fujisawa Pharmaceutical Co., Ltd.
Osaka-shi, Osaka 541-8514 (JP)
- TOMISHIMA, Masaki,
Fujisawa Pharmaceutical Co. Ltd
Osaka-shi, Osaka 541-8514 (JP)
- HAYASHIDA, Hisashi,
Fujisawa Pharmaceutical Co. Ltd
Osaka-shi, Osaka 541-8514 (JP)

• IMANISHI, Masashi,

Fujisawa Pharmaceutical Co. Ltd
Osaka-shi, Osaka 541-8514 (JP)

• SPEARS, Glen W.,

Fujisawa Pharmaceutical Co., Ltd.
Osaka-shi, Osaka 541-8514 (JP)• ITO, Kiyotaka, Fujisawa Pharmaceutical Co., Ltd.
Osaka-shi, Osaka 541-8514 (JP)

• TAKAHASHI, Fumie,

Fujisawa Pharmaceutical Co., Ltd
Osaka-shi, Osaka 541-8514 (JP)

• MIYAKE, Hiroshi,

Fujisawa Pharmaceutical Co., Ltd.
Osaka-shi, Osaka 541-8514 (JP)

(74) Representative:

Gille Hrabal Struck Neidlein Prop Roos
Patentanwälte
Brucknerstrasse 20
40593 Düsseldorf (DE)

(54) NOVEL AMIDE COMPOUNDS

(57) A compound of the formula (I):



or



wherein

R¹ is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents,R² is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents, or thienyl which may have suitable substituents,

A is a group of the formula:

in which R³ and R⁴ are each hydrogen or linked together to form imino,R⁵ is hydrogen or lower alkyl,

t is 0, 1 or 2,

p, m and n are each 0 or 1,

X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents,

EP 1 264 820 A1

EP 1 264 820 A1

Y is bond, lower alkylene, or lower alkenylene,
and a salt thereof.

EP 1 264 820 A1

Description

TECHNICAL FIELD

5 [0001] The present invention relates to novel amide compounds and salts thereof. More particularly, it relates to novel amide compounds and salts thereof which have pharmacological activities such as 5-hydroxytryptamine (5-HT) antagonism and the like.

10 [0002] Said compounds or salts thereof are useful as a 5-HT antagonist, especially as a 5-HT_{2c} receptor antagonist, for treating or preventing central nervous system (CNS) disorders such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimer's disease, sleep disorders, bulimia, panic attacks; withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines; schizophrenia; and also disorders associated with spinal trauma and/or head injury such as hydrocephalus, and the like in human beings or animals.

BACKGROUND ART

15 [0003] Some compounds having 5-HT_{2c} receptor antagonism activity have been known as described in the international patent application (International Publication Number WO95/21844, WO95/29177) published based on the Patent Cooperation Treaty, and in JP11-130750A.

DISCLOSURE OF INVENTION

20 [0004] The compounds and salts thereof of the present invention are novel and can be represented by the following general formula (I):




wherein

30 R¹ is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents, R² is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents, or thienyl which may have suitable substituents, A is a group of the formula:



or




in which R³ and R⁴ are each hydrogen or linked together to form imino,

50 R⁵ is hydrogen or lower alkyl,
t is 0, 1 or 2,
p, m and n are each 0 or 1,

55 X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents,
Y is bond, lower alkylene, or lower alkenylene.

[0005] According to the present invention, the object compounds (I) can be prepared by the following processes:

Process 1




(II)

or a salt thereof

(III)

or a salt thereof


amidation



(I)

or a salt thereof

Process 2




(IV)

or a salt thereof

(V)

or a salt thereof


condensation




(Ia)

or a salt thereof


Process 3




Process 4




Process 5



Process 6




Process 7



(1e)

or a salt thereof

hydrogenation



(1f)

or a salt thereof


Process 8



(1g)

or a salt thereof

hydrogenation




(1h)

or a salt thereof

Process 9

5




10

or a salt thereof

hydrogenation

15




or a salt thereof

20

Process 10


25



30


or a salt thereof

35



40

or a salt thereof




45

or a salt thereof

50



55

Process 11



(XIV)


or a salt thereof



(II)


or a salt thereof

Process 12



(II)

or a salt thereof



(Im)

or a salt thereof

wherein

R¹, R², A, X and Y are each as defined above,Y² is lower alkenylene,Y³ is lower alkylene,R⁶ is lower alkyl.

[0006] The object compounds (I) or salts thereof can be prepared, for example, in accordance with the procedures described in the Examples in the present description or similar procedures thereto.

[0007] The material used for the object compounds (I) or salts thereof can be prepared, for example, in accordance

with the procedures described in the Preparations in the present description or similar procedures thereto.

[0008] Suitable salt of the compounds (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), (Il), (Im), (In), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), and (XV) are conventional non-toxic pharmaceutically acceptable salt and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g. sodium salt, potassium salt, cesium salt, etc.), and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt;

a salt with an organic base, for example, an organic amine salt (e.g. triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.);

an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, phosphate, etc.);

an organic carboxylic or sulfonic acid addition salt (e.g. formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, etc.);

a salt with a basic or acidic amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.); and the like.

[0009] In the above and subsequent description of the present specification, suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof are explained in detail as follows.

[0010] The term "lower" is intended to mean 1 to 6 carbon atom(s), preferably 1 to 4 carbon atom(s), unless otherwise indicated.

[0011] Suitable "lower alkyl" may include a straight or branched alkane residue having 1 to 6 carbon atom(s) such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl.

[0012] Suitable "heterocyclic group" may include saturated or unsaturated monocyclic or polycyclic heterocyclic group containing at least one hetero-atom such as an oxygen, sulfur, nitrogen atom and the like, such as

unsaturated 3 to 8-membered (more preferable 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), 3-triazolthionyl, triazinyl etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;

unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indoliziny, benzimidazolyl, tetrahydrobenzimidazolyl, quinoliny, isoquinoliny, tetrahydroisoquinoliny, indazolyl, benzotriazolyl, quinazoliny, quinoxaliny, phthalazinyl, 3H-pyrrolo[1,2-c][1,4]oxadiny, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s), for example; thiophenyl, dihydrodithinyl, etc.;

unsaturated heterocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, thiadiazolyl (e.g. 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.), etc.;

unsaturated condensed heterocyclic group containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, indeno[3,2-d]thiazolyl, etc.;

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholinyl, etc.;

unsaturated condensed heterocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzisoxazolyl, etc.;

unsaturated heterocyclic group containing 1 or 2 oxygen atom(s), for example, chromenyl, etc., and the like.

[0013] Suitable "condensed phenyl" may include fluorenyl, naphthyl, indolyl, carbazolyl, 2,3-cyclopentenindolyl, 2,3-dihydrobenzo[b]oxepiny, 2,3-dihydrobenzo[b]thiepinyl, chromenyl.

[0014] Suitable "bivalent heterocyclic group containing nitrogen" may include a saturated or unsaturated monocyclic or polycyclic heterocyclic group containing at least one hetero-atom as a nitrogen atom, such as

unsaturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyridinylene, pyrimidinylene, etc.;

saturated 3 to 8-membered (more preferably 5 or 6-membered) heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, piperadinylene, etc.;

unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, isoindolinylenes, etc.

[0015] Suitable "lower alkenylene" may include a straight or branched one having 2 to 6 carbon atom(s) such as vinylene, 1-propenylene, isopropenylene, 1-butenylene, 2-butenylene, 1-pentenylene, 1-hexenylene, and the like, in which preferable one having 2 to 4 carbon atoms, and the most preferred one is vinylene or isopropenylene.

[0016] Suitable "lower alkylene" may include a straight or branched one having 1 to 6 carbon atom(s) such as methylene, ethylene, trimethylene, propylene, tetramethylene, pentamethylene, hexamethylene, dimethylmethylenes, and the like, in which preferable one having 1 to 4 carbon atoms, and the most preferred one is methylene.

[0017] Suitable substituent group in the term "heterocyclic group which may have substituents" or "phenyl which may have substituents" may include lower alkyl (can be referred to the ones exemplified above), lower alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy, t-butoxy, pentyloxy, 4-methylpentyloxy, hexyloxy, etc.), halogen (e.g. chloro, bromo, fluoro, iodo), trihalo (lower) alkyl or dihalo (lower) alkyl (lower alkyl moiety and halogen moiety can be referred to the ones exemplified above), heterocyclic group (can be referred to the ones exemplified above), lower alkylamino (e.g. dimethylamino, etc.), lower alkylsulfonfylamino (e.g. methylsulfonfylamino, etc.), lower alkanoyl (e.g. acetyl, propanoyl, etc.), lower alkanoylamino (e.g. acetylamino, etc.) oxid, oxo, thioxo.

[0018] More Suitable substituent groups in the term "heterocyclic group which may have substituents" may include lower alkyl (can be referred to the ones exemplified above, preferably methyl).

[0019] More suitable substituents groups in the term "condensed phenyl which may have substituents" or "phenyl which may have substituents" or "thienyl which may have substituents" in R² may include halogen (can be referred to the ones exemplified above, preferably fluoro or chloro), trihalo (lower) alkyl (can be referred to the ones exemplified above, preferably trifluoromethyl), lower alkoxy (can be referred to the ones exemplified above), lower alkyl (can be referred to the ones exemplified above), cyano, thienyl, halothienyl, phenyl, halophenyl, lower alkylation phenyl (e.g. 1-methyl-1-phenylmethyl, etc.), lower alkansulfonfyl (can be referred to the ones exemplified above).

[0020] Suitable substituents in the term "phenylene which may have substituents" or "bivalent heterocyclic group containing nitrogen which may have suitable substituents" in X may include lower alkyl (can be referred to the ones exemplified above), halogen (can be referred to the ones exemplified above), lower alkoxy (can be referred to the ones exemplified above), trihalo (lower) alkyl (can be referred to the ones exemplified above), heterocyclic group (can be referred to the ones exemplified above), lower alkylsulfonfylamino (can be referred to the ones exemplified above), cyano.


[0021] The embodiment of the compounds (I) will be explained as follows.

[0022] Preferable compounds (I) may be compounds (I) such as


R¹ is imidazolyl, pyridyl, isoquinolynyl, thienyl, phenyl, benzothiazonyl, thiazolyl, pyrazolyl, oxazolyl, chromenyl, benzimidazolyl, indolyl, isoquinolyl, piperazinyl, triazolyl, pyrimidinyl, pyrazinyl, isoxazolyl, triazinyl, pyridazinyl, thiaziazolyl, benzimidazolyl, benzisoxazolyl,

R² is fluorenyl, naphthyl, indolyl, carbazolyl, 2,3-cyclopentenolindolyl, 2,3-dihydrobenzo[b]oxepinyl, 2,3-dihydrobenzo[b]thiepinyl, chromenyl

A is a group of the formula:



or



in which R³ and R⁴ are each hydrogen or linked together to form imino,

R⁵ is hydrogen,

t is 0, 1 or 2,

p, m and n are each 0 or 1,

EP 1 264 820 A1

X is pyridinylene, phenylene, pyrimidinylene, piperazinylene, isoindolynylene, and,
Y is vinylene, 1-propenylene, methylene or ethylene,

and a salt thereof.

5 [0023] More preferable compound such as

R¹ is phenyl, unsaturated heteromonocyclic group containing 1 to 4 nitrogen atom(s) which have 1 to 3 lower alkyl,
R² is phenyl which have trihalo (lower) alkyl, indolyl which have 1 to 3 lower alkyl, calbazolyl,
A is a bond or a group of the formula:

10



15

in which R³ and R⁴ are linked together to form imino,

20

R⁵ is hydrogen,
p is 1, n is 0,

X is phenylene which have 1 to 3 halogen and lower alkoxy,
and
Y is bond or vinylene

25

and a salt thereof.

[0024] The processes 1 to 12 for preparing the object compounds (I) of present invention are explained in detail in the following.

30

Process 1

[0025] The object compound (I) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (III) or a salt thereof, and by subjecting them to amidation reaction.

35

[0026] This reaction is usually carried out in a conventional organic solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, diethyl ether, dioxane, tetrahydrofuran, N,N-dimethylformamide, dimethylacetamide, acetone, acetonitrile, chloroform, methylene chloride, ethylene chloride, ethyl acetate, pyridine, triethylamine, benzene, or a mixture thereof.

40

[0027] The reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal carbonate, alkali metal bicarbonate, tri(lower)alkylamine [e.g. triethylamine, etc.], pyridine, dimethylaminopyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

[0028] The reaction may also be carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-di-ethylaminocyclohexyl)carbodiimide; N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N,N'-carbonylbis-(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; diphenyl phosphorylazide; thionyl chloride; oxalyl chloride; lower alkyl haloformate [e.g. ethyl chloroformate, isopropyl chloroformate, etc.]; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl) isoxazolium hydroxide intramolecular salt; benzotriazol-1-yl-oxy-tris-(dimethylamino) phosphoniumhexafluorophosphate; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, trichloromethyl chloroformate, phosphorus oxychloride, etc.; or the like.

45

50

[0029] The reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating.

[0030] The reaction of this method can be carried out by a conventional manner or the manners of Examples mentioned below.

55

EP 1 264 820 A1

Process 2

[0031] The object compound (Ia) or a salt thereof can be prepared by reacting the compound (IV) or a salt thereof with the compound (V) or a salt thereof, and by subjecting them to condensation reaction.

5 [0032] This reaction is usually carried out in a conventional organic solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, isopropyl alcohol, diethyl ether, dioxane, tetrahydrofuran, N,N-dimethylformamide, acetone, acetonitrile, chloroform, methylene chloride, ethylene chloride, ethyl acetate, pyridine, triethylamine, benzene, or a mixture thereof.

10 [0033] The reaction may also be carried out in the presence of an organic or inorganic acid such as formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, methanesulfonic acid, hydrochloric acid, hydroiodic acid, hydrobromic acid, sulfuric acid, or the like.

[0034] The reaction temperature is not critical and the reaction is usually carried out at ambient temperature or under heating.

15 [0035] The reaction of this method can be carried out by a conventional manner or the manners of Examples mentioned below.

Process 3

20 [0036] The object compound (Ib) or a salt thereof can be prepared by reacting the compound (VI) or a salt thereof with the compound (VII) or a salt thereof, and by subjecting them to condensation reaction.

[0037] The reaction is usually carried out in a conventional organic solvent which does not adversely influence the reaction such as water, methanol, ethanol, propanol, diethyl ether, dioxane, tetrahydrofuran, N,N-dimethylformamide, acetone, acetonitrile, chloroform, methylene chloride, ethylene chloride, ethyl acetate, pyridine, triethylamine, benzene, or a mixture thereof.

25

Process 4

[0038] The object compound (I) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (VIII) or a salt thereof, and by subjecting them to amidation reaction.

30 [0039] This method can be carried out in substantially the same manner as Process 1, and therefore the reaction method and reaction conditions (e.g. solvent, reaction temperature, etc.) are to be referred to those as explained in Process 1.

Process 5

35

[0040] The object compound (Ic) or a salt thereof can be prepared by reacting the compound (VI) or a salt thereof with the compound (IX) or a salt thereof.

[0041] This method can be carried out by a conventional manner or the manner of Example 122 mentioned below.

40

Process 6

[0042] The object compound (Id) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XI) or a salt thereof.

[0043] This method can be carried out by a conventional manner or the manner of Example 92 mentioned below.

45

Process 7

[0044] The object compound (If) or a salt thereof can be prepared by hydrogenating the compound (Ie) or a salt thereof.

50 [0045] This method can be carried out by a conventional manner or the manner of Example 100 mentioned below.

Process 8

55 [0046] The object compound (Ih) or a salt thereof can be prepared by hydrogenating the compound (Ig) or a salt thereof.

[0047] This method can be carried out by a conventional manner or the manner of Example 108 mentioned below.

EP 1 264 820 A1

Process 9

[0048] The object compound (Ij) or a salt thereof can be prepared by hydrogenating the compound (Ii) or a salt thereof.

[0049] This method can be carried out by a conventional manner or the manner of Example 194 mentioned below.

Process 10

[0050] The object compound (Ik) or a salt thereof can be prepared by reacting the compound (XII) or a salt thereof with the compound (XIII) or a salt thereof.

[0051] This method can be carried out by a conventional manner or the manner of Example 99 mentioned below.

Process 11

[0052] The object compound (II) or a salt thereof can be prepared by reacting the compound (XIV) or a salt thereof with the compound (XV) or a salt thereof.

[0053] This method can be carried out by a conventional manner or the manner of Example 209 mentioned below.

Process 12

[0054] The object compound (Im) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the sodium nitrite.

[0055] This method can be carried out by a conventional manner or the manner of Example 210 mentioned below.

[0056] The reaction may also be carried out in the presence of inorganic or organic acid such as formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, methanesulfonic acid, hydrochloric acid, hydroiodic acid, hydrobromic acid, sulfuric acid, or the like.

[0057] The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature or under heating.

[0058] The reaction of this method can be carried out by a conventional manner or the manners of Examples mentioned below.

[0059] The object compound (I) of the present invention can be isolated and purified in a conventional manner, for example, extraction, precipitation, fractional crystallization, recrystallization, column chromatography, and the like.

[0060] The object compound (I) thus obtained can be converted to its salt by a conventional method.

[0061] The object compound (I) and a salt thereof may include a solvate [e.g., enclosure compound (e.g., hydrate, etc.)].

[0062] The object compound (I) of the present invention exhibit pharmacological activities such as 5-HT antagonism, especially, 5-HT_{2c} antagonism, and the like and therefore are useful as 5-HT antagonist for treating or preventing central nervous system (CNS) disorders such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimer's disease, sleep disorders, bulimia, panic attacks; withdrawal from drug abuse such as cocaine, ethanol, nicotine, and benzodiazepines; schizophrenia; and also disorders associated with spinal trauma and/or head injury such as hydrocephalus, and the like.

[0063] In order to illustrate the usefulness of the object compounds (I) of the present invention, pharmacological activity of the representative compounds of the present invention are shown below.

Test Method

[³H]-mesulergine binding

[0064] The affinity of test drugs for the 5-HT_{2c} binding site can be determined by assessing their ability to displace [³H]-mesulergine in the rat prefrontal cortex. The method employed was similar to that of Pazos et al, 1984.

[0065] The membrane suspension (500 μ l) was incubated with [³H]-mesulergine (1 nM) in Tris hydrochloric acid buffer solution (pH 7.4) containing calcium chloride 4mM and ascorbic acid 0.1% at 37°C for 30 minutes. Non-specific binding was measured in the presence of mianserin (1 μ M). 30nM spiperone was used to prevent binding to 5-HT_{2A} sites. Test drugs (10⁻⁶M) were added in a volume of 100 μ l. The total assay volume was 1000 μ l. Incubation was stopped by rapid filtration using a Brandel cell harvester and radioactivity measured by scintillation counting.

Test compound

(a) (3E)-N-[3-(imidazol-1-yl)phenyl]-4-phenyl-3-butenamide

5 Test Result

[0066] An examination result is shown in Table 1.

Table 1

Compound	Inhibition (%)
(a)	82

[0067] For therapeutic or preventive administration, the compound (I) of the present invention and a salt thereof can be used in the form of the conventional pharmaceutical preparation which contains said compounds as an active ingredient, in admixture with a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral and external administration. The pharmaceutical preparations may be in solid form such as tablet, granule, powder, capsule, or liquid form such as solution, suspension, syrup, emulsion, lemonade, and the like.

[0068] If needed, there may be included in the above preparation auxiliary substances, stabilizing agents, wetting agents and other commonly used additives such as lactose, citric acid, tartaric acid, stearic acid, magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter, ethylene glycol, and the like.

[0069] While the dosage of the compound (I) may vary from and also depend upon the age and conditions of the patient, a kind of diseases, a kind of the compounds (I) to be applied, etc. In general amounts between 0.01mg and about 500mg per day may be administered to a patient. An average single dose of about 0.05mg, 0.1mg, 0.25mg, 0.5mg, 1mg, 20mg, 50mg, 100mg of the object compound (I) of the present invention may be used in treating diseases.

[0070] The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.

30 Preparation 1

[0071] A mixture of 3-nitroaniline, phenylacetic acid, 4-dimethylaminopyridine, 1-[3-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and dichloromethane was stirred overnight at room temperature. Diluted with ethyl acetate, washed in turn with brine, diluted hydrochloric acid (three times), water, diluted aqueous solution of sodium hydroxide (three times), and brine, and dried over magnesium sulfate, filtered, and evaporated. Recrystallized from ethyl acetate to give N-(3-nitrophenyl) phenylacetamide.

mp:133-134°C

IR(KBr):3242,1657cm⁻¹

MS:257(M+1)

NMR(DMSO, δ):3.70(2H,s), 7.20-7.38(5H,m), 7.60(1H,dd,J=8.2Hz,8.2Hz), 7.88-7.95 (2H,m), 8.63(1H,dd, J=2.1Hz,2.1Hz), 10.66(1H,br s)

45 Preparation 2

[0072] A mixture of N-(3-nitrophenyl)phenylacetamide, iron powder, ammonium chloride, ethanol, and water was heated at reflux for 1 hour. After cooling to ambient temperature, filtered through Celite, washed with methanol and evaporated. Dissolved into dichloromethane and diluted aqueous solution of sodium hydroxide. Separated, and extracted with dichloromethane (twice). Combined organic layers were dried with magnesium sulfate, evaporated, then purified by silica gel column chromatography (dichloromethane/methanol/ammonia) and then recrystallized with methanol to give N-(3-aminophenyl)phenylacetamide.

mp:141-142°C

IR(KBr):1678cm⁻¹

MS:227(M+1)

NMR(DMSO, δ):3.58(2H,s), 5.03(2H,s), 6.23(1H,d,J=7.8Hz), 6.68(1H,d,J=7.7Hz), 6.80-6.96(2H,m), 7.18-7.42 (5H,m), 9.82(1H,s)

Elemental analysis:

EP 1 264 820 A1

Calculated+(H₂O)_{1/5}:C;73,15,H;6.31,N;12.19
Found:C;73.37,H;6.17,N;12.26

Preparation 3

[0073] This was prepared in a manner similar to Preparation 1 to give N-(3-nitrophenyl) cinnamamide from 3-nitroaniline and cinnamic acid.

mp:162-164°C

IR(KBr):3354,1687,1627,1550cm⁻¹

MS:269(M+1)

NMR(DMSO, δ):6.82(1H,d,J=15.8Hz), 7.40-7.58(3H,m), 7.60-7.71(4H,m), 7.91-8.03 (2H,m), 8.76(1H,dd, J=2.1Hz,2.1Hz), 10.72(1H,br s)

Preparation 4

[0074] This was prepared in a manner similar to Preparation 2 to give N-(3-aminophenyl)cinnamamide.

MS:239(M+1)

NMR(DMSO, δ):5.09(2H,br s), 6.28(1H,d,J=7Hz), 6.77-7.04(4H,m), 7.35-7.68(6H,m), 9.87(1H,s)

Preparation 5

[0075] A mixture of 1-fluoro-3-iodo-5-nitrobenzene (2.45g), 1,2-dimethylimidazole (1.77g), potassium carbonate (2.54g), palladium (II) acetate (103mg), and N,N-dimethylformamide (60ml) were stirred at 140°C for 14 hours. After cooling, the reaction mixture was poured into water (100ml) and extracted with ethyl acetate (twice, 100ml each time). The combined extracts were washed with water (twice, 200ml each time) and brine (100ml). The separated organic layer was dried over magnesium sulfate, decolorized (activated carbon), and filtered. The solvent was evaporated to give a residue which was purified by silica gel chromatography (dichloromethane-methyl alcohol) to give 5-(3-fluoro-5-nitrophenyl)-1, 2-dimethyl-1H-imidazole (1.01g) as yellow crystals.

MS:236(M+1)

NMR(DMSO, δ):2.37(3H,s), 3.62(3H,s), 7.17(1H,s), 7.8-7.9(1H,m), 8.0-8.2(2H,m)

Preparation 6

[0076] To a solution of 5-(3-fluoro-5-nitrophenyl)-1,2-dimethyl-1H-imidazole (400mg) in methyl alcohol (5ml) was added sodium methoxide (28% solution in methanol (1.64g)). The mixture was heated at reflux for 44 hours. After cooling, the reaction mixture was poured into water (30ml) and extracted with ethyl acetate (30ml) and dichloromethane (30ml). The separated organic layer was evaporated to give a residue which was purified by silica gel chromatography (dichloromethane-methyl alcohol) to give 3-(1,2-dimethyl-1H-imidazol-5-yl)-5-nitrophenyl methyl ether (220mg) as yellow crystals.

MS:248(M+1)

NMR(DMSO, δ):2.37(3H,s), 3.59(3H,s), 3.93(3H,s), 7.08(1H,s), 7.4-7.5(1H,m), 7.6-7.7(1H,m), 7.7-7.9(1H,m)

Preparation 7

[0077] To a mixture of 3-(1,2-dimethyl-1H-imidazol-5-yl)-5-nitrophenyl methyl ether (208mg), activated carbon (312mg), and tetrahydrofuran (3.1ml) were added iron (II) chloride hexahydrate (21mg) and hydrazine monohydrate (0.31ml). The mixture was heated at 80°C for 1 hour. After cooling, the reaction mixture was evaporated. The resultant residue was diluted with ethyl acetate (40ml) and washed with water (twice, 30ml each time) and brine (20ml). The separated organic layer was dried over magnesium sulfate and filtered. The solvent was evaporated to give 3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyaniline (186mg) as crystals.

MS:218(M+1)

NMR(DMSO, δ):2.32(3H,s), 3.49(3H,s), 3.68(3H,s), 5.20(2H,br s), 6.0-6.3(3H,m), 6.74(1H,s)

EP 1 264 820 A1

Preparation 8

[0078] Trifluoroacetic acid (8.0g) was added to 2-bromo-6-chloro-4-nitroaniline (10.0g) in N,N-dimethylformamide (80ml), followed by sodium nitrite (2.88g) in water (5ml) and the pale brown suspension was stirred at ambient temperature for 1 hour. To the mixture was added triethylamine (12.1g) and the deep red effervescing mixture was stirred for a further 1 hour before being partitioned between ethyl acetate (400ml) and water (300ml). The separated organic layer was washed with 1N-hydrochloric acid (twice, 200ml each time), water (200ml), and saturated brine (100ml), and then dried over magnesium sulfate and filtered. The solvent was evaporated to give a crude which was purified by silica gel chromatography, and eluted with ethyl acetate-hexane to give 3-bromo-5-chloronitrobenzene (2.5g) as pale yellow crystals.

NMR(DMSO, δ): 8.29(1H, dd, J=1.8Hz, 1.8Hz), 8.32(1H, dd, J=2.0Hz, 1.9Hz), 8.38(1H, dd, J=1.9Hz, 1.8Hz)

Preparation 9

[0079] Palladium(II) acetate (119mg) was added to a mixture of 3-bromo-5-chloronitrobenzene (2.5g), 1,2-dimethylimidazole (2.03g) and potassium carbonate (2.92g) in N,N-dimethylformamide (50ml) at ambient temperature, and the brownish suspension was stirred at 140°C for 3 hours. After cooled to room temperature, the reaction mixture was partitioned between water (200ml) and ethyl acetate (twice, 100ml each time). The combined organic layers were washed with water (twice, 100ml each time) and saturated brine (100ml), and then dried over magnesium sulfate and filtered. Evaporation gave a residue which was triturated with ethyl acetate-hexane to give 5-(3-chloro-5-nitrophenyl)-1,2-dimethyl-1H-imidazole (1.53g) as yellow crystals.

MS:252(M+1)

NMR(DMSO, δ): 2.37(3H, s), 3.61(3H, s), 7.17(1H, s), 8.00(1H, dd, J=1.7Hz, 1.7Hz), 8.17(1H, dd, J=1.9Hz, 1.7Hz), 8.22(1H, dd, J=2.0Hz, 2.0Hz)

Preparation 10

[0080] To a solution of 5-(3-chloro-5-nitrophenyl)-1,2-dimethyl-1H-imidazole (13.6g) in a mixture of ethanol (272ml) and water (136ml) were added ammonium chloride (1.45g), Celite (27g), and iron powder (9.05g) with stirring at 70°C. The stirring was continued at reflux for 2 hours. The reaction mixture was cooled, diluted with ethyl acetate (500ml), filtered through Celite and evaporated. The resultant residue was dissolved in 1N-hydrochloric acid (200ml), washed with dichloromethane (3 times, 100ml each time), alkalized with 1N-sodium hydroxide and extracted with dichloromethane (3 times, 100ml each time). The combined organic layers were dried over magnesium sulfate and filtered. Evaporation gave a residue which was triturated with ethyl acetate-ether to give 3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)aniline (4.8g) as pale yellow crystals..

MS:222(M+1)

NMR(DMSO, δ): 2.32(3H, s), 3.50(3H, s), 5.53(2H, br s), 6.5-6.6(3H, m), 6.81(1H, s)

Preparation 11

[0081] To a mixture of 3-nitrobenzaldehyde (302mg), 4-amino-2-chloropyridine (308mg), and N,N-dimethylformamide (10ml) was added dropwise titanium (IV) isopropoxide (852mg) at ambient temperature with stirring. After stirring for 27 hours, the reaction mixture was added sodium triacetoxyborohydride (2.12g) and the stirring was continued for 7 days. The reaction mixture was diluted with ethyl acetate (20ml), cooled with 1N-sodium hydroxide (2.1ml), and stirred for 30 minutes. The resultant precipitate was filtered off and the filtrate was washed with water (3 times, 20ml each time). The separated organic layer was dried over magnesium sulfate and filtered. The solvent was evaporated to give a residue which was triturated with ethyl acetate-hexane to give N-(3-nitrobenzyl)-N-(2-chloro-4-pyridyl)amine (383mg) as crystals.

MS:264(M+1)

NMR(DMSO, δ): 4.52(2H, d, J=6.2Hz), 6.4-6.7(2H, m), 7.5-7.9(4H, m), 8.1-8.3(2H, m)

Preparation 12

[0082] To a mixture of N-(3-nitrobenzyl)-N-(2-chloro-4-pyridyl)amine (264mg), ammonium chloride (27mg), ethyl al-

EP 1 264 820 A1

cohol (5ml), tetrahydrofuran (2.5ml), and water (2.5ml) were added Celite (270mg) and iron powder (168mg) with stirring at 70°C.

[0083] The stirring was continued at reflux for 2 hours. The reaction mixture was cooled, diluted with ethyl acetate (20ml), and filtered through Celite. The filtrate was washed with water (twice, 30ml each time) and brine (20ml). The separated organic layer was dried over magnesium sulfate and filtered. The solvent was evaporated to give N-(3-aminobenzyl)-N-(2-chloro-4-pyridyl)amine (250mg).

MS:234(M+1)

NMR(DMSO, δ): 4.16(2H,d,J=5.8Hz), 5.06(2H,br s), 6.3-6.6(5H,m), 6.97(1H,t, J=7.6Hz), 7.39(1H,t,J=5.8Hz), 7.79(1H,d,J=5.8Hz)

Preparation 13

[0084] To a suspension of 5-fluoro-2-methoxybenzenecarbothioamide (4.04g) in acetone (22ml) was added methyl iodide (2.71ml) at room temperature. Stirred overnight. Next day added isopropyl ether(22 ml), collected, and washed with isopropyl ether (3 times, 5ml each time) to give methyl-5-fluoro-2-methoxybenzenecarbimidothioate hydroiodide (6.62g) as rusty orange crystals.

mp:122-123°C

MS:200(free+1)

NMR(DMSO, δ): 2.70(3H,s), 3.37(2H,br s), 3.86(3H,s), 7.29(1H,dd,J=9.2Hz,4.3Hz), 7.43-7.53(2H,m)

Preparation 14

[0085] To N-[3-[(tert-butoxycarbonyl)amino]phenyl]-2-methoxycinnamide (0.75g) was added 4N hydrochloric acid (10ml) in ethyl acetate. After one hour at room temperature was added ethyl acetate (100ml) and 1N sodium hydroxide (50ml). The separated organic layer was washed with diluted aqueous sodium hydroxide (twice), brine, dried over magnesium sulfate, filtered, evaporated, and recrystallized from ethyl acetate/diethyl ether to give N-(3-aminophenyl)-2-methoxycinnamide (339mg) as yellow crystals.

mp:137-139°C

MS:269(M+1)

NMR(DMSO, δ): 3.88(3H,s), 5.08(2H,s), 6.27(1H,d,J=8.1Hz), 6.75-7.14(6H,m), 7.39 (1H,dd,J=7.1Hz,7.1Hz), 7.55 (1H,d,J=7.6Hz), 7.76(1H,d,J=15.8Hz), 9.84(1H,s)

Preparation 15

[0086] A mixture of N-(3-cyanophenyl)-2-chlorocinnamide (10.19g), thioacetamide (13.5g), dioxane (18ml), and 4N HCl (18ml) in dioxane was heated at 100°C for 30 minutes. Cooled, poured into ice/water (400ml), allowed to stand for 30 minutes. Collected by filtration, washed with water. Slurried in dichloromethane (500ml) and collected, and then slurried in methanol (10ml), collected, and washed with methanol (twice, 5ml each time) to give N-[3-(aminocarbothioyl)phenyl]-2-chlorocinnamide (8.13g) as light brown crystals.

mp:195-197°C

MS:339(M+Na)

NMR(DMSO, δ): 6.91(1H,d,J=15.6Hz), 7.35-7.60(5H,m), 7.73-7.95(3H,m), 8.19 (1H,s), 9.52(1H,s), 9.90(1H,s), 10.50(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.4}:C;59.31,H;4.29,N;8.65

Found:C;59.37,H;4.14,N;8.66

Preparation 16

[0087] To a suspension of tert-butyl 3-aminophenylcarbamate (416mg), 2-chlorocinnamic acid (365mg), 4-dimethylaminopyridine (12mg) and dichloromethane (5ml) was added at room temperature 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (575mg). Stirred for 2 days. Diluted with ethyl acetate (50ml), washed with 0.1N hydrochloric acid (3 times, 25ml each time), water, saturated aqueous sodium hydrogen carbonate (3 times, 25ml each time), brine, dried over magnesium sulfate, filtered, and evaporated to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]-

EP 1 264 820 A1

2-chlorocinnamamide (0.77g) as a white foam.

MS:317(M-C₄H₈+1)

NMR(DMSO, δ): 1.48(9H,s), 6.91(1H,d,J=15.6Hz), 7.07(1H,d,J=7.7Hz), 7.19(1H,dd, J=8.1Hz,8.1Hz), 7.40-7.65(4H,m), 7.71-7.77(1H,m), 7.85(1H,d,J=15.6Hz), 7.86-7.89 (1H,m), 9.40(1H,s), 10.27(1H,s).

Preparation 17

[0088] This was prepared in a manner similar to Preparation 14 to give N-(5-amino-2-fluorophenyl)-2-chlorocinnamamide.

mp:184-185°C

MS:291(M+1)

NMR(DMSO, δ): 5.00(2H,s), 6.24-6.34(1H,m), 6.91(1H,dd,J=11.0Hz,8.7Hz), 7.12(1H, d,J=15.6Hz)7.30-7.40(1H,m), 7.41-7.50(2H,m), 7.52-7.59(1H,m), 7.72-7.79(1H,m), 7.85(1H,d,J=15.7Hz), 9.76(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.2}:C;61.21,H;4.25,N;9.52

Found:C;61.13,H;3.99,N;9.38

Preparation 18

[0089] This was prepared in a manner similar to Preparation 16 to give N-[5-[(tert-butoxycarbonyl)amino]-2-fluorophenyl]-2-chlorocinnamamide.

mp:203-205°C

MS:335(M-C₄H₈+1), 291(M-BOC+1)

NMR(DMSO, δ): 1.48(9H,s), 7.04-7.21(3H,m), 7.40-7.49(2H,m), 7.53-7.60(1H,m), 7.73-7.80(1H,m), 7.88(1H,d, J=15.7Hz) 8.25(1H,d,J=7.7Hz), 9.41(1H,s), 9.99(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.2}:C;60.90,H;5.21,N;7.10

Found:C;60.87,H;5.01,N;6.98

Preparation 19

[0090] This was prepared in a manner similar to Preparation 4 to give tert-butyl 3-amino-4-fluorophenylcarbamate.

MS:127(M-BOC+1)

NMR(DMSO, δ): 1.45(9H,s), 5.00(2H,s), 6.60-7.20(3H,m), 9.01(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.5}:C;56.16,H;6.85,N;11.91

Found:C;56.29,H;6.52,N;11.83

Preparation 20

[0091] This was prepared in a manner similar to Preparation 4 to give 4-(1,3-thiazol-4-yl)aniline.

mp:93-95°C

MS:177(M+1)

NMR(DMSO, δ): 5.28(2H,br s), 6.56-6.64(2H,m), 7.62-7.68(2H,m), 7.73(1H,d,J =1.9Hz), 9.08(1H,d,J=1.9Hz)

Elemental analysis:

Calculated:C;61.34,H;4.58,N;15.89

Found:C;61.29,H;4.53,N;15.89

Preparation 21

[0092] A mixture of phosphorus pentasulfide (6.66g), dioxane (75ml), and N,N-dimethylformamide (30ml) was heated at gentle reflux for one hour under nitrogen atmosphere. Cooled and decanted from the yellow foam. One third of this solution was then added to 2-bromo-1-(4-nitrophenyl) ethanone (1.22g) and the resulting solution was heated at reflux

EP 1 264 820 A1

for one hour. Cooled to room temperature, added water (300ml), neutralized to basic with magnesium carbonate (5g). After one hour collected by filtration, washed with water (3 times) to give 4-(4-nitrophenyl)-1,3-thiazole (1.03g) as a brown solid.

5 MS:207(M+1)
NMR(DMSO, δ): 8.23-8.36(4H,m), 8.54(1H,d,J=1.8Hz), 9.29(1H,d,J=1.8Hz)

Preparation 22

10 **[0093]** This was prepared in a manner similar to Preparation 4 to give 4-(1,3-oxazol-5-yl)aniline.

MS:161(M+1)
NMR(DMSO, δ): 5.45(2H,br s), 6.58-6.66(2H,m), 7.30(1H,s), 7.34-7.39(2H,m), 8.25 (1H,s)
Elemental analysis:
15 Calculated+(H₂O)_{0.25}: C;65.64,H;5.20,N;17.01
Found: C;65.53,H;4.97,N;16.85

Preparation 23

20 **[0094]** This was prepared in a manner similar to Preparation 4 to give 4-(1H-pyrazol-1-yl)aniline.

MS:160(M+1)
NMR(DMSO, δ): 5.20(2H,s), 6.42(1H,dd,J=2.0Hz,2.0Hz), 6.58-6.67(2H,m), 7.37-7.46 (2H,m), 7.60(1H,d,
J=1.5Hz), 8.18(1H,d,J=2.4Hz)

25

Preparation 24

[0095] A mixture of pyrazole (0.82g), 4-fluoro-1-nitrobenzene (1.41g), potassium carbonate (1.66g) and N,N-dimethylformamide (20ml) was heated at 110°C for 4 hours. Cooled, poured into water (100ml). After one hour collected by
30 filtration, washed with water to give 1-(4-nitrophenyl)-1H-pyrazole (2.68g) as pale yellow crystals.

MS:190(M+1)
NMR(DMSO, δ): 6.67(1H,dd,J=2.6Hz,1.8Hz), 7.89(1H,d,J=1.6Hz), 8.08-8.18(2H,m), 8.32-8.42(2H,m), 8.74(1H,d,
J=2.6Hz)

35

Preparation 25

[0096] A solution of di-tert-butyl dicarbonate(7.86g), 4-fluoro-3-nitroaniline(4.68g), and tetrahydrofuran (60ml) was heated at reflux for three days. Evaporated. Purified by silica gel column chromatography (hexane/ethyl acetate) to
40 give tert-butyl 4-fluoro-3-nitrophenylcarbamate (9.08g) as orange crystals.

MS:157(M-BOC+1)
NMR(CDCl₃, δ): 1.53(9H,s), 6.62(1H,br s), 7.21(1H,dd,J=9.0Hz,9.0Hz), 7.61(1H,ddd,J=9.0Hz,3.1Hz,3.1Hz), 8.14
(1H,dd,J=6.4Hz,2.8Hz)

45

Preparation 26

[0097] A mixture of 2-(4-nitrophenyl)-2-oxoethylformamide (0.64g), toluene (10ml) and phosphorus oxychloride (2ml) was heated at reflux for one hour. Cooled and carefully added to ice/water (100ml), added dichloromethane (200ml),
50 then neutralized with potassium carbonate. Separated, extracted with dichloromethane (twice). Combined organic layers were dried over magnesium sulfate, filtered, and evaporated. Purified by silica gel column chromatography, eluted with dichloromethane-methanol to give 5-(4-nitrophenyl)-1,3-oxazole (0.50g) as brown crystals.

MS:191(M+1)
55 NMR(DMSO, δ): 8.01(2H,d,J=9.0Hz), 8.03(1H,s), 8.34(2H,d,J=9.0Hz), 8.62(1H,s)

EP 1 264 820 A1

Preparation 27

5 **[0098]** To a suspension of formyl[2-(4-nitrophenyl)-2-oxoethyl]formamide (0.80g) in methanol (15ml) was added one drop of triethylamine. Stirred for one hour at room temperature. Evaporated and recrystallized from ethyl acetate to give 2-(4-nitrophenyl)-2-oxoethylformamide (0.66g) as brown crystals.

MS:209(M+1)

NMR(CDCl₃, δ): 4.86(2H,dd,J=4.6Hz,0.8Hz), 6.62(1H,br s), 8.11-8.20(2H,m), 8.33-8.41(3H,m)

10 Preparation 28

[0099] To a solution of 2-bromo-1-(4-nitrophenyl)ethanone (2.44g) in N,N-dimethylformamide (10ml) was added at room temperature diformylimide sodium salt (0.95g). Stirred 1 hour. Poured into water (100 ml), added ethyl acetate (100ml), separated, washed with water (twice), brine, dried over magnesium sulfate, filtered, and evaporated. Recrys-
15 tallized from ethyl acetate (5ml) to give formyl[2-(4-nitrophenyl)-2-oxoethyl]formamide (0.83g) as tan crystals.

MS:237(M+1)

NMR(CDCl₃, δ): 5.12(2H,s), 8.14(2H,d,J=8.9Hz), 8.38(2H,d,J=8.9Hz), 9.05(2H,s)

20 Preparation 29

[0100] This was prepared in a manner similar to Preparation 4 to give 4-(1-methyl-1H-imidazol-4-yl)aniline.

mp:168-179°C

25 MS:174(M+1)

NMR(DMSO, δ): 3.63(3H,s), 4.98(2H,br s), 6.52(2H,d,J=8.4Hz), 7.26(1H,d,J=1.2Hz), 7.38(2H,d,J=8.4Hz), 7.49 (1H,d,J=1.2Hz)

Elemental analysis:

Calculated+(H₂O)_{0.15}: C;68.28,H;6.47,N;23.89

30 Found: C;68.24,H;6.35,N;24.02

Preparation 30

[0101] To a solution of 4-(4-nitrophenyl)-1H-imidazole (2.34g) in N,N-dimethylformamide (25ml) was added potas-
35 sium carbonate (1.71g) and then methyl iodide (1.56ml). Stirred at room temperature for 4 hours. Poured into water/ice (300ml). After 30 minutes collected by filtration, washed with water, and air dried to give 1-methyl-4-(4-nitrophenyl)-1H-imidazole as brown crystals.

mp:185-187°C

40 MS:204(M+1)

NMR(DMSO, δ): 3.72(3H,s), 7.76(1H,d,J=1.1Hz), 7.92(1H,d,J=1.1Hz), 7.95-7.99(2H,m), 8.19-8.25(2H,m)

Elemental analysis:

Calculated+(H₂O)_{0.25}: C;57.83,H;4.61,N;20.23

45 Found: C;57.83,H;4.34,N;20.26

Preparation 31

[0102] A solution of 2-bromo-1-(4-nitrophenyl)ethanone (4.88g) and formamide (20ml) was placed in a 190°C oil bath for one hour. Cooled, poured into water/ice (200ml), added 3N hydrochloric acid (20ml). After 30 minutes, filterd
50 off the insolubles. To the clear orange filtrate was added enough sodium hydroxide to make strongly basic (about 3.0g). After 30 minutes, collected by filtration, washed with water; dried at 60°C under reduced pressure to give 4-(4-nitroph-
enyl)-1H-imidazole (2.34g) as a brown solid.

MS:190(M+1)

55 NMR(DMSO, δ): 7.83(1H,s), 7.95(1H,s), 8.03(2H,d,J=8.9Hz), 8.22(2H,d,J=8.9Hz), 12.47(1H,br s)

EP 1 264 820 A1

Preparation 32

[0103] This was prepared in a manner similar to Preparation 13 to give 5-chloro-2-methoxybenzenecarbimidothioate hydroiodide.

mp:162-163°C

MS:216(free+1)

NMR(DMSO, δ):2.73(3H,s), 3.38(2H,br s), 3.88(3H,s), 7.32(1H,d,J=9.0Hz), 7.63(1H, d,J=2.6Hz), 7.72(1H,dd, J=9.0Hz,2.7Hz)

Elemental analysis:

Calculated+(EtOAc)_{0.1}:C;32.03,H;3.37,N;3.97

Found:C;31.96,H;3.17,N;4.30

Preparation 33

[0104] This was prepared in a manner similar to Preparation 13 to give methyl 3-(2-chlorocinnamoylamino)benzene-carbimidothioate hydroiodide.

mp:208-210°C

MS:331(free+1)

NMR(DMSO, δ):2.81(3H,s), 3.44(2H,s), 6.90(1H,d,J=15.6Hz), 7.41-7.69(5H,m), 7.76-7.83(1H,m), 7.86-7.99(2H, m), 8.41(1H,s), 10.72(1H,s)

Elemental analysis:

Calculated:C;44.51,H;3.51,N;6.11

Found:C;44.88,H;3.50,N;6.11

Preparation 34

[0105] This was prepared in a manner similar to Preparation 15 to give 5-chloro-2-methoxybenzenecarbothioamide.

mp:145-146°C

MS:202(M+1)

NMR(DMSO, δ):3.81(3H,s), 7.09(1H,d,J=8.9Hz), 7.42(1H,dd,J=8.9Hz,2.8Hz), 7.60 (1H,d,J=2.8Hz), 9.42(1H,s), 10.09(1H,s)

Elemental analysis:

Calculated:C;47.65,H;4.00,N;6.95

Found:C;47.48,H;3.87,N;6.80

Preparation 35

[0106] This was prepared in a manner similar to Preparation 16 to give N-(3-amino-5-chlorophenyl)-2-trifluoromethylcinnamamide.

mp:167-170°C

MS:341(M+1)

NMR(DMSO, δ):5.49(2H,s), 6.33(1H,dd,J=1.9Hz,1.9Hz), 6.80-6.94(2H,m), 6.99(1H, dd,J=1.8Hz,1.8Hz), 7.55-7.95(5H,m), 10.19(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.5}:C;54.95,H;3.75,N;8.01

Found:C;55.04,H;3.63,N;7.63

Preparation 36

[0107] This was prepared in a manner similar to Preparation 65 to give 5-chloro-2-methoxybenzamide.

mp:137-139°C

MS:186(M+1)

NMR(DMSO, δ):3.88(3H,s), 7.17(1H,d,J=8.9Hz), 7.52(1H,dd,J=8.9Hz,2.8Hz)7.68 (2H,br s), 7.72(1H,d,J=2.8Hz).

EP 1 264 820 A1

Preparation 37

[0108] This was prepared in a manner similar to Preparation 66 to give methyl 5-chloro-2-methoxybenzoate.

5 MS:201(M+1)
NMR(DMSO, δ): 3.79(3H,s), 3.82(3H,s), 7.19(1H,d,J=8.8Hz), 7.55-7.65(2H,m)

Preparation 38

10 [0109] This was prepared in a manner similar to Preparation 16 to give N-(3-amino-5-(trifluoromethyl)phenyl)-2-chlorocinnamamide.

mp:177-179°C

MS:341(M+1)

15 NMR(DMSO, δ): 5.66(2H,s), 6.58(1H,s), 6.86(1H,d,J=15.6Hz), 7.13(1H,s), 7.25(1H,s), 7.42-7.60(3H,m), 7.74-7.80(1H,m), 7.78(1H,d,J=15.6Hz), 10.30(1H,s)

Elemental analysis:

Calculated: C;56.40, H;3.55, N;8.22

Found: C;56.36, H;3.65, N;8.08

20

Preparation 39

[0110] This was prepared in a manner similar to Preparation 16 to give N-(3-amino-5-cyanophenyl)-2-trifluoromethylcinnamamide.

25

mp:191-193°C

MS:332(M+1)

NMR(DMSO, δ): 5.73(2H,s), 6.62(1H,dd,J=1.6Hz,1.6Hz), 6.86(1H,d,J=15.4Hz), 7.16(1H,d,J=1.6Hz,1.6Hz), 7.27(1H,dd,J=1.6Hz,1.6Hz), 7.60-8.00(5H,m), 10.36(1H,s)

30

Preparation 40

[0111] This was prepared in a manner similar to Preparation 14 to give N-(3-aminophenyl)- α -methylcinnamamide.

35 mp:140-142°C

MS:253(M+1)

NMR(DMSO, δ): 2.08(3H,d,J=1.3Hz), 5.04(2H,s), 6.28(1H,dd,J=8.2Hz,1.2Hz), 6.80(1H,dd,J=8.1Hz,1.2Hz), 6.93(1H,dd,J=7.8Hz,7.8Hz), 7.03(1H,dd,J=1.2Hz,1.2), 7.23(1H,q,J=1.3Hz), 7.32-7.47(5H,m), 9.62(1H,s)

Elemental analysis:

40 Calculated: C;76.17, H;6.39, N;11.10

Found: C;76.08, H;6.39, N;11.14

Preparation 41

45 [0112] This was prepared in a manner similar to Preparation 14 to give N-(3-aminophenyl)-4-methylcinnamamide.

mp:90-94°C

MS:253(M+1)

50 NMR(DMSO, δ): 2.34(3H,s), 5.08(2H,s), 6.20(1H,d,J=8.2Hz), 6.72-7.02(4H,m), 7.25(2H,d,J=7.9Hz), 7.44-7.55(3H,m), 9.83(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.9}: C;71.57, H;6.68, N;10.43

Found: C;71.59, H;6.64, N;10.37

Preparation 42

[0113] This was prepared in a manner similar to Preparation 14 to give N-(3-aminophenyl)-3-methylcinnamamide.

EP 1 264 820 A1

MS:253(M+1)

NMR(DMSO, δ):2.34(3H,s), 5.09(2H,s), 6.27(1H,d,J=8.2Hz), 6.76-7.02(4H,m), 7.18-7.43(4H,m), 7.49(1H,d,J=15.7Hz), 9.85(1H,s)

5 Preparation 43

[0114] This was prepared in a manner similar to Preparation 14 to give N-(3-aminophenyl)-2-methylcinnamamide.

ms:141-142°C

10 MS:253(M+1)

NMR(DMSO, δ):2.40(3H,s), 5.08(2H,s), 6.28(1H,d,J=8.3Hz), 6.74(1H,d,J=15.6Hz), 6.79-6.99(3H,m), 7.21-7.36(3H,m), 7.51-7.61(1H,m), 7.76(1H,d,J=15.6Hz), 9.88(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.1}:C;75.63,H;6.43,N;11.02

15 Found:C;75.35,H;6.34,N;11.03

Preparation 44

20 [0115] This was prepared in a manner similar to Preparation 16 to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]- α -methylcinnamamide.

MS:353(M+1), 297(M-C₄H₉+1), 253(M-BOC+1)

NMR(DMSO, δ):1.48(9H,s), 2.09(3H,d,J=1.2Hz), 7.06(1H,d,J=8.1Hz), 7.17(1H,dd,J=8.0Hz,8.0Hz), 7.26-7.49(7H,m), 7.94(1H,s), 9.34(1H,s), 9.90(1H,s)

25

Preparation 45

[0116] This was prepared in a manner similar to Preparation 16 to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]-4-methylcinnamamide.

30

MS:353(M+1), 297(M-C₄H₉+1), 253(M-BOC+1)

NMR(DMSO, δ):1.48(9H,s), 2.34(3H,s), 6.80(1H,d,J=15.7Hz), 7.06(1H,d,J=8.1Hz), 7.17(1H,dd,J=8.0Hz,8.0Hz), 7.21-7.29(2H,m), 7.41-7.59(4H,m), 7.84(1H,s), 9.37(1H,s), 10.12(1H,s)

35 Preparation 46

[0117] This was prepared in a manner similar to Preparation 16 to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]-3-methylcinnamamide.

40 MS:353(M+1), 297(M-C₄H₉+1), 253(M-BOC+1)

NMR(DMSO, δ):1.49(9H,s), 2.35(3H,s), 6.85(1H,d,J=15.7Hz), 7.07(1H,d,J=8.4Hz), 7.12-7.59(7H,m), 7.84(1H,s), 9.38(1H,s), 10.14(1H,s)

Preparation 47

45

[0118] This was prepared in a manner similar to Preparation 16 to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]-2-methylcinnamamide.

MS:353(M+1), 297(M-C₄H₉+1), 253(M-BOC+1)

50 NMR(DMSO, δ):1.49(9H,s), 2.41(3H,s), 6.77(1H,d,J=15.6Hz), 7.05(1H,d,J=8.6Hz), 7.18(1H,t,J=8.1Hz), 7.24-7.35(4H,m), 7.46(1H,d,J=8.2Hz), 7.51-7.61(1H,m), 7.79(1H,d,J=15.6Hz), 7.88(1H,s), 9.38(1H,s), 10.17(1H,s)

Preparation 48

55

[0119] This was prepared in a manner similar to Preparation 16 to give N-(3-amino-5-chlorophenyl)-2-chlorocinnamamide.

EP 1 264 820 A1

mp:147-149°C

MS:307(M+1)

NMR(DMSO, δ): 5.48(2H,s), 6.32(1H,dd,J=1.9Hz,1.9Hz), 6.81(1H,dd,J=1.9Hz,1.9Hz), 6.85(1H,d,J=15.7Hz), 7.00(1H,dd,J=1.9Hz,1.9Hz), 7.40-7.49(2H,m), 7.53-7.59(1H,m), 7.72-7.59(1H,m), 7.72-7.78(1H,m), 7.84(1H,d,J=15.7Hz), 10.15(1H,s)

Elemental analysis:

Calculated:C;58.65,H3.94,N;9.12

Found:C;58.62,H;3.85,N;8.85

10 Preparation 49

[0120] This was prepared in a manner similar to Preparation 4 to give 3,5-diaminobenzonitrile.

mp:156-159°C

MS:134(M+1)

NMR(DMSO, δ): 5.22(4H,s), 6.05(3H,s).

Preparation 50

20 [0121] This was prepared in a manner similar to Preparation 16 to give N-(3-cyanophenyl)-2-chlorocinnamamide.

mp:198-200°C

MS:283(M+1)

NMR(DMSO, δ): 6.88(1H,d,J=15.7Hz), 7.42-7.50(2H,m), 7.51-7.64(3H,m), 7.74-7.92 (2H,m), 7.92(1H,d,J=15.7Hz), 8.22(1H,s), 10.67(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.1}:C;67.54,H;3.97,N;9.85

Found:C;67.33,H;3.81,N;9.87

30 Preparation 51

[0122] A solution of tertbutyl 3-nitrophenylcarbamate (9.01g) in methanol (90ml) was stirred under an atmosphere of hydrogen for 8 hours. Filtered through Celite, washed with methanol, and evaporated. Purified by silica gel column chromatography (hexane/ethyl acetate) to give tertbutyl 3-aminophenylcarbamate as light pink crystals.

mp:104-106°C

MS:209(M+1), 109(M-BOC+1)

NMR(DMSO, δ): 1.45(9H,s), 4.96(2H,s), 6.15(1H,dd,J=7.2Hz,1.2Hz), 6.52(1H,d,J= 7.9Hz), 6.80(1H,s), 6.84(1H,dd,J=7.9Hz,7.9Hz), 8.98(1H,s)

40 Preparation 52

[0123] This was prepared in a manner similar to Preparation 14 to give N-(3-aminophenyl)-2-trifluoromethylcinnamamide.

mp:141-142°C

MS:307(M+1)

NMR(DMSO, δ): 5.11(2H,s), 6.30(1H,d,J=8.7Hz), 6.78-7.01(4H,m), 7.62(1H,dd,J =7.3Hz,7.3Hz), 7.72-7.91(4H,m), 10.02(1H,s)

Elemental analysis:

Calculated:C;62.74,H;4.28,N;9.15

Found:C;62.63,H;4.27,N;9.09

55 Preparation 53

[0124] This was prepared in a manner similar to Preparation 4 to give N-(3-aminophenyl)-4-chlorocinnamamide.

mp:167-168°C

EP 1 264 820 A1

MS:273(M+1)
NMR(DMSO, δ):5.10(2H,s), 6.28(1H,d,J=8.2Hz), 6.78-7.01(4H,m), 7.46-7.69(5H,m), 9.89(1H,s)
Elemental analysis:
Calculated:C;66.06,H;4.80,N;10.27
Found:C;65.86,H;4.78,N;10.16

Preparation 54

[0125] This was prepared in a manner similar to Preparation 16 to give N-(3-nitrophenyl)-4-chlorocinnamamide.

mp:255-256°C
MS:303(M+1)
NMR(DMSO, δ):6.82(1H,d,J=15.7Hz), 7.53(2H,d,J=8.5Hz), 7.59-7.72(4H,m), 7.90-8.03(2H,m), 8.74(1H,dd, J=2.1Hz,2.1Hz), 10.73(1H,s)
Elemental analysis:
Calculated:C;59.52,H;3.66,N;9.25
Found:C;59.20,H;3.58,N;9.19

Preparation 55

[0126] This was prepared in a manner similar to Preparation 16 to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]-2-trifluoromethylcinnamamide.

mp:172-173°C
MS:307(M-BOC+1)
NMR(DMSO, δ):1.48(9H,s), 6.92(1H,d,J=15.4Hz), 7.07(1H,d,J=8.1Hz), 7.19(1H,dd,J=8.1Hz,8.1Hz), 7.45(1H,d, J=8.0Hz), 7.63(1H,dd,J=7.4Hz), 7.77-7.96(5H,m), 9.40(1H,s), 10.31(1H,s)

Preparation 56

[0127] This was prepared in a manner similar to Preparation 14 to give N-(3-aminophenyl)-3-methoxycinnamamide.

MS:269(M+1)
NMR(DMSO, δ):3.80(3H,s), 5.09(2H,s), 6.27(1H,d,J=8.6Hz), 6.77-7.02(5H,m), 7.15-7.21(2H,m), 7.36(1H,dd, J=8.0Hz,8.0Hz), 7.50(1H,d,J=15.7Hz), 9.86(1H,s)

Preparation 57

[0128] This was prepared in a manner similar to Preparation 16 to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]-2-methoxycinnamamide.

MS:313(M-C₄H₉+1), 269(M-BOC+1)
NMR(DMSO, δ):1.48(9H,s), 3.89(3H,s), 6.89(1H,d,J=15.8Hz), 6.98-7.21(4H,m), 7.38(1H,d,J=7.1Hz), 7.45(1H,d, J=8.0Hz), 7.55(1H,d,J=7.6Hz), 7.78(1H,d,J=15.8Hz), 7.86(1H,s), 9.37(1H,s), 10.12(1H,s)

Preparation 58

[0129] This was prepared in a manner similar to Preparation 16 to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]-3-methoxycinnamamide.

MS:313(M-C₄H₉+1), 269(M-BOC+1)
NMR(DMSO, δ):1.48(9H,s), 3.81(3H,s), 6.85(1H,d,J=15.7Hz), 6.94-7.24(5H,m), 7.31-7.50(2H,m), 7.54(1H,d, J=15.8Hz), 7.84(1H,s), 9.38(1H,s), 10.16(1H,s)

Preparation 59

[0130] This was prepared in a manner similar to Preparation 14 to give N-(3-aminophenyl)-3-chlorocinnamamide.

EP 1 264 820 A1

mp:112-114°C

MS:273(M+1)

NMR(DMSO, δ):5.10(2H,s), 6.28(1H,d,J=7Hz), 6.70-7.00(4H,m), 7.41-7.60(4H,m), 7.67(1H,s), 9.88(1H,s)

5 Preparation 60

[0131] This was prepared in a manner similar to Preparation 14 to give N-(3-aminophenyl)-2-chlorocinnamamide.

mp:159-161°C

10 MS:273(M+1)

NMR(DMSO, δ):5.11(2H,s), 6.29(1H,d,J=7.6Hz), 6.78=7.08(4H,m), 7.39-7.54(2H,m), 7.54-7.63(1H,m), 7.71-7.83(1H,m) 7.83(1H,d,J=15.6Hz), 9.98(1H,s)

15 Preparation 61

[0132] This was prepared in a manner similar to Preparation 16 to give N-[3-[(tert-butoxycarbonyl)amino]phenyl]-3-chlorocinnamamide.

MS:395(M+Na)

20 NMR(DMSO, δ):1.48(9H,s), 6.90(1H,d,J=15.8Hz), 7.47(1H,d,J=8.1Hz), 7.19(1H,dd,J=8.0Hz,8.0Hz), 7.40-7.62(5H,m), 7.68(1H,s), 7.84(1H,s), 9.40(1H,s), 10.18(1H,s)

Preparation 62

25 [0133] This was prepared in a manner similar to Preparation 64 to give 5-chloro-2-methoxybenzonitrile.

mp:97-99°C

MS:168(M+1)

30 NMR(DMSO, δ):3.92(3H,s), 7.28(1H,d,J=9.1Hz), 7.74(1H,dd,J=9.1Hz,2.7Hz), 7.91(1H,d,J=2.6Hz)

Preparation 63

[0134] This was prepared in a manner similar to Preparation 15 to give 5-fluoro-2-methoxybenzenecarbothioamide.

35 mp:141-142°C

MS:184(M-1)

NMR(DMSO, δ):3.80(3H,s), 7.07(1H,dd,J=9.1Hz,4.5Hz), 7.23(1H,ddd,J=9.0Hz, 9.0Hz,3.3Hz), 7.44(1H,dd,J=9.4Hz,3.2Hz), 9.41(1H,s), 10.09(1H,s)

Elemental analysis:

40 Calculated:C;51.88,H;4.35,N;7.56

Found:C;51.82,H;3.98,N;7.39

Preparation 64

45 [0135] At 5 °C was added phosphorus oxychloride (2.33ml) to N,N-dimethylformamide (15ml). Stirred 30 minutes at 5 °C under nitrogen and added 5-fluoro-2-methoxybenzamide (1.40g). Stirred 1 hour at 5°C. Poured into water (100ml), allowed to stand for 30 minutes, collected by filtration, washed with water, and air dried to give 5-fluoro-2-methoxybenzonitrile (1.45g) as white crystals.

50 mp:113-114°C

IR(KBr):2229cm⁻¹

MS:152(M+1)

NMR(DMSO, δ):3.90(3H,s), 7.27(1H,dd,J=9.4Hz,4.2Hz), 7.58(1H,ddd,J=9.2Hz, 9.2Hz,3.2Hz), 7.75(1H,dd,J=8.2Hz,3.2Hz)

55

Preparation 65

[0136] A solution of methyl 5-fluoro-2-methoxybenzoate (2.20g), N,N-dimethylformamide (10ml), and sodium meth-

EP 1 264 820 A1

oxide (100mg) was heated at 100°C for 7 hours. Cooled to room temperature, diluted with ethyl acetate (100ml), washed with water (three times, 100ml each time), brine (100ml), dried over Magnesium sulfate, filtered, evaporated, and purified by silica gel column chromatography (dichloromethane/methanol) to give 5-fluoro-2-methoxybenzamide (1.48g) as white crystals.

mp:144-146°C

IR(KBr):3448,1674cm⁻¹

MS:170(M+1)

NMR(DMSO, δ):3.88(3H,s), 7.16(1H,dd,J=9.1Hz,4.4Hz), 7.33(1H,ddd,J=9.1Hz; 9.1Hz,3.4Hz), 7.53(1H,dd,J=9.4Hz,3.3Hz), 7.70(2H,s)

Preparation 66

[0137] To a mixture of 5-fluoro-2-hydroxybenzoic acid (2.0g), potassium carbonate (4.42g), and N,N-dimethylformamide (25ml) was added at room temperature methyl iodide (3.98ml). Stirred at room temperature for four hours. Diluted with ethyl acetate (100ml), washed with water (twice, 100ml each time), brine (twice, 100ml each time), dried over Magnesium sulfate, filtered, and evaporated to give 5-fluoro-2-methoxymethylbenzoate (2.23g) as a yellow liquid.

MS:185(M+1), 153(M-CH₃OH+1)

NMR(DMSO, δ):3.79(3H,s), 3.81(3H,s), 7.18(1H,dd,J=8.7Hz,4.2Hz), 7.35-7.48 (2H,m).

Preparation 67

[0138] This was prepared in a manner similar to Preparation 25 to give tertbutyl 3-nitrophenylcarbamate.

MS:139(M-BOC+1)

NMR(DMSO, δ):1.50(9H,s), 7.54(1H,dd,J=8.1Hz,8.1Hz), 7.73-7.86(2H,m), 8.48(1H, dd,J=2.1Hz,2.1Hz), 9.91(1H,s)

Preparation 68

[0139] This was prepared in a manner similar to Preparation 16 to give N-(4-cyanophenyl)-2-chlorocinnamamide.

mp:206-207°C

MS:283(M+1)

NMR(DMSO, δ):6.90(1H,d,J=15.7Hz), 7.42-7.61(3H,m), 7.74-7.98(6H,m), 10.75 (1H,s)

Preparation 69

[0140] This was prepared in a manner similar to Preparation 15 to give N-[4-(aminocarbothioyl)phenyl]-2-chlorocinnamamide.

MS:317(M+1)

NMR(DMSO, δ):6.91(1H,d,J=15.6Hz), 7.40-7.99(9H,m), 9.40(1H,s), 9.74(1H,s), 10.59(1H,s)

Preparation 70

[0141] This was prepared in a manner similar to Preparation 13 to give 4-(2-chlorocinnamoylamino)benzenecarbidithioate hydroiodide.

MS:331(free+1)

NMR(DMSO, δ):2.84(3H,s), 6.94(1H,d,J=15.6Hz) 7.20-8.00(9H,m), 10.90(1H,s)

Preparation 71

[0142] This was prepared in a manner similar to Preparation 82 to give 4-[(2-methyl-3-pyridyl)oxy]benzonitrile.

MS:211(M+1)

EP 1 264 820 A1

NMR(DMSO, δ): 2.34(3H,s), 7.01-7.11(2H,s), 7.35(1H,dd,J=8.2Hz,4.7Hz), 7.54(1H, dd,J=8.2Hz,1.4Hz), 7.80,7.91(2H,m), 8.40(1H,dd,J=4.7Hz,1.4Hz)

Preparation 72

[0143] This was prepared in a manner similar to Preparation 15 to give 4-[(2-methyl-3-pyridyl)oxy]benzenecarbothioamide.

MS:245(M+1)

NMR(DMSO, δ): 2.37(3H,s), 6.89-6.96(2H,m), 7.32(1H,dd,J=8.1Hz,4.6Hz), 7.44(1H, dd,J=8.2Hz,1.5Hz), 7.92-7.99(2H,m), 8.35(1H,dd,J=4.6Hz,1.5Hz), 9.42(1H,s), 9.79 (1H,s)

Preparation 73

[0144] This was prepared in a manner similar to Preparation 13 to give methyl 4-[(2-methyl-3-pyridyl)oxy]benzenecarbimidothioate hydroiodide.

MS:259(free+1)

NMR(DMSO, δ): 2.45(3H,s), 2.85(3H,s), 7.0-8.2(7H,m)

Preparation 74

[0145] This was prepared in a manner similar to Preparation 82 to give 4-[(2-pyridylmethyl)amino]benzonitrile.

MS:210(M+1)

NMR(DMSO, δ): 4.43(2H,d,J=6.1Hz), 6.63-6.70(2H,m), 7.23-7.47(5H,m), 7.75(1H, ddd,J=7.6Hz,7.6Hz,1.8Hz), 8.50-8.56(1H,m)

Preparation 75

[0146] This was prepared in a manner similar to Preparation 15 to give 4-[(2-pyridylmethyl)amino]benzenecarbothioamide.

MS:244(M+1)

NMR(DMSO, δ): 4.43(2H,d,J=6.1Hz), 6.54(2H,d,J=8.9Hz), 7.07(1H,t,J=6.0Hz), 7.22-7.36(2H,m), 7.74(1H,ddd, J=7.7Hz,7.7Hz,1.8Hz), 7.80(2H,d,J=8.9Hz), 8.50-8.57 (1H,m), 8.97(1H,s), 9.21(1H,s)

Preparation 76

[0147] This was prepared in a manner similar to Preparation 13 to give methyl 4-[(2-pyridylmethyl)amino]benzenecarbimidothioate hydroiodide.

MS:258(free+1)

NMR(DMSO, δ): 2.75(3H,s), 4.54(2H,d,J=6.3Hz), 6.77(2H,d,J=9.0Hz), 7.24-7.32 (1H,m), 7.34(1H,d,J=7.9Hz), 7.70-7.83(3H,m), 7.95-8.05(1H,m), 8.51-8.57(1H,m)

Preparation 77

[0148] This was prepared in a manner similar to Preparation 16 to give N-[5-[(tert-butoxycarbonyl)amino]-2-fluorophenyl]-2-trifluoromethylcinnamamide.

MS:325(M-BOC+1)

NMR(DMSO, δ): 1.47(9H,s), 6.4-8.3(9H,m), 9.40(1H,s), 10.02(1H,s)

Preparation 78

[0149] This was prepared in a manner similar to Preparation 14 to give N-(5-amino-2-fluorophenyl)-2-trifluoromethylcinnamamide.

EP 1 264 820 A1

mp:173-175°C

MS:325(M+1)

NMR(DMSO, δ):5.00(2H,s), 6.25-6.35(1H,m), 6.91(1H,dd,J=10.9Hz,8.7Hz), 7.14(1H, d,J=15.3Hz), 7.36(1H,dd, J=6.6Hz,2.6Hz), 7.62(1H,dd,J=7.2Hz,7.2Hz), 7.73-7.92 (4H,m), 9.80(1H,s)

5

Preparation 79

[0150] This was prepared in a manner similar to Preparation 82 to give 4-[(1-oxido-3-pyridyl)oxy]benzonitrile.

10 mp:174-176°C

MS:213(M+1)

NMR(DMSO, δ):7.15(1H,dd,J=8.4Hz,1.8Hz), 7.25-7.35(2H,m), 7.46(1H,dd, J=8.6Hz,6.5Hz), 7.85-7.95(2H,m), 8.13(1H,d,J=6.4Hz), 8.28(1H,dd,J=1.9Hz,1.9Hz)

15 Preparation 80

[0151] This was prepared in a manner similar to Preparation 15 to give 4-[(1-oxido-3-pyridyl)oxy]benzenecarbothioamide.

20 MS:247(M+1)

NMR(DMSO, δ):7.07(1H,dd,J=8.6Hz,2.1Hz), 7.12-7.20(2H,m), 7.42(1H,dd,J=8.6Hz, 6.4Hz), 7.95-8.03(2H,m), 8.09(1H,dd,J=6.4Hz,1.9Hz), 8.18(1H,dd,J=1.9Hz, 1.9Hz), 9.50(1H,s), 9.86(1H,s)

Preparation 81

25

[0152] This was prepared in a manner similar to Preparation 13 to give methyl 4-[(1 oxido-3-pyridyl)oxy]benzene-carbimidothioate hydroiodide.

MS:261(free+1)

30 NMR(DMSO, δ):2.81(3H,s), 7.15-7.22(1H,m), 7.31-7.43(2H,m), 7.49(1H,dd,J=8.5Hz, 6.4Hz), 7.91-8.09(2H,m), 8.14-8.19(1H,m), 8.30(1H,dd,J=1.9Hz,1.9Hz)

Preparation 82

35 **[0153]** A mixture of 1-acetylpiperazine (3.84g), 4-fluorobenzonitrile (3.03g), potassium carbonate (4.15g) and N,N-dimethylformamide (15ml) was stirred at 150°C for four hours. Cooled to room temperature, added to ethyl acetate (250ml), water (250ml), separated, washed with water (100ml), brine (100ml), dried over magnesium sulfate, filtered, and evaporated. Purified by silica gel column chromatography (dichloromethane/methanol) to give 4-(4-acetyl-1-piperazinyl) benzonitrile (3.16g) as white crystals.

40

mp:103-105°C

MS:229(M+1)

NMR(DMSO, δ):2.04(3H,s), 3.29-3.45(4H,m), 3.51-3.61(4H,m), 6.97-7.07(2H,m), 7.55-7.65(2H,m)

45 Preparation 83

[0154] This was prepared in a manner similar to Preparation 15 to give 4-(4-acetyl-1-piperazinyl)benzenecarbothioamide.

50 MS:264(M+1)

NMR(DMSO, δ):2.04(3H,s), 3.20-3.40(4H,m), 3.50-3.64(4H,m), 6.92(2H,d,J=8.9Hz), 7.92(2H,d,J=8.9Hz), 9.17 (1H,s), 9.43(1H,s)

Preparation 84

55

[0155] This was prepared in a manner similar to Preparation 13 to give methyl 4-(4-acetyl-1-piperazinyl)benzene-carbimidothioate hydroiodide.

EP 1 264 820 A1

MS:278(free+1)

NMR(DMSO, δ): 2.05(3H,s), 2.77(3H,s), 3.4-3.7(8H,m), 7.08(2H,d,J=9.1Hz), 7.84(2H, d,J=9.1Hz)

Preparation 85

[0156] This was prepared in a manner similar to Preparation 16 to give N-(3-amino-5-chlorophenyl)-2-cyanocinnamamide.

mp:261-263°C

MS:298(M+1)

NMR(DMSO, δ): 5.50(2H,br s), 6.34(1H,dd,J=1.9Hz,1.9Hz), 6.84(1H,dd,J=1.8Hz, 1.8Hz), 7.00(1H,dd,J=1.8Hz, 1.8Hz), 7.01(1H,d,J=15.3Hz), 7.61(1H,ddd,J=7.6Hz, 7.6Hz,1.4Hz), 7.76(1H,d,J=15.5Hz), 7.75-7.97(3H,m), 10.24(1H,s)

Preparation 86

[0157] This was prepared in a manner similar to Preparation 16 to give (2E)-N-(3-amino-5-chlorophenyl)-3-(2-pyridyl)-2-propenamide.

mp:101-103°C

MS:273(M+1)

NMR(DMSO, δ): 4.57(2H,br s), 6.31(1H,dd,J=1.9Hz,1.9Hz), 6.86(1H,dd,J=1.8Hz, 1.8Hz), 6.98(1H,dd,J=1.8Hz, 1.8Hz), 7.28(1H,d,J=15.3Hz), 7.34-7.44(1H,m), 7.52-7.66(2H,m), 7.86(1H,ddd,J=7.7Hz,7.7Hz,1.8Hz), 8.62-8.65(1H,m), 10.18(1H,s)

Preparation 87

[0158] To a solution of 2-(aminomethyl)pyridine (20.94g) in tetrahydrofuran (100ml) was added 2-chloro-5-nitropyridine (13.95g) and the mixture was stirred at ambient temperature for 5 hours. The mixture was poured into ice-water, stirred for 10 minutes. The precipitate was collected by filtration, washed with water and dried to give 2-(pyridine-2-ylmethylamino)-5-nitropyridine (18.87g).

APCI-mass;m/z231(M+H⁺)

NMR(DMSO, δ): 4.72(2H,d,J=5.6Hz), 6.72(2H,d,J=9.1Hz), 7.2-7.4(2H,m), 7.76(1H,dt, J=1.7Hz,7.7Hz), 8.15(1H, dd,J=2.8Hz,9.4Hz), 8.53(1H,d,J=4.4Hz), 8.67(1H,t,J=5.6Hz), 8.90(1H,d,J=2.8Hz)

Preparation 88

[0159] A suspension of 2-(pyridine-2-ylmethylamino)-5-nitropyridine (460mg), iron powder (555mg) and ammonium chloride (166mg) in ethanol (10ml) and water (1ml) was refluxed for 2 hours. The insoluble material was filtered off, and the filtrate was evaporated. The residue was diluted with ethyl acetate and washed with aqueous sodium hydrogen carbonate (saturated) and brine. The separated organic layer was dried over sodium sulfate and evaporated to give 5-amino-2-(pyridine-2-ylmethylamino)pyridine (0.36g).

APCI-mass;m/z201(M+H⁺)

NMR(DMSO, δ): 4.29(2H,s), 4.43(1H,d,J=6.1Hz), 6.23(1H,t,J=6.1Hz), 6.37(1H,d, J=8.6Hz), 6.83(1H,dd,J=2.8Hz, 8.6Hz), 7.1-7.3(1H,m), 7.29(1H,d,J=8.0Hz), 7.42(1H,d, J=2.7Hz), 7.69(1H,dt,J=1.7Hz,7.6Hz), 8.48(1H,d,J=4.8Hz)

Preparation 89

[0160] To a suspension of 3-chloro-5-nitro-2-(pyridine-2-ylmethylamino)pyridine (1.16g), charcoal (2g) and iron (III) chloride hexahydrate (116mg) in tetrahydrofuran (100ml) was added hydrazine hydrate (2.3ml) and the mixture was refluxed for 2.5 hours. The insoluble material was filtered off and the filtrate was evaporated to give 5-amino-3-chloro-2-(pyridine-2-ylmethylamino)pyridine (1.03g).

APCI-mass;m/z235(M+H⁺)

NMR(DMSO, δ): 4.54(2H,d,J=5.5Hz), 4.65(2H,broad s), 6.23(1H,t,J=5.6Hz), 7.05(1H, d,J=2.4Hz), 7.1-7.3(2H,m), 7.42(1H,d,J=2.4Hz), 7.70(1H,dt,J=1.8Hz,7.7Hz), 8.4-8.6 (2H,m)

EP 1 264 820 A1

Preparation 90

5 **[0161]** To a suspension of 5-nitro-2-(pyridine-2-ylmethylamino)pyridine (10g) in acetonitrile (200ml) was added N-chlorosuccinimide (7.54g) and the mixture was stirred at 60°C for 5 hours and at 50°C for 14 hours. The mixture was cooled to ambient temperature and the precipitate was collected by filtration, washed with acetonitrile and dried to give 3-chloro-5-nitro-2-(pyridine-2-ylmethylamino)pyridine (8.87g).

10 APCI-mass;m/z265(M+H⁺)
NMR(DMSO, δ): 4.85(2H,d,J=5.9Hz), 7.3-7.4(2H,m), 7.87(1H,dt,J=1.7 Hz,7.7Hz), 8.45(1H,d,J=2.4Hz), 8.5-8.7(2H,m), 8.86(1H,d,J=2.4Hz)

Preparation 91

15 **[0162]** To a suspension of 4-fluoro-3-nitrophenylformamide (5.60g) and potassium carbonate (5.44g) in N,N-dimethylformamide (28ml) was added 2-bromo-3-butanone (4.1ml) and the mixture was stirred for 24 hours. The mixture was diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate and evaporated to give 4-fluoro-3-nitrophenyl(1-methyl-2-oxo-propyl)formamide (6.83g).

20 APCI-mass;m/z255(M+H)
NMR(DMSO, δ): 1.32(3H,d,J=7.0Hz), 2.10(3H,s), 4.75(1H,q,J=7.0Hz), 7.78-7.86 (2H,m), 8.14-8.19(1H,m), 8.54(1H,s)

Preparation 92

25 **[0163]** To a suspension of 4-fluoro-3-nitrophenyl(1-methyl-2-oxo-propyl)formamide (6.80g), ammonium acetate (20.6g) and acetic acid (5.30ml) in xylene (140ml) was refluxed for 1.5 hours. To the mixture was added ethyl acetate and an aqueous solution of sodium hydroxide (1N, 200ml) and the mixture was stirred for 10 minutes. The aqueous layer was separated and extracted with ethyl acetate. The organic layer was combined, washed with water and brine, dried over magnesium sulfate and evaporated. The crude solid was washed with ethyl acetate and the washing was concentrated in vacuo. The residue was purified by silica gel column chromatography, eluted with methanol/dichloromethane (2-4%) to give 1-(4-fluoro-3-nitrophenyl)-4,5-dimethyl-1H-imidazole (1.29g).

35 APCI-mass;m/z236(M+H)
NMR(DMSO, δ): 2.10(6H,s), 7.75(1H,s), 7.73-7.82(1H,m), 7.87-7.95(1H,m), 8.19-8.23(1H,m)

Preparation 93

40 **[0164]** A suspension of 1-(4-fluoro-3-nitrophenyl)-4,5-dimethyl-1H-imidazole (480mg) in methanol (2.5ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 96mg) under hydrogen atmosphere for 3 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give 5-(4,5-dimethyl-1H-imidazol-1-yl)-2-fluoroaniline (418mg).

45 APCI-mass;m/z206(M+H)
NMR(DMSO, δ): 2.03(3H,s), 2.08(3H,s), 5.46(2H,s), 6.35-6.53(1H,m), 6.69(1H,dd, J=8.0Hz,2.7Hz), 7.10(1H,dd, J=8.5Hz,2.7Hz), 7.53(1H,s)

Preparation 94

50 **[0165]** To a suspension of 3-iodo-4-methoxypyridine (0.62g), 3-nitrophenylboronic acid (0.57g) and tetrakis(triphenylphosphine)palladium(0) (152mg) in dimethoxyethane (10ml) was added aqueous sodium carbonate (2M, 3.43ml) and the mixture was stirred at 60°C for 6 hours. The mixture was diluted with ethyl acetate and washed with aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was purified with silica gel (25g) column chromatography and eluted with 40-80% ethyl acetate in n-hexane to give 3-(4-methoxypyridin-3-yl)nitrobenzene (84mg).

55 APCI-mass;m/z231(M+H⁺)
1H-NMR(DMSO-d₆): δ : 3.90(3H,s), 7.24(1H,d,J=5.8Hz), 7.75(1H,t,J=8.0Hz), 8.00 (1H,d,J=8.0Hz), 8.24(1H,dt, J=8.2Hz,1.1Hz), 8.35(1H,t,J=1.0Hz), 8.48(1H,s), 8.53(1H, d,J=7.6Hz)

EP 1 264 820 A1

Preparation 95

[0166] This was prepared in a manner similar to Example 91 to give N-(4-nitrophenyl)-9H-fluorene-1-carboxamide.

5 APCI-mass;m/z331(M+H⁺)
¹H-NMR(DMSO-d₆): δ; 4.22(2H,s), 7.3-7.7(4H,m), 7.79(1H,d,J=7.5Hz), 8.08(2H,d, J=9.2Hz), 8.16(1H,d, J=7.5Hz), 8.30(2H,d,J=9.2Hz), 10.94(1H,s)

Preparation 96

10 [0167] This was prepared in a manner similar to Preparation 141 to give N-(4-aminophenyl)-9H-fluorene-1-carboxamide.

15 APCI-mass;m/z301(M+H⁺)
¹H-NMR(DMSO-d₆): δ; 4.17(2H,s), 4.94(2H,m), 6.56(2H,d,J=9.2Hz), 7.3-7.7(9H,m), 7.96(1H,d,J=6.6Hz), 8.06(1H,d,J=7.3Hz), 9.93(1H,s)

Preparation 97

20 [0168] To a suspension of 5-nitro-N-(2-pyridylmethyl)-2-pyridylamine (516mg) in methanol (10ml) and tetrahydrofuran (5ml) was hydrogenated over 10% palladium on carbon (50% wet, 100mg) under hydrogen atmosphere for 6 hours. The catalyst was filtered off and the filtrate was evaporated. The residue was added a solution of hydrogen chloride in 4N 1,4-dioxane (2ml) and stirred for 10 minutes. The precipitate was collected by filtration, washed with ethyl acetate and dried to give N²-pyridine-2-ylmethyl-pyridine-2,5-diamine (612mg).

25 APCI-mass;m/z201(M(free)+H⁺)
¹H-NMR(DMSO-d₆): δ; 4.89(2H,s), 6.95(1H,d,J=9.1Hz), 7.59(1H,dd,J=9.1,2.5Hz), 7.7-7.9(3H,m), 8.38(1H,t, J=7.9Hz), 8.77(1H,d,J=5.1Hz)

Preparation 98

[0169] This was prepared in a manner similar to Example 91 to give N-(2-chloro-4-pyridyl)-9H-fluorene-1-carboxamide.

35 APCI-mass;m/z321(M+H⁺)
¹H-NMR(DMSO-d₆): δ; 4.21(3H,s), 7.3-7.8(6H,m), 7.9-8.1(2H,m), 8.17(1H,d,J=7.2Hz), 8.34(1H,d,J=5.6Hz), 10.91(1H,s)

Preparation 99

40 [0170] To a solution of 5-[(9H-fluorene-1-ylcarbonyl)amino]methylnicotinate (305mg) in methanol (3ml) and tetrahydrofuran (3ml) was added aqueous sodium hydroxide (1N, 1.15ml) and the mixture was stirred at 60°C for 2 hours. After cooling, to the mixture was added hydrochloric acid (1N, 1.2ml) and the precipitate was collected by filtration to give 5-[(9H-fluorene-1-ylcarbonyl)amino]nicotinic acid (270mg).

45 APCI-mass;m/z331(M+H⁺)
¹H-NMR(DMSO-d₆): δ; 4.23(2H,s), 7.3-7.5(4H,m), 7.82(1H,d,J=7.1Hz), 7.99(1H,d, J=8.0Hz), 8.15(1H,d, J=7.1Hz), 8.7-8.9(2H,m), 9.15(1H,d,J=2.0Hz), 10.73(1H,s), 13.0-14.0(1H,broad s)

Preparation 100

50 [0171] A mixture of 2-chloropyrimidine (5.73g) and 2-aminomethylpyridine (13.53g) was stirred at 140°C for 30 minutes. To the mixture was diluted with ethyl acetate and washed with brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with isopropyl ether, collected by filtration, wash with isopropyl ether and dried to give N-(2-pyridylmethyl)-2-pyrimidinylamine (5.91g).

55 APCI-mass;m/z187.20(M+H⁺)
¹H-NMR(DMSO-d₆): δ; 4.58(2H,d,J=6.3Hz), 6.59(1H,t,J=4.8Hz), 7.2-7.4(2H,m), 7.6-7.8(2H,m), 8.27(2H,d,

EP 1 264 820 A1

J=4.7Hz), 8.49(1H,d,J=4.7Hz)

Preparation 101

5 [0172] To a suspension of N-(2-pyridylmethyl)-2-pyridinamine (3.0g) in sulfuric acid (10ml) was added potassium nitrate (6.52g) in portions and the mixture was stirred at 60°C for 14 hours and at 70°C for 20 hours. After cooling, the mixture was poured into ice-water and pH was adjusted to 9.0 with aqueous sodium hydroxide (4N). The precipitate was collected by filtration and washed with water and methanol to give 5-nitro-N-(2-pyridylmethyl)-2-pyrimidinylamine (1.57g).

10 APCI-mass;m/z232.20(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.73(2H,d,J=5.9Hz), 7.2-7.4(2H,m), 7.75(1H,dt,J=1.6Hz, 7.7Hz), 8.50(1H,d,J=4.7Hz), 9.08(2H,dd,J=3.4Hz,5.1Hz), 9.28(1H,t,J=5.9Hz)

15 Preparation 102

[0173] This was prepared in a manner similar to Preparation 141 to give N2-(2-pyridylmethyl)-2,5-pyrimidinyldiamine.

20 APCI-mass;m/z202.27(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.4-4.6(4H,m), 6.78(1H,t,J=6.2Hz), 7.2-7.4(2H,m), 7.69(1H, dt,J=1.7Hz,7.7Hz), 7.79(2H, s), 8.47(1H,d,J=4.8Hz)

Preparation 103

25 [0174] To a solution of 2-aminomethylpyrazine (2.18g) and triethylamine (4.05g) in tetrahydrofuran (50ml) was added 2-chloro-5-nitropyridine (3.17g). The mixture was stirred at 60°C for 6 hours, poured into ice-water and stirred for 10 minutes. The precipitate was collected by filtration, washed with water and dried to give 5-nitro-N-(2-pyrazinylmethyl)-2-pyridylamine (4.06g).

30 APCI-mass;m/z232.20(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.78(2H,d,J=5.9Hz), 6.72(1H,d,J=9.4Hz), 8.16(1H,dd, J=2.8Hz,9.4Hz), 8.5-8.9(4H,m), 8.89(1H,d,J=2.8Hz)

Preparation 104

35 [0175] This was prepared in a manner similar to Example 142 to give 3-chloro-5-nitro-N-(2-pyrazinylmethyl)-2-pyridylamine.

40 APCI-mass;m/z266.27,268.27(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.87(2H,d,J=6.0Hz), 8.43(1H,d,J=2.4Hz), 8.3-8.5(4H,m), 8.86(1H,d,J=2.4Hz)

Preparation 105

45 [0176] This was prepared in a manner similar to Preparation 138 to give 3-chloro-N²-(2-pyrazinylmethyl)-2,5-pyridyldiamine.

50 APCI-mass;m/z236.27,238.20(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.5-4.7(4H,m), 6.32(1H,t,J=5.9Hz), 7.05(1H,d,J=2.4Hz)7.40 (1H,d,J=2.4Hz), 8.4-8.7(3H, m)

Preparation 106

[0177] This was prepared in a manner similar to Preparation 141 to give 3-(4-methoxypyridin-3-yl)aniline.

55 APCI-mass;m/z201(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.81(3H,s), 5.10(2H,s), 6.5-6.7(2H,m), 7.04(1H,d,J=7.8Hz), 7.12(1H,d,J=5.8Hz), 7.5-7.7 (1H,m), 8.26(1H,s), 8.41(1H,d,J=5.7Hz)

EP 1 264 820 A1

Preparation 107

[0178] This was prepared in a manner similar to Preparation 109 to give 3-(1-methyl-2-difluoromethyl-1H-imidazol-5-yl)nitrobenzene.

APCI-mass;m/z254(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.78(3H,s), 7.22(1H,t,J=52.1Hz), 7.33(1H,s), 7.81(1H,t, J=7.9Hz), 8.01(1H,d,J=7.9Hz), 8.2-8.4(2H,m)

Preparation 108

[0179] This was prepared in a manner similar to Preparation 141 to give 3-(1-methyl-2-difluoromethyl-1H-imidazol-5-yl)aniline.

APCI-mass;m/z224(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.69(3H,s), 5.25(2H,s), 6.5-6.7(3H,m), 7.01(1H,t,J=26.5Hz), 7.1-7.2(2H,m)

Preparation 109

[0180] To a solution of N-[2-[3-[hydroxy(oxido)amino]phenyl]-2-oxoethyl]acetamide (475mg) in toluene (5ml) was added a solution of ethylamine in ethanol (20% w/v, 2ml) and acetic acid (1ml). The mixture was stirred at 95°C for 30 hours and diluted with ethyl acetate. The solution was washed with saturated aqueous sodium hydrogen carbonate and brine. The organic layer was separated, dried over magnesium sulfate and evaporated. The residue was purified with column chromatography (silica gel, dichloromethane (25g) in 2% methanol) to give 3-(1-ethyl-2-methyl-1H-imidazol-5-yl)nitrobenzene (304mg).

APCI-mass;m/z232(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;1.17(3H,t,J=7.2Hz), 2.39(3H,s), 4.00(2H,q,J=7.2Hz), 7.03 (1H,s), 7.75(1H,t,J=7.8Hz), 7.88(1H,d,J=7.8Hz), 8.1-8.3(2H,m)

Preparation 110

[0181] This was prepared in a manner similar to Preparation 141 to give 3-(1-ethyl-2-methyl-1H-imidazol-5-yl)aniline.

APCI-mass;m/z202.4(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;1.14(3H,t,J=7.1Hz), 2.34(3H,s), 3.91(2H,q,J=7.1Hz), 5.18 (2H,s), 6.4-6.6(3H,m), 6.69(1H,s), 7.0-7.2(1H,m)

Preparation 111

[0182] This was prepared in a manner similar to Preparation 141 to give N²-(2-pyrazinylmethyl)-2,5-diaminopyridine.

APCI-mass;m/z202(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.32(2H,s), 4.49(1H,d,J=6.1 6.34(1H,t,J=6.1Hz), 6.41 (1H,d,J=8.6Hz), 6.84(1H,dd, J=8.6Hz,2.8Hz), 7.41(1H,d,J=2.7Hz), 8.46(1H,s), 8.55 (2H,s)

Preparation 112

[0183] To a suspension of 5-bromopyrimidine (1.0g), 2-methoxyphenylboronic acid (1.05g) and sodium carbonate (2.0g) in 95% ethanol (10ml) was added 10% palladium on carbon (50% wet, 0.4g) and the mixture was refluxed for 36 hours. The solvents were removed by evaporation. To the residue was added ethyl acetate and water and the mixture was stirred for 10 minutes. The catalyst were filtered off and the organic layer of the filtrate was separated. The solution was washed with aqueous 1N sodium hydroxide and brine successively, dried over magnesium sulfate and evaporated to give 2-(pyrimidin-5-yl)anisole (984mg).

APCI-mass;m/z187.2(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.82(3H,s), 7.08(1H,dt,J=1.0Hz,7.4Hz), 7.19(1H,d,J=8.0Hz) 7.4-7.6(2H,m), 8.93(2H,s), 9.13(1H,s)

EP 1 264 820 A1

Preparation 113

[0184] To a suspension of 2-(pyrimidine-5-yl)anisole (830mg) in sulfuric acid (5ml) and acetic acid (10ml) was added potassium nitrate (450mg) in portions at 0°C. The mixture was stirred at 5°C for 1 hour and poured into ice-water. The suspension was adjusted to pH 8.0 with aqueous 4N sodium hydroxide and extracted with ethyl acetate. The organic layer was separated, washed with saturated aqueous sodium hydrogen carbonate and brine, dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give 3-(pyrimidine-5-yl)-4-methoxynitrobenzen (443mg).

APCI-mass;m/z232(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.96(3H,s), 7.42(1H,d,J=9.4Hz), 8.3-8.4(2H,m), 9.02(2H,s), 9.21(1H,s)

Preparation 114

[0185] To a suspension of 3-nitrophenylisothiocyanate (1.8g) and acetylhydrazine (740mg) in n-butanol was added 1,8-diazabicyclo[5.4.0]undeca-7-ene (0.36ml). The mixture was refluxed for 8 hours and evaporated. To the residue was added 1N hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration, washed with methanol and dried to give 5-methyl-4-(3-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-thione (1.56g).

APCI-mass;m/z237.33(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.14(3H,s), 7.87(1H,t,J=7.9Hz), 7.97(1H,dt,J=8.2Hz,1.6Hz), 8.3-8.5(2H,m), 13.77(1H, broad s)

Preparation 115

[0186] To a suspension of 5-methyl-4-(3-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-thione (1.0g) in acetic acid (20ml) was added a solution of sodium nitrite (1.17g) in water (6ml) dropwise at 5°C and the mixture was stirred at 100°C for 4.5 hours. The solvents were removed by evaporation and to the residue was added water. The solution was adjusted to pH 9.0 with 1N aqueous sodium hydroxide. The precipitate was collected by filtration, washed with water and dried to give 3-methyl-4-(3-nitrophenyl)-4H-1,2,4-triazole (564mg).

APCI-mass;m/z205(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.39(3H,s), 7.88(1H,t,J=8.0Hz), 8.03(1H,m), 8.37(1H,m), 8.43(1H,t,J=4.1Hz), 8.79(1H,s)

Preparation 116

[0187] This was prepared in a manner similar to Preparation 141 to give 3-(3-methyl-4H-1,2,4-triazol-4-yl)aniline.

APCI-mass;m/z175(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.31(3H,s), 5.49(2H,s), 6.5-6.6(2H,m), 6.67(1H,dd,J=7.9Hz, 1.8Hz), 7.17(1H,t,J=8.0Hz), 8.58(1H,s)

Preparation 117

[0188] This was prepared in a manner similar to Preparation 141 to give 4-methoxy-3-(5-pyrimidinyl)aniline.

APCI-mass;m/z202.27(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.66(3H,s), 4.82(2H,m), 6.6-6.8(2H,m), 6.91(1H,dd,J=7.2Hz, 2.1Hz), 8.86(2H,s), 9.10(1H, s)

Preparation 118

[0189] To a mixture of 2-(3-nitrophenyl)-1,3-dioxolane (12.8g), ammonium chloride (1.75g), ethyl alcohol (100ml) and water (50ml) were added Celite (12.8g) and iron powder (11.0g) under stirring at 70°C. The stirring was continued at reflux for 40 minutes. After cooling, the reaction mixture was diluted with ethyl acetate (250ml) and filtered through Celite. The filtrate was washed with saturated aqueous sodium hydrogen carbonate (200ml) and brine (100ml). The separated organic layer was dried over magnesium sulfate, decolorized with activated carbon and filtered. The solvent

EP 1 264 820 A1

was evaporated to give 3-(1,3-dioxolan-2-yl)aniline (9.76g) as oil.

MS:166(M+1)

NMR(DMSO, δ):3.8-4.1(4H,m), 5.10(2H,br s), 5.55(1H,s), 6.4-6.7(3H,m), 7.00(1H,t, J=7.7Hz)

5

Preparation 119

[0190] This was prepared in a manner similar to Example 156 to give N-[3-(1,3-dioxolan-2-yl)phenyl]-9H-fluorene-1-carboxamide (6.29g).

10

MS:358(M+1)

NMR(DMSO, δ):3.8-4.2(4H,m), 4.20(2H,br s), 5.75(1H,s), 7.18(1H,d,J=7.6Hz), 7.2-8.1(9H,m), 8.11(1H,d, J=7.0Hz), 10.40(1H,s)

15

Preparation 120

[0191] To a mixture of N-[3-(1,3-dioxolan-2-yl)phenyl]-9H-fluorene-1-carboxamide (5.90g) in tetrahydrofuran (110ml) was added 1N hydrochloric acid (20ml) at ambient temperature. After stirring for 3 hours, the reaction mixture was diluted with ethyl acetate (300ml) and washed with water (twice, 100ml), saturated aqueous sodium hydrogencarbonate (100ml) and brine (100ml). The organic layer was dried over magnesium sulfate and filtered. Evaporation gave a residue which was triturated with ethyl acetate (40ml) to give N-(3-formylphenyl)-9H-fluorene-1-carboxamide (4.44g) as pale brown crystals.

20

MS:314(M+1)

25

NMR(DMSO, δ):4.22(2H,br s), 7.3-7.9(7H,m), 7.9-8.2(3H,m), 8.45(1H,br s), 10.04 (1H,s), 10.63(1H,br s)

Preparation 121

[0192] This was prepared in a manner similar to Example 122 to give 2-chloro-N-(3-nitrobenzyl)-4-pyridylamine.

30

MS:264(M+1)

NMR(DMSO, δ):4.52(2H,d,J=6.2Hz), 6.5-6.7(2H,m), 7.5-7.9(4H,m), 8.0-8.3(2H,m)

Preparation 122

35

[0193] This was prepared in a manner similar to Preparation 118 to give N-(3-aminobenzyl)-N-(2-chloro-4-pyridyl) amine.

MS:234(M+1)

40

NMR(DMSO, δ):4.16(2H,d,J=5.8Hz), 5.06(2H,br s), 6.36-6.6(5H,m), 6.97(1H,t, J=7.6Hz), 7.39(1H,t,J=5.8Hz), 7.79(1H,d,J=5.8Hz)

Preparation 123

45

[0194] To a suspension of 2-chloro-N-(3-nitrobenzyl)-4-pyridylamine (264mg) in methanol (10ml) was added palladium on carbon(10%, 50% wet, 50mg), and the resultant mixture was hydrogenated under atmospheric pressure of hydrogen for 3 hours. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure to give N-(3-aminobenzyl)-N-(4-pyridyl)amine (232mg).

50

MS:200(M+1)

NMR(DMSO, δ):4.36(2H,d,J=5.8Hz), 6.4-6.6(3H,m), 6.7-7.2(3H,m), 8.15(2H,d, J=6.5Hz), 9.22(1H,t,J=5.8Hz)

Preparation 124

55

[0195] To a mixture of 1,1'-thiocarbonyldiimidazole (1.87g), imidazole (143mg), acetonitrile (27ml) were added a suspension of 3-nitrobenzylamine hydrochloride (1.32g) in acetonitrile (7ml) and imidazole (477mg) at 2~4°C. After stirring for 3 hours at ambient temperature, to the reaction mixture was added 4-fluoro-1,2-benzenediamine (1,77g) under stirring. The reaction mixture was stirred at 50°C for 3 hours, and at ambient temperature for 20 hours. The

EP 1 264 820 A1

reaction mixture was evaporated under reduced pressure to give a residue which was purified by silica gel chromatography and eluted with ethyl acetate-n-hexane=2/3 to give N-(2-amino-4-fluorophenyl)-N'-(3-nitrobenzyl)thiourea (2.28g).

5 MS:321(M+1)
NMR(DMSO, δ): 4.80(2H,d,J=5.9Hz), 5.17(2H,br s), 6.2-6.6(2H,m), 6.8-7.1(1H,m), 7.61(1H,t,J=7.9Hz), 7.78(1H,d,J=7.7Hz), 7.8-8.2(3H,m), 9.00(1H,br s)

Preparation 125

10 [0196] To a mixture of N-(2-amino-4-fluorophenyl)-N'-(3-nitrobenzyl)thiourea (2.03g) in toluene (50ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.82g) at ambient temperature. The mixture was heated at 110°C for 30 minutes. After cooling, the reaction mixture was diluted with ethyl acetate (50ml) and washed with 5%-aqueous sodium hydrogen carbonate (80ml), water (twice, 50ml each time) and brine (50ml). The organic layer was
15 dried over magnesium sulfate and filtered. Evaporation gave a residue which was purified by silica gel chromatography and eluted with ethyl acetate to give 5-fluoro-N-(3-nitrobenzyl)-1H-benzimidazol-2-amine (676mg) as crystals.

MS:287(M+1)
20 NMR(DMSO, δ): 4.64(2H,d,J=6.1Hz), 6.5-6.8(1H,m), 6.8-7.2(2H,m), 7.2-7.6(1H,m), 7.63(1H,t,J=7.9Hz), 7.83(1H,d,J=7.6Hz), 8.12(1H,d,J=8.2Hz), 8.24(1H,br s), 11.00 (1H,br s)

Preparation 126

[0197] This was prepared in a manner similar to Preparation 118 to give N'-(3-aminobenzyl)-5-fluoro-1H-benzimidazol-2-amine.
25

MS:257(M+1)
NMR(DMSO, δ): 4.35(2H,d,J=6.1Hz), 5.01(2H,br s), 6.3-6.8(4H,m), 6.8-7.2(4H,m)

30 Preparation 127

[0198] This was prepared in a manner similar to Preparation 124 to give N-(2-amino-4-methoxyphenyl)-N'-(3-nitrobenzyl)thiourea.

35 MS:333(M+1)
NMR(DMSO, δ): 3.67(3H,s), 4.79(2H,d,J=5.9Hz), 4.87(2H,br s), 6.18(1H,dd, J=2.7Hz,8.6Hz), 6.34(1H,d,J=2.7Hz), 6.84(1H,d,J=8.6Hz), 7.60(1H,t,J=7.8Hz), 7.7-7.9(2H,m), 8.0-8.2(2H,m), 8.95(1H,br s)

Preparation 128

40 [0199] This was prepared in a manner similar to Preparation 125 to give 5-methoxy-N-(3-nitrobenzyl)-1H-benzimidazol-2-amine.

MS:299(M+1)
45 NMR(DMSO, δ): 3.69(3H,s), 4.62(2H,d,J=6.0Hz), 6.4-6.6(1H,m), 6.73(1H,br s), 6.9-7.4(2H,m), 7.62(1H,t,J=7.9Hz), 7.84(1H,d,J=7.7Hz), 8.0-8.2(1H,m), 8.24(1H,br s), 10.7-10.9(1H,m)

Preparation 129

50 [0200] This was prepared in a manner similar to Preparation 118 to give N-(3-aminobenzyl)-5-methoxy-1H-benzimidazol-2-amine.

MS:269(M+1)
55 NMR(DMSO, δ): 3.69(3H,s), 4.33(2H,d,J=6.0Hz), 5.00(2H,br s), 6.3-6.6(4H,m), 6.72(1H,d,J=2.3Hz), 6.8-7.1(3H,m), 10.51(1H,br s)

EP 1 264 820 A1

Preparation 130

[0201] A mixture of 5-(3-fluoro-5-nitrophenyl)-1,2-dimethyl-1H-imidazole (400mg) and morpholine (5ml) was heated at reflux for 36 hours. After cooling, the reaction mixture was diluted with ethyl acetate (50ml) and washed with water (twice, 30ml each time). The separated organic layer was evaporated to give a residue which was triturated with isopropyl ether to give crude crystals. The crude crystals were dissolved in dichloromethane, dried over magnesium sulfate, decolorized with activated carbon, and then filtered. Evaporation gave a residue which was triturated with isopropyl ether to give 4-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-nitrophenyl] morpholine (327mg) as pure crystals.

MS:303(M+1)
NMR(DMSO, δ): 2.36(3H,s), 3.2-3.4(4H,m), 3.57(3H,s), 3.6-3.9(4H,m), 7.03(1H,s), 7.3-7.4(1H,m), 7.5-7.7(2H,m)

Preparation 131

[0202] To a mixture of 4-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-nitrophenyl] morpholine (320mg), activated carbon (480mg), and tetrahydrofuran (4.8ml) were added iron (III) chloride hexahydrate (32mg) and hydrazine monohydrate (0.48ml). The mixture was heated at 80°C for 1 hour. After cooling, the reaction mixture was evaporated. The resultant residue was diluted with ethyl acetate (50ml) and washed with water (twice, 40ml each time) and brine (30ml). The separated organic layer was dried over magnesium sulfate and filtered. The solvent was evaporated to give 3-(1,2-dimethyl-1H-imidazol-5-yl)-5-(4-morpholinyl)aniline (277mg) as crystals.

MS:273(M+1)
NMR(DMSO, δ): 2.31(3H,s), 2.9-3.1(4H,m), 3.48(3H,s), 3.6-3.8(4H,m), 5.03(2H,br s), 6.0-6.2(3H,m), 6.71(1H,s)

Preparation 132

[0203] A solution of 3,5-diaminobenzene (3.0g) in formic acid (30ml) was refluxed for 12 hours. After cooling, the mixture was poured into ice-water and stirred for 10 minutes. The precipitate was collected by filtration, washed with water and dried to give N-(3-chloro-5-formylaminophenyl)formamide (3.64g).

APCI-mass;m/z199.07(M+H⁺)
¹H-NMR(DMSO-d₆): δ ;7.48(2H,s), 7.73(1H,s), 8.28(2H,s), 10.41(2H,s)

Preparation 133

[0204] A suspension of 3,5-dinitrobenzonitrile (2.75g) in methanol (15ml) and tetrahydrofuran (15ml) was hydrogenated over 10 % palladium on carbon (50% wet) under hydrogen atmosphere for 6 hours. The catalyst was filtered off. The filtrate was concentrated, purified with silica gel column chromatography and eluted with dichloromethane in 0-1% methanol to give 3-cyano-5-nitroaniline (951mg).

ESI-mass;m/z162.3(M-H⁺)
¹H-NMR(DMSO-d₆): δ ;6.33(2H,s), 7.24(1H,s), 7.6-7.8(2H,m)

Preparation 134

[0205] This was prepared in a manner similar to Preparation 132 to give N-formyl-3-cyano-5-nitroaniline.

APCI-mass;m/z190.20(M-H⁺)
¹H-NMR(DMSO-d₆): δ ;8.32(1H,s), 8.44(2H,m), 8.76(1H,s), 10.94(1H,s)

Preparation 135

[0206] To a suspension of N-formyl-3-cyano-5-nitroaniline (994mg) and potassium carbonate (862mg) in N,N-dimethylformamide (10ml) was added 2-bromo-3-butanone (864mg) and the mixture was stirred for 2 hours. The mixture was diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate and evaporated.

[0207] To the residue was added ammonium acetate (4.01g) and acetic acid (1ml) in xylene (20ml) was refluxed for 30 minutes. To the mixture was added ethyl acetate and an 1N aqueous solution of sodium hydroxide (100ml) and the mixture was refluxed for 10 minutes. The aqueous layer was separated and washed with water and brine, dried over

EP 1 264 820 A1

magnesium sulfate and evaporated. The residue was purified with column chromatography with silica gel (25g), and eluted with 2% methanol/dichloromethane to give 4,5-dimethyl-1-(3-cyano-5-nitrophenyl)imidazole (0.81g).

APCI-mass;m/z243.13(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.16(3H,s), 7.87(1H,s), 8.50(1H,t,J=1.7Hz), 8.55(1H,m), 8.81 (1H,t,J=1.7Hz)

Preparation 136

[0208] To a suspension of N-(3-chloro-5-formylamino-phenyl)formamide (1g) in N,N-dimethylformamide (10ml) was added 60% sodium hydride in mineral oil dispersion (201mg) and the mixture was stirred for 30 minutes. To the mixture was added 2-bromo-3-butanone (760mg) in N,N-dimethylformamide (5ml) and the mixture was stirred for 2 hours. The mixture was diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate and evaporated to give N-[3-chloro-5-[formyl-(1-methyl-2-oxo-propyl)amino]phenyl]formamide (560mg).

APCI-mass;m/z268.73(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;1.32(3H,d,J=7.1Hz), 2.14(3H,s), 4.66(1H,q,J=7.1Hz), 7.1-7.3 (2H,m), 7.42(1H,s), 7.73 (1H,s), 8.3-8.5(2H,m), 10.51(1H,s)

Preparation 137

[0209] A suspension of N-[3-chloro-5-[formyl-(1-methyl-2-oxo-propyl)amino]phenyl]formamide (443mg), ammonium acetate (1.27g) and acetic acid (0.5ml) in xylene (10ml) was stirred at 130°C for 30 minutes. To the mixture was added ethyl acetate and 1N aqueous solution of sodium hydroxide (100ml) and the mixture was stirred for 10 minutes. The aqueous layer was separated and washed with water and brine, dried over magnesium sulfate and evaporated. The residue was dissolved in 6N hydrochloric acid (1ml) and methanol (1ml) and the solution was stirred for 1 hour. To the mixture was added aqueous sodium hydroxide (1N, 10ml) and ethyl acetate (20ml). The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated. The residue was triturated with isopropyl ether, collected by filtration and dried to give 4,5-dimethyl-1-(3-chloro-5-aminophenyl)imidazole (287mg).

APCI-mass;m/z222.33,224.37(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.06(3H,s), 2.08(3H,s), 5.75(2H,s), 6.44(1H,t,J=1.9Hz), 6.52 (1H,t,J=1.9Hz), 6.64(1H,t,J=1.9Hz), 7.58(1H,s)

Preparation 138

[0210] To a suspension of 4,5-dimethyl-1-(3-cyano-5-nitrophenyl)imidazole (125mg), iron(III) chloride (8mg) and charcoal (120mg) in tetrahydrofuran (1ml) was added hydrazine hydrate (0.15ml) and the mixture was stirred at 80°C for 1 hour. The catalyst was filtered off, and the filtrate was diluted with ethyl acetate. The solution was washed with 1N aqueous sodium hydroxide and brine. The organic layer was dried over magnesium sulfate and evaporated to give 4,5-dimethyl-1-(3-cyano-5-aminophenyl)imidazole (106mg).

APCI-mass;m/z213.20(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.07(3H,s), 2.08(3H,s), 5.94(2H,s), 6.79(1H,t,J=2.0Hz), 6.9-7.2(2H,m), 7.62(1H,s)

Preparation 139

[0211] A suspension of 3,5-dinitroaniline (5.0g) in methanol (25ml) and tetrahydrofuran (25ml) was hydrogenated over 10 % palladium on carbon (50% wet) under hydrogen atmosphere for 7 hours. The catalyst was filtered off and the filtrate was concentrated. To the residue was added formic acid (50ml) and the mixture was refluxed for 1 hour. After cooling, the mixture was poured into water. The precipitate was collected by filtration and dried. The precipitate was purified with column chromatography with silica gel (50g), and eluted with 30-50% ethyl acetate in hexane to give N-formyl-3-methoxy-5-nitroaniline (1.73g).

APCI-mass;m/z195.07(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.89(3H,s), 7.4-7.6(2H,m), 8.14(1H,t,J=1.9Hz), 8.37(1H,s), 10.63(1H,s)

EP 1 264 820 A1

Preparation 140

[0212] This was prepared in a manner similar to Preparation 135 to give 4,5-dimethyl-1-(3-methoxy-5-nitrophenyl)imidazole.

APCI-mass;m/z248.20(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.12(3H,s), 2.14(3H,s), 3.94(3H,s), 7.50(1H,t,J=2.1Hz), 7.7-7.9(2H,m)

Preparation 141

[0213] A suspension of 4,5-dimethyl-1-(3-methoxy-5-nitrophenyl)imidazole (500mg) in methanol (10ml) was hydrogenated over 10% palladium on carbon (50% wet, 100mg) under hydrogen atmosphere for 3 hours. The catalyst was filtered off and the filtrate was concentrated to give 4,5-dimethyl-1-(3-methoxy-5-aminophenyl)imidazole.

APCI-mass;m/z218.33(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.06(3H,s), 2.08(3H,s), 3.69(3H,s), 5.41(2H,s), 6.04(1H,t, J=2.0Hz), 6.09(1H,t,J=2.0Hz), 6.18(1H,t,J=2.0Hz), 7.52(1H,s)

Preparation 142

[0214] To a suspension of 4-methyl-1-(3-nitrophenyl)-1H-imidazole (3.2g) in acetonitrile (2ml) was added N-chlorosuccinimide (2.73g) and the mixture was stirred at 70°C for 6 hours. The mixture was diluted with ethyl acetate, washed with 1N aqueous sodium hydroxide, water and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was purified with column chromatography with silica gel (50g), and eluted with 30% ethyl acetate in n-hexane to give 5-chloro-4-methyl-1-(3-nitrophenyl)-1H-imidazole (642mg).

APCI-mass;m/z238.27(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.18(3H,s), 7.8-8.1(2H,m), 8.08(1H,s), 8.3-8.5(2H,m)

Preparation 143

[0215] This was prepared in a manner similar to Preparation 138 to give 3-(5-chloro-4-methyl-1H-imidazol-1-yl)aniline.

APCI-mass;m/z208.20,210.13(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.13(3H,s), 5.47(2H,s), 6.5-6.7(3H,m), 7.15(1H,t,J=7.9Hz), 7.80(1H,s)

Preparation 144

[0216] A mixture of 2-chloro-3-methyl-5-nitropyridine (967mg) and 2-pyridylmethanamine (1.7ml) in tetrahydrofuran (10ml) was stirred for 18 hours. The mixture was poured into water and stirred for 1 hour. The precipitated solid was collected by filtration, washed with water, and dried to give 3-methyl-5-nitro-N-(2-pyridylmethyl)-2-pyridinamine (985mg).

APCI-mass;m/z245(M+1)

NMR(200MHz,DMSO-d₆): δ ;2.25(3H,s), 4.79(2H,d,J=5.9Hz), 7.23(1H,d,J=7.4Hz), 7.26(1H,d,J=7.7Hz), 7.71(1H,td,J=7.7Hz,1.8Hz), 8.01(1H,t,J=5.9Hz), 8.08(1H,t, J=2.6Hz), 8.49-8.53(1H,m), 8.77(1H,d,J=2.6Hz)

Preparation 145

[0217] A suspension of 3-methyl-5-nitro-N-(2-pyridylmethyl)-2-pyridinamine (970mg) in methanol (15ml) and tetrahydrofuran (15ml) was hydrogenated over palladium (10% w/w, 50% wet, 450mg) on carbon under hydrogen atmosphere for 5 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give 3-methyl-N²-(2-pyridylmethyl)-2,5-pyridyldiamine (851mg).

APCI-mass;m/z215(M+1)

NMR(200MHz,DMSO-d₆): δ ;2.07(3H,s), 4.24(2H,s), 4.53(2H,d,J=5.8Hz), 5.75(1H,t, J=5.8Hz), 6.73(1H,d, J=2.6Hz), 7.16-7.28(3H,m), 7.66(1H,td,J=7.6Hz,1.8Hz), 8.47(1H, d,J=4.0Hz)

EP 1 264 820 A1

Preparation 146

[0218] A mixture of 2-chloro-5-nitro-3-(trifluoromethyl)pyridine (226mg) and 2-pyridylmethanamine (0.2ml) in tetrahydrofuran (2.0ml) was stirred for 18 hours. The mixture was poured into water and stirred for 1 hour. The precipitated solid was collected by filtration, washed with water, and dried to give 5-nitro-N-(2-pyridylmethyl)-3-(trifluoromethyl)-2-pyridinamine (277mg).

APCI-mass;m/z299(M+1)

NMR(200MHz,DMSO-d6): δ ;4.86(2H,s), 7.24(1H,d,J=7.6Hz), 7.27(1H,d,J=5.1Hz), 7.75(1H,td,J=7.6Hz,1.8Hz), 8.46(1H,s), 8.47(1H,s), 8.51(1H,dd,J=6.3Hz,1.6Hz), 9.08(1H,d,J=2.6Hz)

Preparation 147

[0219] A suspension of 5-nitro-N-(2-pyridylmethyl)-3-(trifluoromethyl)-2-pyridinamine (265mg) in methanol (3.0ml) and tetrahydrofuran (3.0ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 82mg) under hydrogen atmosphere for 3 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give N²-(2-pyridylmethyl)-3-(trifluoromethyl)-2,5-pyridyldiamine (240mg).

APCI-mass;m/z269(M+1)

NMR(200MHz,DMSO-d6): δ ;4.59(2H,d,J=5.4Hz), 4.74(2H,s), 6.27(1H,t,J=5.4Hz), 7.19(1H,s), 7.20(1H,s), 7.25(1H,s), 7.70(2H,td,J=7.6Hz,1.7Hz), 8.49(1H,d,J=4.6Hz)

Preparation 148

[0220] A mixture of 2-chloro-5-nitropyridine (650mg), N-methyl (2-pyridyl) methanamine (600mg) and triethylamine (0.7ml) in tetrahydrofuran (6ml) was stirred for 18 hours. The mixture was poured into water and stirred for 1 hour. The precipitated solid was collected by filtration, washed with water, and dried to give N-methyl-5-nitro-N-(2-pyridylmethyl)-2-pyridinamine (563mg).

APCI-mass;m/z245(M+1)

NMR(200MHz,DMSO-d6): δ ;3.27(3H,s), 5.01(2H,s), 6.83(1H,d,J=9.5Hz), 7.23(1H,d, J=7.4Hz), 7.28(1H,dd, J=7.5Hz,4.9Hz), 7.76(1H,td,J=7.7Hz,1.8Hz), 8.23(1H,dd, J=9.5Hz,2.8Hz), 8.51(1H,d,J=4.1Hz), 8.95(1H,d, J=2.8Hz)

Preparation 149

[0221] A suspension of N-methyl-5-nitro-N-(2-pyridylmethyl)-2-pyridinamine (200mg) in methanol (3.0ml) and tetrahydrofuran (3.0ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 93mg) under hydrogen atmosphere for 3 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give N²-methyl-N²-(2-pyridylmethyl)-2,5-pyridyldiamine (174mg).

APCI-mass;m/z215(M+1)

NMR(200MHz,DMSO-d6): δ ;2.97(3H,s), 4.41(2H,br), 4.70(2H,s), 6.47(1H,d, J=8.7Hz), 6.91(1H,dd,J=5.8Hz, 2.8Hz), 7.07(1H,d,J=7.8Hz), 7.21(1H,dd,J=6.4Hz, 4.9Hz), 7.55(1H,d,J=2.4Hz), 7.67(1H,td,J=7.7Hz,1.8Hz), 8.48(1H,d,J=2.8Hz)

Preparation 150

[0222] A mixture of N-methyl-5-nitro-N-(2-pyridylmethyl)-2-pyridinamine (194mg) and N-chlorosuccinimide (135mg) in acetonitrile (2.5ml) was stirred at 60°C under nitrogen atmosphere for 4 hours. The mixture was diluted with dichloromethane, washed with 1N aqueous solution of sodium hydroxide (30ml), water and brine, dried over magnesium sulfate and evaporated under reduced pressure to give 3-chloro-N-methyl-5-nitro-N-(2-pyridylmethyl)-2-pyridinamine (216mg).

APCI-mass;m/z279(M+1)

NMR(200MHz,DMSO-d6): δ ;3.32(3H,s), 5.03(2H,s), 7.26-7.35(2H,m), 7.77(1H,td, J=7.7Hz,1.8Hz), 8.40(1H,d, J=2.4Hz), 8.51(1H,dt,J=3.8Hz,0.8Hz), 8.91(1H,d,J=2.4Hz)

EP 1 264 820 A1

Preparation 151

[0223] To a suspension of 3-chloro-N-methyl-5-nitro-N-(2-pyridylmethyl)-2-pyridinamine (200mg) and activated carbon (330mg) in tetrahydrofuran (4.0ml) was added iron(III) chloride hexahydrate (20mg) and hydrazine monohydrate (0.4ml) and refluxed for 2 hours. After cooling, the reaction mixture was evaporated under reduced pressure. The residue was diluted with ethyl acetate, washed with water and brine, then dried over magnesium sulfate and evaporated under reduced pressure to give 3-chloro-N²-methyl-N²-(2-pyridylmethyl)-2,5-pyridyldiamine (185mg).

APCI-mass;m/z249(M+1)
NMR(200MHz,DMSO-d₆): δ ;2.66(3H,s), 4.29(2H,s), 5.15(2H,s), 7.07(1H,d,J=2.5Hz), 7.20-7.26(1H,m), 7.44(1H,d,J=7.8Hz), 7.59(1H,d,J=2.5Hz), 7.74(1H,td,J=7.7Hz, 1.8Hz), 8.45-8.48(1H,m)

Preparation 152

[0224] A mixture of 2-chloro-5-nitropyridine (665mg), (4-methyl-2-pyridyl) methanamine (1.0g) and triethylamine (0.53ml) in tetrahydrofuran (8ml) was stirred for 18 hours. The mixture was diluted with ethyl acetate, washed with water, saturated aqueous solution of sodium hydrogen carbonate and brine, then dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (silica gel 100g, eluting with 1-4% methanol/dichloromethane) to give N-[(4-methyl-2-pyridyl)methyl]-5-nitro-2-pyridinamine (300mg).

APCI-mass;m/z245(M+1)
NMR(200MHz,DMSO-d₆): δ ;2.29(3H,s), 4.80(2H,d,J=5.3Hz), 6.71(1H,d,J=8.8Hz), 7.11(1H,d,J=5.1Hz), 7.16(1H,s), 8.15(1H,dd,J=9.4Hz,2.8Hz), 8.38(1H,d,J=5.0Hz), 8.63(1H,t,J=5.3Hz), 8.90(1H,d,J=2.8Hz)

Preparation 153

[0225] A suspension of N-[(4-methyl-2-pyridyl)methyl]-5-nitro-2-pyridinamine (150mg) in methanol (2.0ml) and tetrahydrofuran (2.0ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 56mg) under hydrogen atmosphere for 6 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give N²-[(4-methyl-2-pyridyl)methyl]-2,5-pyridyldiamine (133mg).

APCI-mass;m/z215(M+1)
NMR(200MHz,DMSO-d₆): δ ;2.25(3H,s), 4.29(2H,br), 4.38(2H,d,J=6.1Hz), 6.17(1H,t, J=6.1Hz), 6.36(1H,d, J=8.6Hz), 6.82(1H,dd,J=2.8Hz,8.6Hz), 7.04(1H,d,J=5.0Hz), 7.13 (1H,s), 7.42(1H,d,J=2.7Hz), 8.33(1H,d,J=5.0Hz)

Preparation 154

[0226] A mixture of 2-chloro-5-nitropyridine (1.35g), (3-methyl-2-pyridyl) methanamine (4.2g) and triethylamine (4.7ml) in tetrahydrofuran (20ml) was stirred for 18 hours. The mixture was poured into water and stirred for 1 hour. The precipitated solid was collected by filtration, washed with water, triturated with diisopropyl ether and methanol, and dried to give N-[(3-methyl-2-pyridyl)methyl]-5-nitro-2-pyridinamine (776mg).

APCI-mass;m/z245(M+1)
NMR(200MHz,DMSO-d₆): δ ;2.34(3H,s), 4.71(2H,d,J=4.9Hz), 6.79(1H,d,J=9.2Hz), 7.24(1H,dd,J=7.6Hz,4.8Hz), 7.61(1H,dd,J=7.6Hz,0.8Hz), 8.13(1H,dd,J=9.3Hz,2.7Hz), 8.37(1H,dd,J=4.8Hz,1.1Hz), 8.48(1H,br) 8.92(1H,d, J=2.7Hz)

Preparation 155

[0227] A suspension of N-[(3-methyl-2-pyridyl)methyl]-5-nitro-2-pyridinamine (200mg) in methanol (3.0ml) and tetrahydrofuran (3.0ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 90mg) under hydrogen atmosphere for 3 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give N²-[(3-methyl-2-pyridyl)methyl]-2,5-pyridyldiamine (147mg).

APCI-mass;m/z215(M+1)
NMR(200MHz,DMSO-d₆): δ ;2.31(3H,s), 4.31(2H,br), 4.40(2H,d,J=5.1Hz), 5.98(1H,t, J=5.1Hz), 6.49(1H,d, J=8.6Hz), 6.85(1H,dd,J=8.6Hz,2.8Hz), 7.20(1H,dd,J=7.5Hz, 4.8Hz), 7.49(1H,d,J=2.6Hz), 7.57(1H,d,J=7.4Hz), 8.36(1H,d,J=4.8Hz)

EP 1 264 820 A1

Preparation 156

[0228] A mixture of 2-chloro-5-nitropyridine (1.0g), [3-chloro-5-(trifluoromethyl)-2-pyridyl]methanamine hydrochloride (1.86g) and triethylamine (1.7ml) in tetrahydrofuran (10ml) was stirred for 18 hours. The mixture was poured into water and stirred for 1 hour. The precipitated solid was collected by filtration, washed with water, and dried to give N-[[3-chloro-(5-trifluoromethyl)-2-pyridyl]methyl]-5-nitro-2-pyridinamine (1.12g).

APCI-mass;m/z333(M+1)

NMR(200MHz,DMSO-d6): δ ;4.94(2H,d,J=5.6Hz), 6.79(2H,d,J=9.0Hz), 8.16(1H,dd J=9.3Hz,2.8Hz), 8.49(1H,s), 8.66(1H,br 8.87(1H,d,J=2.8Hz 8.89(1H,s)

Preparation 157

[0229] A suspension of N-[[3-chloro-(5-trifluoromethyl)-2-pyridyl]methyl]-5-nitro-2-pyridinamine (300mg) in methanol (3.0ml) and tetrahydrofuran (3.0ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 85mg) under hydrogen atmosphere for 6 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give N²-[[3-chloro-(5-trifluoromethyl)-2-pyridyl]methyl]-2,5-pyridyldiamine (315mg).

APCI-mass;m/z303(M+1)

NMR(200MHz,DMSO-d6): δ ;4.72(2H,s), 6.55(2H,br), 6.70(1H,d,J=8.9Hz), 7.03-7.15 (3H,m), 7.52(1H,d, J=8.3Hz), 8.88(1H,s)

Preparation 158

[0230] A mixture of 2-chloro-5-nitropyridine (1.0g) and 3-pyridylmethanamine (1.28ml) in tetrahydrofuran (10ml) was stirred for 18 hours. The mixture was poured into water and stirred for 1 hour. The precipitated solid was collected by filtration, washed with water, and dried to give 5-nitro-N-(3-pyridylmethyl)-2-pyridinamine (1.08g).

APCI-mass;m/z231(M+1)

NMR(200MHz,DMSO-d6): δ ;4.65(2H,d,J=5.8Hz), 6.65(1H,d,J=9.3Hz), 7.36(1H,dd, J=7.7Hz,4.8Hz), 7.73(1H,dd, J=1.8Hz,7.8Hz), 8.15(1H,dd,J=9.3Hz,2.8Hz), 8.47(1H,dd, J=4.8Hz,1.5Hz), 8.57(1H,d,J=1.9Hz), 8.62(1H,t, J=5.7Hz), 8.92(1H,d,J=2.8Hz)

Preparation 159

[0231] A suspension of 5-nitro-N-(3-pyridylmethyl)-2-pyridinamine (400mg) in methanol (5.0ml) and tetrahydrofuran (5.0ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 160mg) under hydrogen atmosphere for 6 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give N²-(3-pyridylmethyl)-2,5-pyridyldiamine (330mg).

APCI-mass;m/z201(M+1)

NMR(200MHz,DMSO-d6): δ ;4.31(2H,br), 4.36(2H,d,J=6.2Hz), 6.21(1H,t,J=6.2Hz), 6.34(1H,d,J=8.6Hz), 6.82(1H, dd,J=8.6Hz,2.8Hz), 7.29(1H,dd,J=7.8Hz,4.8Hz), 7.43 (1H,d,J=2.7Hz), 7.69(1H,d,J=7.8Hz), 8.40(1H,dd,J=4.8Hz, 1.5Hz), 8.52(1H,d,J=1.9Hz)

Preparation 160

[0232] A mixture of 2-chloro-5-nitropyridine (1.0g) and 2-(2-pyridyl)ethylamine (1.66ml) in tetrahydrofuran (6.5ml) was stirred for 18 hours. The mixture was poured into water and stirred for 1 hour. The precipitated solid was collected by filtration, washed with water, and dried to give 5-nitro-N-[2-(2-pyridyl)ethyl]-2-pyridinamine (1.5g).

APCI-mass;m/z245(M+1)

NMR(200MHz,DMSO-d6): δ ;3.02(2H,t,J=7.3Hz), 3.78(2H,br), 6.55(1H,d,J=9.4Hz), 7.23(1H,dd,J=7.6Hz,4.8Hz), 7.28(1H,d,J=7.9Hz), 7.71(1H,td,J=7.7Hz,1.8Hz), 8.09 (1H,d,J=7.2Hz), 8.21(1H,br), 8.51(1H,d,J=4.8Hz), 8.92(1H, d,J=2.7Hz)

EP 1 264 820 A1

Preparation 161

5 **[0233]** A suspension of 5-nitro-N-[2-(2-pyridyl)ethyl]-2-pyridinamine (200mg) in methanol (3.0ml) and tetrahydrofuran (3.0ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 80mg) under hydrogen atmosphere for 3 hours. The catalyst was filtered off, and the filtrate was evaporated under reduced pressure to give N²-[2-(2-pyridyl)ethyl]-2,5-pyridyldiamine (184mg).

APCI-mass;m/z215(M+1)

10 NMR(200MHz,DMSO-d₆): δ ;2.93(2H,t,J=7.4Hz), 3.47(2H,td,J=7.4Hz,5.9Hz), 4.27 (2H,s), 5.60(1H,t,J=5.9Hz), 6.29(1H,d,J=8.6Hz), 6.81(1H,dd,J=8.6Hz,2.8Hz), 7.20(1H, dd,J=7.5Hz,4.9Hz), 7.25(1H,d,J=8.6Hz), 7.47(1H,d,J=2.7Hz), 7.68(1H,td,J=7.6Hz, 1.9Hz), 8.48(1H,d,J=4.0Hz)

Preparation 162

15 **[0234]** To a solution of 5-chloro-1,3-benzenediamine (1.43g) in tetrahydrofuran (10ml) at 0°C under nitrogen atmosphere was added n-butyl lithium (5.8ml) in hexane dropwise. A precipitate appeared. Stirred for 30 minutes and added 3-chloro-1,2-benzisoxazole (0.77g) all at once. After 1 hour at 0°C, removed the cold bath and stirred at room temperature for 1 hour until all dissolved to give a clear, black solution. Added water (10ml) dropwise, ethyl acetate (100ml), water (100ml), and separated. Washed with water (50ml) plus 1N hydrochloric acid (2ml, three times), saturated aqueous sodium hydrogen carbonate (twice), brine, dried over magnesium sulfate, filtered, and evaporated. Purified by silica gel column chromatography (dichloromethane/methanol) and then recrystallized from dichloromethane to give N-1-(1,2-benzisoxazol-3-yl)-5-chloro-1,3-benzenediamine (0.63g) as green crystals.

mp:192-194°C

25 MS:260(M+1)

NMR(DMSO, δ):5.49(2H,s), 6.23(1H,dd,J=1.8Hz,1.8Hz), 6.92(2H,s), 7.32-7.41 (1H,m), 7.58-7.70(2H,m), 8.13 (1H,d,J=7.9Hz), 9.42(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.05}:C;59.92,H;3.91,N;16.12

30 Found:C;60.15,H;4.02,N;15.76

Preparation 163

35 **[0235]** This was prepared in a manner similar to Preparation 13 to give methyl 4-(4-acetyl-1-piperazinyl)benzene-carbimidothioate hydroiodide.

MS:278(free+1)

NMR(DMSO, δ):2.05(3H,s), 2.77(3H,s), 3.4-3.7(8H,m), 7.08(2H,d,J=9.1Hz), 7.84(2H, d,J=9.1Hz)

Preparation 164

40 **[0236]** To a suspension of 7-chloro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (157mg) in dichloromethane (3ml) was added oxalyl chloride (0.16ml) and N,N-dimethylformamide (1drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-aminopyridine (66mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was recrystallized from methanol-isopropyl ether and collected by filtration to give 7-chloro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid pyridine-3-ylamide (168mg).

APCI-mass;m/z301(M+H⁺)

55 ¹H-NMR(DMSO-d₆): δ ;2.98(2H,t,J=4.3Hz), 4.27(2H,t,J=4.6Hz), 7.01(1H,d,J=8.7Hz), 7.2-7.5(3H,m), 7.56(1H,d,J=2.6Hz), 8.11(1H,dq,J=8.3Hz,1.5Hz), 8.29(1H,dd,J=4.7Hz, 1.4Hz), 8.85(1H,d,J=2.1Hz), 10.16(1H,s)

Preparation 165

[0237] To a suspension of 8-methoxy-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (103mg) in dichloromethane

EP 1 264 820 A1

(1ml) was added oxalyl chloride (0.1ml) and N,N-dimethylformamide (1drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-aminopyridine (49mg) in dichloromethane (2ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (2ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol and isopropyl ether to give 8-methoxy-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid pyridine-3-ylamide (103mg).

APCI-mass;m/z297(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.94(2H,t,J=4.6Hz), 3.77(3H,s), 4.26(2H,t,J=4.6Hz), 6.55(1H, d,J=2.5Hz), 6.68(1H,dd, J=2.3Hz,8.6Hz), 7.26(1H,s), 7.3-7.5(2H,m), 8.10(1H,d, J=8.4Hz), 8.27(1H,d,J=3.4Hz), 8.85(1H,d,J=2.3Hz), 10.06(1H,s)

Preparation 166

[0238] To a suspension of 8-methoxy-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (103mg) in dichloromethane (1ml) was added oxalyl chloride (0.1ml) and N,N-dimethylformamide (1drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-aminopyridine (49mg) in dichloromethane (2ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (2ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol and isopropyl ether to give 8-methoxy-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid pyridine-4-ylamide (62mg).

APCI-mass;m/z297(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.93(2H,t,J=4.5Hz), 3.77(3H,s), 4.26(2H,t,J=4.6Hz), 6.55(1H, d,J=2.5Hz), 6.69(1H,dd, J=2.6Hz,8.4Hz), 7.25(1H,s), 7.38(1H,d,J=8.6Hz), 7.68(2H,d, J=6.1Hz), 8.43(2H,d,J=6.1Hz), 10.21(1H,s)

Preparation 167

[0239] This was prepared in a manner similar to Preparation 16 to give (2E)-N-(3-amino-5-chlorophenyl)-3-(1H-indole-3-yl)-2-propenamide.

MS:312(M+1)

NMR(DMSO, δ):5.43(2H,s), 6.28(1H,dd,J=1.9Hz,1.9Hz), 6.77(1H,d,J=15.6Hz), 6.82(1H,dd,J=1.9Hz,1.9Hz), 7.02(1H,dd,J=1.9Hz,1.9Hz), 7.18-7.25(2H,m), 7.44-7.50 (1H,m), 7.74(1H,d,J=15.6Hz) 7.83(1H,s), 7.91-7.97(1H,m), 9.81(1H,s), 11.64(1H,s)

Preparation 168

[0240] To a suspension of 5-bromonicotinic acid (1.01g) and triethylamine (0.73ml) in tert-butanol (15ml) was added diphenylphosphoryl azide (1.08ml). The mixture was refluxed for 6 hours and diluted with ethyl acetate. The solution was washed with water, aqueous solution of sodium hydrogen carbonate, and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified with column chromatography with silica gel (50g), and eluted with 2% methanol in dichloromethane to give 3-bromo-5-tert-butoxycarbonylaminopyridine (1.12g).

ESI-mass;m/z295(M+Na⁺)

¹H-NMR(DMSO-d₆): δ ;1.53(9H,s), 6.78(1H,broad s), 8.34(3H,s)

Preparation 169

[0241] To a suspension of 3-bromo-5-tert-butoxycarbonylaminopyridine (410mg), diethyl(3-pyridyl)borane (287mg), tetrakis(triphenylphosphine)palladium (87mg), and tetra-n-butylammonium bromide (48mg) in tetrahydrofuran (10ml) was added powdered potassium carbonate (297mg) and the mixture was refluxed for 12 hours. After cooling, the mixture was diluted with ethyl acetate, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified with column chromatography with silica gel (25g), and eluted with 5% methanol in dichloromethane to give [3,3']bipyridyl-5-yl-carbamic acid tert-

EP 1 264 820 A1

butyl ester (201mg).

ESI-mass; m/z 294($M+Na^+$)

1H -NMR(DMSO- d_6): δ :1.54(9H,s), 6.83(1H,broad s), 7.3-7.5(1H,m), 7.91(1H,dt, $J=8.0$ Hz, $J=2.0$ Hz), 8.30(1H,s),
5 8.43(1H,d, $J=2.5$ Hz), 8.51(1H,d, $J=2.0$ Hz), 8.65(1H,dd, $J=4.9$ Hz, $J=1.6$ Hz), 8.87(1H,d, $J=1.7$ Hz)

Preparation 170

[0242] To a solution of [3,3']bipyridyl-5-yl-carbamic acid tert-butyl ester (100mg) in methanol (1ml) was added 12N
10 hydrochloric acid (0.5ml). The mixture was stirred for 18 hours and evaporated under reduced pressure. The residue
was triturated with isopropyl ether, filtered and dried to give 3-amino-5-(pyridine-3-yl)pyridine dihydrochloride (84mg).

ESI-mass; m/z 172(M (free)+ H^+)

1H -NMR(DMSO- d_6): δ :7.9-8.1(3H,m), 8.14(1H,d, $J=2.3$ Hz), 8.50(1H,d, $J=1.4$ Hz), 8.55(1H,d, $J=8.6$ Hz), 8.87(1H,
15 dd, $J=5.4$ Hz,1.4Hz), 9.16(1H,d, $J=1.8$ Hz)

Preparation 171

[0243] To a solution of 9H-fluorene-1-carboxylic acid (0.49g) in dichloromethane (2ml) were added in turn oxalyl
20 chloride (0.4ml) and a catalytic amount of N,N-dimethylformamide (2drops) at ambient temperature. After stirring at
ambient temperature for 1 hour, the reaction mixture was evaporated in vacuo, and the residue was added in dichlo-
romethane (5ml) to give a solution of 9H-fluorene-1-carboxyl chloride. To a solution of 5-amino-methyl nicotinic acid
(0.53g) in dichloromethane (5ml) were added pyridine (1.0ml) and the acid chloride solution at 0°C. After stirring at
25 0°C for 1 hour, the reaction mixture was diluted with dichloromethane, washed with aqueous potassium carbonate
(10%) and brine, and dried over potassium carbonate. Evaporation gave a residue which was triturated with diisopropyl
ether to give 5-[(9H-fluorene-1-carbonyl)-amino]-nicotinic acid methyl ester (0.492g).

APCI-mass;345(m/z , $[M+H]^+$)

NMR(DMSO- d_6 ,d);4.23(2H,s), 4.61(2H,brs), 7.35-7.44(2H,m), 7.55-7.66(2H,m), 7.82 (1H,d, $J=7.6$ Hz), 7.99(1H,d,
30 $J=6.4$ Hz), 8.16(1H,d, $J=7.2$ Hz), 8.80-8.89(2H,m), 9.17(1H, d, $J=2.4$ Hz), 10.77(1H,s)

Preparation 172

[0244] To a solution of 5-[(9H-fluorene-1-carbonyl)-amino]-nicotinic acid methyl ester (0.105g) in methanol (3ml) was
35 added hydrazine monohydrate (0.56ml), and the mixture was heated at reflux for 6 hours. After cooling to ambient
temperature, the resultant precipitate was collected by filtration, washed with methanol to give 9H-fluorene-1-carbox-
ylic acid (5-hydrazinocarbonyl-pyridine-3-yl)-amide (85mg).

APCI-mass;345(m/z , $[M+H]^+$)

NMR(DMSO- d_6 ,d);4.23(2H,s), 4.61(2H,brs), 7.35-7.50(2H,m), 7.55-7.67(2H,m), 7.80 (1H,d, $J=7.6$ Hz), 7.98(1H,d,
40 $J=6.7$ Hz), 8.15(1H,d, $J=6.8$ Hz), 8.63-8.66(1H,m), 8.72(1H, d, $J=1.8$ Hz), 9.06(1H,d, $J=2.4$ Hz), 10.00(1H,s) 10.68
(1H,s)

Example 1

[0245] A mixture of S-methyl benzothioimide hydriodide and N-(3-aminophenyl) phenylacetamide in methanol was
45 heated at reflux. The most amine was used in 4 hours. The mixture was cooled, diluted with water, added 1N sodium
hydroxide, then, extracted with dichloromethane/methanol (10:1) (twice). The combined organic layer was dried over
magnesium sulfate, filtered, and evaporated. The residue was purified by silica gel column chromatography (dichlo-
50 romethane/methanol \rightarrow dichloromethane/methanol/ammonia), and recrystallized with methanol to give N-[3-(iminoben-
zylamino)phenyl]phenylacetamide.

mp:213-214°C

IR(KBr):3483,3328,1683,1635 cm^{-1}

MS:330($M+1$)

NMR(DMSO, δ):3.62(2H,s), 6.24(2H,br s), 6.52(1H,d, $J=6.9$ Hz), 7.09-7.55(11H,m), 7.88-8.01(2H,m), 10.07(1H,s)

EP 1 264 820 A1

Example 2

[0246] This was prepared in a manner similar to Example 1 to give N-[3-(iminobenzylamino)phenyl]cinnamamide.

5 mp:115-117°C
IR(KBr):1672,1630cm⁻¹
MS:342(M+1)
NMR(DMSO, δ):6.45(2H,br s), 6.60(1H,d,J=7.2Hz), 6.85(1H,d,J=15.7Hz), 7.21-7.71 (12H,m), 7.93-8.00(2H,m),
10.14(1H,br s)
10 Elemental analysis:
Calculated+(H₂O)_{1/3}(EtOAc)_{1/3}:C;74.38,H;5.97,N;11.15
Found:C;74.44,H;6.00,N;10.92

Example 3

15 [0247] To a solution of 3-(1,2-dimethylimidazol-5-yl)aniline (94mg), 2-chlorocinnamic acid (91mg), 4-dimethylaminopyridine (24mg) and dichloromethane (2.5ml) was added at room temperature 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (153mg). Stirred for two days. Diluted with ethyl acetate (50ml), washed with water (three times, 25ml each time), saturated aqueous sodium bicarbonate (three times, 25ml each time), brine (50ml), dried over
20 magnesium sulfate, filtered, and evaporated. Purified by silica gel column chromatography (dichloromethane/methanol), recrystallized from ethyl acetate/diethyl ether to give (2E)-N-3-(1,2-dimethylimidazol-5-yl)phenyl-3-(2-chlorophenyl)-2-propenamide (151mg).

mp:105-109°C
25 MS:352(M+1)
NMR(DMSO, δ):2.36(3H,s), 3.56(3H,s), 6.86(1H,m), 6.90(1H,d,J=15.7Hz), 7.15(1H, d,J=7.7Hz), 7.34-7.70(5H,m), 7.74-7.85(2H,m), 7.90(1H,d,J=15.7Hz), 10.42(1H,s)

Example 4

30 [0248] This was prepared in a manner similar to Example 3 to give (2E)-N-3-(1,2,4-triazol-1-yl)phenyl-3-(2-chlorophenyl)-2-propenamide from 3-(1,2,4-triazol-1-yl) aniline.

mp:201-202°C
35 MS:325(M+1)
NMR(DMSO, δ):6.91(1H,d,J=15.7Hz), 7.42-7.84(7H,m), 7.92(1H,d,J=15.7Hz), 8.26 (1H,s), 8.32(1H,dd,J=1.7Hz, 1.7Hz), 9.28(1H,s), 10.61(1H,br s)

Example 5

40 [0249] This was prepared in a manner similar to Example 3 to give (2E)-N-3-(5-pyrimidinyl)phenyl-3-(2-chlorophenyl)-2-propenamide from 3-(5-pyrimidinyl) aniline.

mp:193-194°C
45 MS:336(M+1)
NMR(DMSO, δ):6.93(1H,d,J=15.7Hz), 7.41-7.62(4H,m), 7.75-7.85(2H,m), 7.92(1H,d, J=15.7Hz), 8.10(1H,s), 9.10(2H,s), 9.22(1H,s), 10.52(1H,s)

Example 6

50 [0250] This was prepared in a mannersimilar to Example 3 to give (2E)-N-3-(1,2-dimethylimidazol-5-yl)phenyl-3-[2-(trifluoromethyl)phenyl]-2-propenamide hydrochloride from 3-(1,2-dimethylimidazol-5-yl)aniline.

mp:280-281°C
55 MS:386(free+1)
NMR(DMSO, δ):2.66(3H,s), 3.69(3H,s), 7.02(1H,d,J=15.4Hz), 7.26(1H,d,J=7.8Hz), 7.55(1H,t,J=7.8Hz), 7.60-7.98(7H,m), 8.08(1H,br s), 10.88(1H,s), 13.5(1h,br s)

EP 1 264 820 A1

Example 7

[0251] This was prepared in a manner similar to Example 3 to give (2E)-N-3-(1,2,4-triazol-1-yl)phenyl-3-[2-(trifluoromethyl)phenyl]-2-propenamide from 3-(1,2,4-triazol-1-yl)aniline.

mp:190-191°C

MS:381(M+Na)

NMR(DMSO, δ):6.92(1H,d,J=15.4Hz), 7.48-7.75(4H,m), 7.76-8.00(4H,m), 8.26 (1H,s), 8.34(1H,br s), 9.29(1H,s), 10.66(1H,s)

Example 8

[0252] This was prepared in a manner similar to Example 3 to give (2E)-N-3-(5-pyrimidinyl)phenyl-3-[2-(trifluoromethyl)phenyl]-2-propenamide from 3-(5-pyrimidinyl)aniline.

mp:181-182°C

MS:392(M+Na)

NMR(DMSO, δ):6.94(1H,d,J=15.3Hz), 7.50-7.96(8H,m), 8.12(1H,s), 9.10(2H,s), 9.22 (1H,s), 10.57(1H,s)

Example 9

[0253] This was prepared in a manner similar to Example 3 to give (2E)-N-[6-(2-methyl-3-pyridyloxy)pyridin-3-yl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide from 3-amino-6-(2-methyl-3-pyridyloxy)pyridine.

mp:214-216°C

MS:400(M+1)

NMR(DMSO, δ):2.31(3H,s), 6.87(1H,d,J=15.4Hz), 7.15(1H,d,J=8.8Hz), 7.30(1H,dd, J=8.1Hz,4.7Hz), 7.52(1H,dd, J=8.1Hz,1.4Hz), 7.64(1H,t,J=7.6Hz), 7.74-7.94(4H,m), 8.22(1H,dd,J=8.8Hz,2.7Hz), 8.33(1H,dd,J=4.7Hz,1.4Hz), 8.38(1H,d,J=2.6Hz), 10.55 (1H,br s)

Example 10

[0254] To a solution of 4-phenyl-3-E-butenic acid in benzene was added thionyl chloride at room temperature, and heated at reflux for 1 hour. After cooled and evaporated, dichloromethane, 3-(imidazol-1-yl)aniline and triethylamine was added and stirred for 1 hour at room temperature. Washed with saturated aqueous sodium bicarbonate, dried over sodium sulfate, filtered and evaporated. Recrystallized from isopropyl ether/ethyl acetate to give (3E)-N-[3-(imidazol-1-yl)phenyl]-4-phenyl-3-butenamide.

mp:130-133°C

IR(Nujol):1680cm⁻¹

MS:304(M+1)

NMR(DMSO, δ):3.20-3.40(2H,m), 6.35-6.55(1H,m), 6.58(1H,d,J=16Hz), 7.12(1H,s), 7.20-7.60(8H,m), 7.63(1H,s), 7.88(1H,br s), 8.15(1H,s), 10.27(1H,br s)

Example 11

[0255] To a mixture of 3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyaniline (95mg), (2E)-3-(2-chlorophenyl)-2-propenoic acid (96mg), 1-hydroxybenzotriazole (71mg), 4-dimethylaminopyridine (64mg) and dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (101mg) with stirring at ambient temperature. The stirring was continued for overnight. The reaction mixture was evaporated to give a residue which was purified by silica gel chromatography (dichloromethane-methyl alcohol) and triturated with ethyl acetate to give (2E)-3-(2-chlorophenyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyphenyl]-2-propenamide (114mg) as colorless crystals.

MS:382(M+1)

NMR(DMSO, δ):2.36(3H,s), 3.56(3H,s), 3.80(3H,s), 6.71(1H,br s), 6.88(1H,d, J=15.6Hz), 6.89(1H,s), 7.31(1H,br s), 7.39(1H,br s), 7.4-7.5(2H,m), 7.5-7.6(1H,m), 7.7-7.8(1H,m), 7.89(1H,d,J=15.6Hz), 10.40(1H,br s)

EP 1 264 820 A1

Example 12

[0256] This was prepared in a manner similar to Example 11 to give (2E)-N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-3-(2-chlorophenyl)-2-propenamide.

MS:387(M+1)

NMR(DMSO, δ): 2.36(3H,s), 3.57(3H,s), 6.86(1H,d,J=15.7Hz), 6.96(1H,s), 7.22(1H, br s), 7.4-7.5(2H,m), 7.5-7.7(1H,m), 7.63(1H,br s), 7.7-7.9(1H,br s), 7.88(1H,br s), 7.91(1H,d,J=15.7Hz), 10.60(1H,br s)

Example 13

[0257] This was prepared in a manner similar to Example 11 to give (2E)-N-[3-[[2-chloro-4-pyridyl]amino]methyl]phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

MS:432(M+1)

NMR(DMSO, δ): 4.35(2H,d,J=5.9Hz), 6.52(1H,br s), 6.5-6.6(1H,m), 6.90(1H,d, J=15.4Hz), 7.06(1H,d,J=7.6Hz), 7.2-7.4(1H,m), 7.5-7.7(4H,m), 7.7-8.0(5H,m), 10.37 (1H,br s)

Example 14

[0258] A solution of S-methyl benzothioimidate hydriodide (279mg), (2E)-N-(3-aminophenyl)-3-(2-methoxyphenyl)-2-propenamide (134mg), and methanol (2ml) was refluxed for two hours. Cooled at room temperature, added dichloromethane (50ml), water (50ml), 1N sodium hydroxide (2ml), and filtered. Extracted with dichloromethane (20ml, twice). Combined organics were dried over magnesium sulfate, filtered, and evaporated. Purified by silica gel column chromatography, eluted with aqueous dichloromethane-methanol-ammonia, followed by recrystallization from ethyl acetate to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-(2-methoxyphenyl)-2-propenamide (150mg) as white crystals.

mp:219-221°C

MS:372(M+1)

NMR(DMSO, δ): 3.89(3H,s), 6.43(2H,br s), 6.59(1H,d,J=6.9Hz), 6.88(1H,d,J=15.8Hz), 7.02(1H,dd,J=7.5Hz, 7.5Hz), 7.10(1H,d,J=8.1Hz), 7.20-7.33(2H,m), 7.35-7.54(5H,m), 7.57(1H,d,J=7.6Hz), 7.79(1H,d,J=15.8Hz), 7.92-8.04(2H,m), 10.10(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.4}:C;72.96,H;5.80,N;11.10

Found:C;72.81,H;5.93,N;10.98

Example 15

[0259] This was prepared in a manner similar to Example 11 to give N-[3-(1 isoquinolylamino)methyl]phenyl]cin-
namamide.

mp:216-218°C

IR(Nujol):3360,1660cm⁻¹

MS:380(M+1)

NMR(DMSO, δ): 4.76(2H,d,J=5.8Hz), 6.80(1H,d,J=15.7Hz), 6.90(1H,d,J=5.6Hz), 7.26(1H,dd,J=7.7Hz,7.7Hz), 7.40-7.74(12H,m), 7.82(1H,d,J=5.8Hz), 8.04(1H,t, J=5.9Hz), 8.32(1H,d,J=8.1Hz), 10.14(1H,s)

Example 16

[0260] This was prepared in a manner similar to Example 14 to give (2E)-N-[2-fluoro-5-[[imino(2-thienyl)methyl]amino]phenyl]-3-(2-chlorophenyl)-2 propenamide.

mp:215-216°C

MS:400(M+1)

NMR(DMSO, δ): 6.49(2H,s), 6.54-6.65(1H,s), 7.08-7.25(3H,m), 7.38-7.79(7H,m), 7.87(1H,d,J=15.7Hz), 9.98(1H,s)

Elemental analysis:

Calculated:C;60.07,H;3.78,N;10.51

EP 1 264 820 A1

Found: C; 59.98, H; 3.57, N; 10.42

Example 17

- 5 [0261] This was prepared in a manner similar to Example 14 to give (2E)-N-[2-fluoro-5-(iminobenzylamino)phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp: 189-191°C

MS: 394(M+1)

- 10 NMR(CDCl₃, δ): 6.4-6.7(3H, m), 7.14-7.29(2H, m), 7.40-7.61(6H, m), 7.69-8.00(5H, m), 9.99(1H, s)

Elemental analysis:

Calculated+(H₂O)_{0.3}: C; 66.18, H; 4.44, N; 10.52

Found: C; 66.21, H; 4.16, N; 10.39

- 15 Example 18

[0262] This was prepared in a manner similar to Example 14 to give (2E)-N-[5-[[[(5-chloro-2-methoxyphenyl)(imino)methyl]amino]-2-fluorophenyl]-3-(2-chlorophenyl)-2-propenamide.

- 20 mp: 229-230°C

MS: 458(M+1)

NMR(CDCl₃, δ): 3.93(3H, s), 5.70(2H, s), 6.59(1H, d, J=15.5 Hz), 6.67-6.75(1H, m), 6.92(1H, d, J=8.9 Hz), 7.11(1H, dd, J=10.7 Hz, 8.6 Hz), 7.26-7.47(4H, m), 7.53(1H, s), 7.61-7.69(1H, m), 8.05-8.21(3H, m)

Elemental analysis:

- 25 Calculated+(H₂O)_{0.2}: C; 60.28, H; 3.96, N; 9.17

Found: C; 60.37, H; 3.76, N; 9.14

Example 19

- 30 [0263] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[N¹-(1,3-benzothiazol-6-yl)amidino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp: 140-142°C

MS: 433(M+1)

- 35 NMR(DMSO, δ): 6.48(2H, br s), 6.91(1H, d, J=15.6 Hz), 7.05(1H, d, J=8.6 Hz), 7.41-8.03 (10H, m), 8.30(1H, s), 9.18(1H, s), 10.48(1H, s)

Elemental analysis:

Calculated+(H₂O)_{1.3}(CH₃OH)₁: C; 61.20, H; 4.64, N; 11.90

Found: C; 61.11, H; 4.47, N; 11.91

- 40

Example 20

[0264] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[N¹-[4-(1,3-thiazol-4-yl)phenyl]amidino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

- 45

mp: 179-180°C

MS: 459(M+1)

NMR(DMSO, δ): 6.40(2H, br s), 6.85-6.99(3H, m), 7.38-7.70(5H, m), 7.74-8.06(6H, m), 8.29(1H, s), 9.18(1H, d, J=1.9 Hz), 10.47(1H, s)

- 50 Elemental analysis:

Calculated+(H₂O)_{1.25}: C; 62.36, H; 4.50, N; 11.64

Found: C; 62.36, H; 4.52, N; 11.36

Example 21

- 55

[0265] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[N¹-[4-(1H-pyrazol-1-yl)phenyl]amidino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

EP 1 264 820 A1

mp:117-119°C

MS:442(M+1)

NMR(DMSO, δ):6.41(2H,br s), 6.51(1H,s), 6.85-7.00(3H,s), 7.35-7.95(11H,m) 8.29(1H,s), 8.41(1H,s) 10.47(1H,

Elemental analysis:

Calculated+(H₂O)_{1.1}:C;65.03,H;4.85,N;15.17

Found:C;64.82,H;4.81,N;15.10

Example 22

[0266] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[N¹-(4-(1,3-oxazol-5-yl)phenyl)amidino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:115-117°C

MS:443(M+1)

NMR(DMSO, δ):6.46(2H,br s), 6.90(1H,d,J=15.6Hz), 6.94(2H,m), 7.41-7.95(11H,m), 8.28(1H,s)8.38(1H,s), 10.46(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.8}(CH₃OH)₁:C;63.81,H;5.07,N;11.45

Found:C;63.81,H;4.83,N;11.51

Example 23

[0267] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[[5-fluoro-2-methoxyphenyl](imino)methyl]amino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:238-239°C

MS:458,460(M+1,C1 isotopes)

NMR(CDCl₃, δ):3.92(3H,s), 5.78(2H,br s), 6.53(1H,d,J=15.5Hz), 6.78(1H,s), 6.93 (1H,dd,J=9.0Hz,4.2Hz), 7.02-7.19(2H,m), 7.24-7.55(5H,m), 7.55-7.65(1H,m), 7.92 (1H,dd,J=7.7Hz,3.5Hz), 8.13(1H,d,J=15.5Hz)

Elemental analysis:

Calculated+(H₂O)_{0.4}:C;59.34,H;4.07,N;9.03

Found:C;59.32,H;4.12,N;8.75

Example 24

[0268] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[[5-chloro-2-methoxyphenyl](imino)methyl]amino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:226-228°C

MS:474,476(M+1,C1 isotopes)

NMR(CDCl₃, δ):3.93(3H,s), 5.72(2H,br s), 6.53(1H,d,J=15.6Hz), 6.79(1H,s), 6.93 (1H,d,J=9.0Hz), 7.08(1H,s), 7.22-7.46(6H,m), 7.58-7.70(1H,m), 8.14(1H,d,J=15.6Hz), 8.17(1H,s)

Elemental analysis:

Calculated:C;58.19,H;3.82,N;8.85

Found:C;58.20,H;3.73,N;8.78

Example 25

[0269] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[N¹-(4-methoxyphenyl)amidino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:129-131°C

MS:406(M+1)

NMR(DMSO, δ):3.74(3H,s), 6.19(2H,s), 6.75-6.96(5H,m), 7.35-7.50(3H,m), 7.53-7.65(2H,m), 7.74-7.80(1H,m), 7.84-7.95(2H,m), 8.26(1H,s), 10.45(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.25}:C;67.32,H;5.03,N;10.24

Found:C;67.00,H;4.97,N;10.24

EP 1 264 820 A1

Example 26

[0270] This was prepared in a manner similar to Example 14 to give (2E)-N-(3-[N¹-(4-(1-methyl-1H-imidazol-4-yl)phenyl)amidino]phenyl)-3-(2-chlorophenyl)-2-propenamide.

mp:142-146°C

MS:456(M+1)

NMR(DMSO, δ):3.68(3H,s), 6.30(2H,br s), 6.80-7.01(3H,m), 7.35-7.81(10H,m), 7.83-7.99(2H,m), 8.26(1H,s), 10.47(1H,s)

Elemental analysis:

Calculated+(H₂O)_{1.75}:C;64.06,H;5.27,N;14.37

Found:C;63.99,H;5.28,N;14.16

Example 27

[0271] This was prepared in a manner similar to Example 14 to give N-[3-[imino(4-isopropylanilino)methyl]phenyl]-2-chlorocinnamamide.

mp:112-118°C

MS:418(M+1)

NMR(DMSO, δ):1.21(6H,d,J=6.9Hz), 2.87(1H,septet,J=6.9Hz), 6.40(2H,br s), 6.81-6.98(3H,m), 7.20(2H,d,J=8.1Hz), 7.38-7.49(3H,m), 7.52-7.66(2H,m), 7.73-7.80(1H,m), 7.82-7.99(2H,m), 8.25(1H,s), 10.47(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.7}:C;69.74,H;5.95,N;9.76

Found:C;69.76,H;6.01,N;9.66

Example 28

[0272] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[N¹-(4-oxo-4H-chromenyl-6-yl)amidino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:151-156°C

MS:444(M+1)

NMR(DMSO, δ):6.31(1H,d,J=6.0Hz), 6.60(2H,br s), 6.81-6.99(2H,m), 7.20-8.00 (10H,m), 8.20-8.39(2H,m), 10.48 (1H,s)

Elemental analysis:

Calculated+(H₂O)_{1.3}(Et₂O)_{0.1}:C;64.26,H;4.58,N;8.85

Found:C;64.25,H;4.47,N;8.58

Example 29

[0273] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[[[5-chloro-2-methoxyphenyl](imino)methyl]amino]phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:227-229°C

MS:508,510(M+1,C1 isotopes)

NMR(CDCl₃, δ):3.93(3H,s), 5.69(2H,s), 6.48(1H,d,J=14.8Hz), 6.79(1H,s), 6.93(1H,d, J=8.8Hz), 7.09(1H,s), 7.26-7.78(7H,m), 8.07-8.18(2H,m)

Elemental analysis:

Calculated:C;56.71,H;3.57,N;8.27

Found:C;56.36,H;3.58,N;8.18

Example 30

[0274] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[[[5-fluoro-2-methoxyphenyl](imino)methyl]amino]phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:213-214°C

EP 1 264 820 A1

MS:492,494(M+1,C1 isotopes)

NMR(CDC_l₃, δ):3.92(3H,s), 5.79(2H,br s), 6.48(1H,d,J=15.3Hz), 6.78(1H,s), 6.93 (1H,dd,J=9.1Hz,4.3Hz), 7.02-7.19(2H,m), 7.39-7.63(4H,m), 7.69-7.77(2H,m), 7.89-7.99(1H,m), 8.05-8.19(1H,m)

Elemental analysis:

Calculated+(H₂O)_{1/2}(CH₃OH)₁:C;56.34,H;4.35,N;7.88

Found:C;56.26,H;4.28,N;7.85

Example 31

[0275] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-(iminobenzylamino)phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:105-115°C

MS:410(M+1)

NMR(DMSO, δ):6.58(3H,br s), 6.86(1H,d,J=15.7Hz), 7.02(1H,s), 7.37-7.64(7H,m), 7.71-8.05(4H,m), 10.38(1H,br s)

Elemental analysis:

Calculated+(H₂O)_{0.2}:C;63.84,H;4.24,N;10.15

Found:C;63.84,H;4.06,N;10.08

Example 32

[0276] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-trifluoromethyl-5-[[imino(2-thienyl)methyl]amino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:206-208°C

MS:450(M+1)

NMR(DMSO, δ):6.74(2H,br s), 6.83-6.92(2H,m), 7.12(1H,dd,J=3.7Hz,3.7Hz), 7.34(1H,s), 7.41-7.51(2H,m), 7.52-7.63(1H,m), 7.65(1H,d,J=4.7Hz), 7.75-7.99(4H,m), 10.54(1H,s)

Elemental analysis:

Calculated+(CH₃OH)_{0.5}(H₂O)_{0.5}:C;54.37,H;3.82,N;8.85

Found:C;54.08,H;3.71,N;8.56

Example 33

[0277] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[[imino(2-thienyl)methyl]amino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:123-124°C

MS:416(M+1)

NMR(DMSO, δ):6.59(1H,dd,J=1.8Hz,1.8Hz), 6.67(2H,br s), 6.86(1H,d,J=15.6Hz), 7.03(1H,s), 7.11(1H,dd, J=5.0Hz,3.7Hz), 7.41-7.49(2H,m), 7.52-7.67(3H,m), 7.72-7.81 (2H,m), 7.89(1H,d,J=15.7Hz), 10.38(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.9}:C;55.54,H;3.91,N;9.71

Found:C;55.54,H;4.02,N;9.50

Example 34

[0278] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[[imino(2-thienyl)methyl]amino]phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:178-179°C

MS:450(M+1)

NMR(DMSO, δ):6.60(1H,dd,J=1.7Hz,1.7Hz), 6.68(2H,br s), 6.87(1H,d,J=15.4Hz), 7.03(1H,s), 7.11(1H,dd, J=4.9Hz,J=3.8Hz), 7.75-7.70(3H,m), 7.71-7.95(5H,m), 10.44 (1H,s)

Elemental analysis:

Calculated:C;56.07,H;3.36,N;9.34

Found:C;55.76,H;3.52,N;9.20

EP 1 264 820 A1

Example 35

[0279] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-(iminobenzylamino)phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:137-139°C

MS:444(M+1)

NMR(DMSO, δ):6.76(3H,br s), 6.87(1H,d,J=15.3Hz), 7.02(1H,s), 7.41-7.69(5H,m), 7.72-7.95(6H,m), 10.42(1H,s)

Elemental analysis:

Calculated+(H₂O)₁:C59.81,H;4.15,N;9.10

Found:C59.92,H;3.99,N;8.89

Example 36

[0280] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-cyano-5-(iminobenzylamino)phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:181-182°C

MS:435(M+1)

NMR(DMSO, δ):6.69(2H,br s), 6.88(1H,d,J=15.3Hz), 6.96(1H,s), 7.34-7.58(4H,m), 7.64(1H,t,J=7.6Hz), 7.76-8.03(7H,m), 10.59(1H,s).

Example 37

[0281] This was prepared in a manner similar to Example 14 to give N-[3-(iminobenzylamino)phenyl]-3-(phenyl)-2-propenamide.

mp:156-158°C

MS:356(M+1)

NMR(DMSO, δ):2.11(3H,s), 6.27(2H,s), 6.57(1H,d,J=7.7Hz), 7.21-7.58(12H,m), 7.91-8.03(2H,m), 9.84(1H,s)

Elemental analysis:

Calculated+(H₂O)_{1/4}:C;76,H;6.02,N;11.67

Found:C;76.75,H;5.88,N;11.52

Example 38

[0282] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-(4-methylphenyl)-2-propenamide.

mp:147-149°C

MS:356(M+1)

NMR(DMSO, δ):2.34(3H,s), 6.36(2H,s), 6.58(1H,d,J=7.7Hz), 6.79(1H,d,J=15.7Hz), 7.20-7.60(11H,m), 7.89-8.02(2H,m), 10.08(1H,s)

Elemental analysis:

Calculated+(H₂O)_{1/4}:C;76.75,H;6.02,N;11.67

Found:C;76.79,H;5.80,N;11.71

Example 39

[0283] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-(3-methylphenyl)-2-propenamide.

mp:179-180°C

MS:356(M+1)

NMR(DMSO, δ):2.35(3H,s), 6.29(2H,s), 6.56(1H,d,J=7.4Hz), 6.83(1H,d,J=15.6Hz), 7.21-7.59(11H,m), 7.93-8.01(2H,m), 10.09(1H,s)

Elemental analysis:

Calculated+(H₂O)_{4/5}:C;67.52,H;5.38,N;9.92

EP 1 264 820 A1

Found: C; 67.61, H; 5.27, N; 10.08

Example 40

5 **[0284]** This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-(2-methylphenyl)-2-propenamide.

mp: 109-114°C

MS: 356(M+1)

10 NMR(DMSO, δ): 2.41(3H,s), 6.29(2H,s), 6.57(1H,d,J=7.5Hz), 6.75(1H,d,J=15.6Hz), 7.19-7.50(9H,m), 7.56-7.61(1H,m), 7.80(1H,d,J=15.6Hz), 7.93-8.01(2H,m), 10.13(1H,s)

Elemental analysis:

Calculated+(H₂O)_{5/4}: C; 73.09, H; 6.27, N; 11.12

Found: C; 73.17, H; 6.30, N; 10.80

15

Example 41

[0285] This was prepared in a manner similar to Example 14 to give (2E)-N-[5-[[5-fluoro-2-methoxyphenyl](imino)methyl]amino]phenyl]-3-(2-trifluoromethyl)-2-propenamide.

20

mp: 220-221°C

MS: 458(M+1)

NMR(DMSO, δ): 3.86(3H,s), 6.26(2H,s), 6.58(1H,d,J=7.2Hz), 6.79-7.42(6H,m), 7.58-7.70(2H,m), 7.76-7.98(4H,m), 10.27(1H,s)

25

Elemental analysis:

Calculated: C; 63.02, H; 4.19, N; 9.19

Found: C; 62.80, H; 4.07, N; 9.09

Example 42

30

[0286] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[N¹-(phenyl)amidino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp: 82-84°C

35

MS: 376(M+1)

NMR(DMSO, δ): 6.23(2H,s), 6.83-7.03(4H,m), 7.27-7.49(5H,m), 7.53-7.66(2H,m), 7.74-7.95(3H,m), 8.27(1H,s), 10.46(1H,s)

Elemental analysis:

Calculated+(H₂O)_{1.75}: C; 64.86, H; 5.32, N; 10.31

40

Found: C; 64.78, H; 5.31, N; 10.29

Example 43

45 **[0287]** This was prepared in a manner similar to Example 11 to give N-[3-[[[1-methyl-1H-benzimidazol-2-yl]amino]methyl]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp: 188-191°C

MS: 417(M+1)

50

NMR(DMSO, δ): 3.56(3H,s), 4.59(2H,d,J=5.9Hz), 6.88(1H,d,J=15.7Hz), 6.90-7.00(2H,m), 7.08-7.21(3H,m), 7.24-7.39(2H,m), 7.40-7.48(2H,m), 7.50-7.60(1H,m), 7.62-7.79(3H,m), 7.86(1H,d,J=15.7Hz), 10.29(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.33}: C; 68.18, H; 5.34, N; 12.55

Found: C; 68.04, H; 5.26, N; 12.53

55

Example 44

[0288] This was prepared in a manner similar to Example 11 to give N-[6-[(2-pyridylmethyl)amino]-3-pyridyl]-3-(2-chlorophenyl)-2-propenamide.

EP 1 264 820 A1

mp:164-165°C

MS:365(M+1)

NMR(DMSO, δ): 4.55(2H,d,J=6.0Hz), 6.59(1H,d,J=8.9Hz), 6.82(1H,d,J=15.6Hz), 7.08(1H,t,J=5.8Hz), 7.19-7.35(2H,m), 7.39-7.46(2H,m), 7.51-7.59(1H,m), 7.65-7.76 (3H,m), 7.82(1H,d,J=15.6Hz), 8.23(1H,d,J=2.5Hz), 8.51(1H,d,J=4.4Hz), 10.06(1H,s)

Elemental analysis:

Calculated:C;65.84,H;4.70,N;15.36

Found:C;65.92,H;4.68,N;15.27

10 Example 45

[0289] This was prepared in a manner similar to Example 11 to give N-[6-[(2-methyl-3-pyridyl)oxy]-3-pyridyl]-3-(2-chlorophenyl)-2-propenamide.

mp:187-189°C

MS:366(M+1)

NMR(DMSO, δ): 2.31(3H,s), 6.86(1H,d,J=15.7Hz), 7.15(1H,d,J=8.8Hz), 7.30(1H,dd, J=8.1Hz,4.7Hz), 7.41-7.60(4H,m), 7.74-7.81(1H,m), 7.89(1H,d,J=15.7Hz), 8.22(1H,dd, J=8.8Hz,2.7Hz), 8.33(1H,dd,J=4.6Hz,J=1.3Hz), 8.38(1H,d,J=2.6Hz), 10.50(1H,s)

Elemental analysis:

Calculated:C;65.67,H;4.41,N;11.49

Found:C;65.43,H;4.42,N;11.37

25 Example 46

[0290] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:82-84°C

MS:410(M+1)

NMR(DMSO, δ): 6.30(2H,br s), 6.59(1H,d,J=7.6Hz), 6.91(1H,d,J=15.3Hz), 7.18-7.50 (6H,m), 7.63(1H,dd, J=7.4Hz,7.4Hz), 7.71-8.03(6H,m), 10.26(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.7}:C;65.46,H;4.63,N;9.96

Found:C;65.47,H;4.60,N;9.86

35 Example 47

[0291] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-(4-chlorophenyl)-2-propenamide.

mp:109-110°C

MS:376(M+1)

NMR(DMSO, δ): 6.29(2H,br s), 6.56(1H,d,J=7.5Hz), 6.84(1H,d,J=15.7Hz), 7.19-7.57 (8H,m), 7.59-7.71(3H,m), 7.90-8.03(2H,m), 10.14(1H,s)

Elemental analysis:

Calculated(CH₃OH)₁:C;67.62,H;5.44,N;10.30

Found:C;67.54,H;5.39,N;10.24

50 Example 48

[0292] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-(3-methoxyphenyl)-2-propenamide.

mp:148-149°C

MS:372(M+1)

NMR(DMSO, δ): 3.81(3H,s), 6.44(2H,br s), 6.60(1H,d,J=7.1Hz), 6.84(1H,d,J=15.7Hz), 6.98(1H,d,J=9.1Hz), 7.16-7.49(9H,m), 7.54(1H,d,J=15.7Hz), 7.90-8.02(2H,m), 10.13 (1H,s)

EP 1 264 820 A1

Elemental analysis:

Calculated+(Et₂O)_{0.5}(H₂O)_{0.2}:C;72.86,H;6.46,N;10.20

Found:C;72.66,H;6.12,N;10.55

5 Example 49

[0293] This was prepared in a manner similar to Example 14 to give N-[3-[[imino(1-methyl-1H-indole-5-yl)methyl]amino]phenyl]cinnamamide.

10 mp:143-148°C

MS:395(M+1)

NMR(DMSO, δ):3.83(3H,s), 6.53(2H,br s), 6.64(2H,br s), 6.85(1H,d,J=15.5Hz), 7.22-7.59(9H,m), 7.60-7.70(2H,m), 7.85(1H,br s), 8.19(1H,s), 10.15(1H,s)

Elemental analysis:

15 Calculated+(H₂O)_{0.9}:C;73.11,H;5.84,N;13.64

Found:C;73.09,H;5.73,N;13.37

Example 50

20 [0294] This was prepared in a manner similar to Example 11 to give N-[3-[(2-quinolylamino)methyl]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:170-171°C

MS:414,416(M+1,C1 isotopes)

25 NMR(DMSO, δ):4.65(2H,d,J=5.7Hz), 6.84(1H,d,J=8.9Hz), 6.88(1H,d,J=15.7Hz), 7.05-7.21(2H,m), 7.30(1H,dd, J=8.0Hz,8.0Hz), 7.35-7.93(12H,m), 10.28(1H,s)

Elemental analysis:

Calculated+(H₂O)_{0.2}:C;71.92,H;4.92,N;10.06

Found:C;71.91,H;4.82,N;9.99

30

Example 51

[0295] This was prepared in a manner similar to Example 14 to give N-[3-[[[4-(dimethylamino)phenyl](imino)methyl]amino]phenyl]cinnamamide.

35

mp:225-227°C

MS:385(M+1)

NMR(DMSO, δ):2.98(6H,s), 6.39(2H,br s), 6.60(1H,d,J=7Hz), 6.73(2H,d,J=8.9Hz), 6.85(1H,d,J=15.6Hz), 7.20-7.70(9H,m), 7.81(2H,d,J=8.4Hz), 10.13(1H,s)

40

Elemental analysis:

Calculated+(H₂O)_{3/4}:C;72.43,H;6.46,N;14.08

Found:C;72.54,H;6.24,N;14.00

Example 52

45

[0296] This was prepared in a manner similar to Example 14 to give (2E)-N-[5-[[[3-methylphenyl](imino)methyl]amino]-2-fluorophenyl]cinnamamide.

mp:105-110°C

50

MS:356(M+1)

NMR(DMSO, δ):2.38(3H,s), 6.65(2H,m), 6.85(1H,d,J=15.7Hz), 7.22-7.84(14H,m), 10.18(1H,s)

Elemental analysis:

Calculated+(H₂O)_{1.25}:C;73.09,H;6.27,N;11.12

Found:C;73.14,H;5.97,N;10.84

55

Example 53

[0297] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-(3-chlo-

EP 1 264 820 A1

rophenyl)-2-propenamide.

mp:260-262°C

MS:376(free+1)

5 NMR(DMSO, δ):6.98(1H,d,J=15.8Hz), 7.18(1H,d,J=7.1Hz), 7.45-7.84(10H,m), 7.90-8.01(3H,m), 9.11(1H,br s), 9.81(1H,br s), 10.70(1H,s), 11.51(1H s)

Elemental analysis:

Calculated:C;64.09,H;4.64,N;10.19

Found:C;63.74,4.56,N;10.06

10

Example 54

[0298] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)phenyl]-3-(2-chlorophenyl)-2-propenamide.

15

mp:262-264°C

MS:376(free+1)

NMR(DMSO, δ):7.01(1H,d,J=15.7Hz), 7.22(1H,d,J=7.1Hz), 7.39-8.01(13H,m), 9.13 (1H,br s), 9.82(1H,br s), 10.81(1H,s), 11.55(1H,br s)

20

Elemental analysis:

Calculated+(H₂O)_{0.1}:C;63.81,H;4.67,N;10.15

Found:C;63.64,4.57,N;10.05

Example 55

25

[0299] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(N¹-(2-fluorophenyl)amidino)phenyl]-3-(2-chlorophenyl)-2-propenamide hydrochloride.

mp:178-180°C

30

MS:394(free+1)

NMR(DMSO, δ):7.02(1H,d,J=15.6Hz), 7.31-7.71(9H,m), 7.73-7.81(1H,m), 7.95-8.03 (2H,m), 8.43(1H,s), 9.21(1H, s), 10.05(1H,s), 10.95(1H,s), 11.60(1H,s)

Example 56

35

[0300] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[[imino(3-thienyl)methyl]amino]phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:121-123°C

40

MS:450(M+1)

NMR(DMSO, δ):6.48(2H,s), 6.57(1H,s), 6.87(1H,d,J=15.4Hz), 6.99(1H,s), 7.50-7.70 (4H,m), 7.73-7.96(4H,m), 8.14(1H,s), 10.41(1H,s).

Example 57

45

[0301] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[N¹-(phenyl)amidino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:218-220°C

50

MS:376(M+1)

NMR(DMSO, δ):6.19(2H,s), 6.81-7.05(4H,m), 7.31(2H,t,J=7.6Hz), 7.41-7.63(3H,m), 7.70-8.04(6H,m), 10.50(1H, s)

Example 58

55

[0302] This was prepared in a manner similar to Example 14 to give N-[3-(1H-benzimidazol-2-yl)phenyl]-3-(2-chlorophenyl)-2-propenamide.

EP 1 264 820 A1

mp:152-154°C

MS:374(M+1)

NMR(DMSO, δ):6.94(1H,d,J=15.7Hz), 7.18-7.27(2H,m), 7.42-7.63(6H,m), 7.76-7.90 (3H,m), 7.94(1H,d, J=15.7Hz), 8.63(1H,s), 10.54(1H,s), 12.94(1H,s)

Example 59

[0303] This was prepared in a manner similar to Example 14 to give N-[3-chloro-5-[[imino[4-[(2-methyl-3-pyridyl)oxy] phenyl]methyl]amino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:105-107°C

MS:517(M+1)

NMR(DMSO, δ):2.39(3H,s), 6.57(3H,br s), 6.86(1H,d,J=15.6Hz), 7.00-7.09(3H,m), 7.28-7.62(6H,m), 7.75-7.81 (1H,m), 7.88(1H,d,J=15.6Hz), 7.95-8.04(2H,m), 8.32-8.36 (1H,m), 10.37(1H,s)

Example 60

[0304] This was prepared in a manner similar to Example 14 to give N-[3-chloro-5-[[imino[4-[(2-pyridylmethyl)amino] phenyl]methyl]amino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:119-122°C

MS:516(M+1)

NMR(DMSO, δ):4.42(2H,d,J=5.9Hz), 6.20(2H,s), 6.50-6.62(3H,m), 6.78(1H,t, J=6.2Hz), 6.86(1H,d,J=15.6Hz), 6.96(1H,s), 7.22-7.80(10H,m), 7.88(1H,d,J=15.6Hz), 8.54(1H,d,J=4.2Hz), 10.33(1H,s)

Example 61

[0305] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)-2-fluorophenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:185-187°C

MS:428(M+1)

NMR(CDCl₃, δ):4.73(2H,br s), 6.56(1H,d,J=15.3Hz), 6.70-6.82(1H,m), 7.10(1H,d J=10.7Hz,8.7Hz), 7.38-7.96(10H, m), 8.02-8.12(2H,m)

Example 62

[0306] This was prepared in a manner similar to Example 14 to give (2E)-N-[2-fluoro-5-[[imino(2-thienyl)methyl]amino]phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:208-209°C

MS:434(M+1)

NMR(CDCl₃, δ):4.96(2H,s), 6.54(1H,d,J=15.3Hz), 6.70-6.81(1H,m), 7.07-7.19 (2H,m), 7.38-7.66(5H,m), 7.70-7.81(2H,m), 8.08-8.24(2H,m)

Example 63

[0307] This was prepared in a manner similar to Example 14 to give N-[3-chloro-5-[[imino[4-(1H-pyrazol-1-yl)phenyl] methyl]amino]phenyl]-3-[2-(trifluoromethyl) phenyl]-2-propenamide.

mp:146-153°C

MS:510(M+1)

NMR(DMSO, δ):6.58-6.70(4H,m), 6.87(1H,d,J=15.5Hz), 7.05(1H,s), 7.58-7.70 (2H,m), 7.78-8.17(9H,m), 8.60(1H, d,J=2.5Hz), 10.43(1H,s)

Example 64

[0308] This was prepared in a manner similar to Example 14 to give N-[3-chloro-5-[[imino[4-[(2-methyl-3-pyridyl)oxy]

EP 1 264 820 A1

phenyl)methyl]amino]phenyl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide.

mp:114-119°C

MS:551(M+1)

5 NMR(DMSO, δ):2.39(3H,s), 6.49-6.63(3H,m), 6.86(1H,d,J=15.3Hz) 6.96-7.03 (3H,m), 7.31(1H,dd,J=8.1Hz, 4.5Hz), 7.42(1H,d,J=7.9Hz), 7.56-7.70(2H,m), 7.76-8.08 (6H,m), 8.34(1H,d,J=4.5Hz), 10.42(1H,s)

Example 65

10 [0309] This was prepared in a manner similar to Example 14 to give N-[3-chloro-5-[[imino[4-[(1-oxido-3-pyridyl)oxy] phenyl)methyl]amino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp:214-216°C

MS:519(M+1)

15 NMR(DMSO, δ):6.58(3H,s), 6.86(1H,d,J=15.6Hz), 7.00-7.09(2H,m), 7.21(2H, d,J=8.7Hz), 7.39-7.54(3H,m), 7.56-7.64(2H,m), 7.76-7.81(1H,m), 7.89(1H,d, J=15.6Hz), 7.98-8.20(4H,m), 10.38(1H,s)

Example 66

20 [0310] This was prepared in a manner similar to Example 14 to give N-[3-[[[4-(4-acetyl-1-piperazinyl)phenylimino] methyl]amino]-5-chlorophenyl-3-(2-chlorophenyl)-2-propenamide.

mp:259-260°C

MS:536(M+1)

25 NMR(DMSO, δ):2.05(3H,s), 3.15-3.38(4H,m), 3.50-3.66(4H,m), 6.36(2H,br s), 6.554 (1H,s), 6.86(1H,d, J=15.6Hz), 6.93-7.08(3H,m), 7.40-7.51(2H,m), 7.52-7.62(2H,m), 7.75-7.94(4H,m), 10.35(1H,s)

Example 67

30 [0311] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-(iminobenzylamino)phenyl]-3-(2-cyanophenyl)-2-propenamide.

mp:220-221°C

MS:401(M+1)

35 NMR(DMSO, δ):6.59(3H,s), 7.02(1H,d,J=15.6Hz), 7.03(1H,s), 7.39-7.57(3H,m), 7.58-7.68 z(2H,m), 7.76-8.08 (6H,m), 10.48(1H,s)

Example 68

40 [0312] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-fluoro-5-(iminobenzyl)phenyl]-3-(2-pyridyl)-2-propenamide.

mp:205-207°C

MS:377(M+1)

45 NMR(DMSO, δ):6.57(3H,br s), 7.05(1H,s), 7.31(1H,d,J=15.3Hz), 7.37-7.49(4H,m), 7.57-7.70(3H,m), 7.80-8.05 (3H,m), 8.65(1H,d,J=4.4Hz), 10.41(1H,s).

Example 69

50 [0313] To a solution of 3-(3-chlorophenyl) acrylic acid (18mg) in N,N-dimethylacetamide (3ml) was added O-(7-aza-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphonate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric acid (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to
55 give (2E)-3-(3-chlorophenyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl) phenyl]-2-propenamide (27mg).

APCI-mass;m/z352(M+H⁺)

EP 1 264 820 A1

Example 70

[0314] To a solution of 3-(4-chlorophenyl)acrylic acid (18mg) in N,N-dimethylacetamide (3ml) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to give (2E)-3-(4-chlorophenyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl) phenyl]-2-propenamide (27mg).

APCI-mass;m/z352(M+H⁺)

Example 71

[0315] To a solution of 3-(2,4-dichlorophenyl)acrylic acid (22mg) in N,N-dimethylacetamide (3ml) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric acid (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to give (2E)-3-(2,4-dichlorophenyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl) phenyl]-2-propenamide (32mg).

APCI-mass;m/z386(M+H⁺)

Example 72

[0316] To a solution of 3-biphenyl-4-yl-acrylic acid (22mg) in N,N-dimethylacetamide (3ml) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric acid (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to give 3-biphenyl-4-yl-N-[3-(2,3-dimethyl-3H-imidazol-4-yl)phenyl] acrylamide (26mg).

APCI-mass;m/z394(M+H⁺)

Example 73

[0317] To a solution of 3-(3,5-difluorophenyl)acrylic acid (18mg) in N,N-dimethylacetamide (3ml) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric acid (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to give (2E)-3-(3,5-difluorophenyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl) phenyl]-2-propenamide (30mg).

APCI-mass;m/z354(M+H⁺)

Example 74

[0318] To a solution of 3-(2,5-difluorophenyl)acrylic acid (18mg) in N,N-dimethylacetamide (3ml) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric acid (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to give (2E)-3-(2,5-difluorophenyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl) phenyl]-2-propenamide (28mg).

APCI-mass;m/z354(M+H⁺)

Example 75

[0319] To a solution of 3-(4-trifluoromethylphenyl)acrylic acid (22mg) in N,N-dimethylacetamide (3ml) was added

EP 1 264 820 A1

O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric acid (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to give (2E)-3-(4-trifluoromethylphenyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-propenamide (27mg).

APCI-mass;m/z386(M+H⁺)

Example 76

[0320] To a solution of 3-[2,5-bis(trifluoromethyl)phenyl]acrylic acid (28mg) in N,N-dimethylacetamide (3ml) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric acid (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to give (2E)-3-[2,5-bis(trifluoromethyl)phenyl]-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-propenamide (33mg).

APCI-mass;m/z454(M+H⁺)

Example 77

[0321] To a solution of 3-phenylsulfanyl-acrylic acid (18mg) in N,N-dimethylacetamide (3ml) was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg) and the mixture was stirred for 30 minutes. To the mixture was added 3-(2,3-dimethyl-3H-imidazol-4-yl)aniline (19mg) and the mixture was stirred for 1 hour. The mixture was diluted with ethyl acetate and washed with aqueous solution of sodium hydroxide (1N) and hydrochloric acid (0.1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated to give N-[3-(2,3-dimethyl-3H-imidazol-4-yl)phenyl]-3-phenylsulfanyl-acrylamide (23mg).

APCI-mass;m/z350(M+H⁺)

Example 78

[0322] To a suspension of 3-(4,5-dimethylimidazol-1-yl)aniline (94mg) and 3-(2-chloro-4-fluorophenyl)acrylic acid in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (144mg) and N,N-dimethylaminopyridine (31mg) and the mixture was stirred for 24 hours. The mixture was diluted with 10% methanol in dichloromethane and washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give (2E)-3-(2-chloro-4-fluorophenyl)-N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-2-propenamide (95mg).

APCI-mass;m/z370(M+H⁺)

NMR(DMSO, δ): 2.11(3H,s), 6.85(1H,d,J=15.6Hz), 7.12(1H,d,J=8.1Hz), 7.36(1H,dt, J=2.6Hz,8.5Hz), 7.50(1H,t, J=8.0Hz), 7.6-7.9(3H,m), 7.8-8.0(3H,m), 10.56(1H,s)

Example 79

[0323] To a suspension of 3-(4,5-dimethylimidazol-1-yl)aniline (78mg) and 3-(2,3-dichlorophenyl)acrylic acid (90mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (120mg) and N,N-dimethylaminopyridine (25mg) and the mixture was stirred for 24 hours. The mixture was diluted with 15% methanol in dichloromethane and washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give (2E)-3-(2,3-dichlorophenyl)-N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-2-propenamide (93mg).

APCI-mass;m/z386,388(M+H⁺)

NMR(DMSO, δ): 2.11(6H,s), 6.93(1H,d,J=15.6Hz), 7.13(1H,d,J=8.7Hz), 7.4-7.6 (2H,m), 7.6-7.9(5H,m), 7.90(1H, d,J=15.6Hz), 10.60(1H,s)

EP 1 264 820 A1

Example 80

[0324] To a suspension of 3-(4,5-dimethylimidazol-1-yl)aniline (94mg) and 3-[2-(trifluoromethyl)phenyl]acrylic acid (109mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (144mg) and N,N-dimethylaminopyridine (31mg) and the mixture was stirred for 24 hours. The mixture was diluted with 15% methanol in dichloromethane and washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give (2E)-3-[2-(trifluoromethyl)phenyl]-N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-2-propenamide (120mg).

APCI-mass;m/z386(M+H⁺)

NMR(DMSO, δ): 2.11(6H,s), 6.90(1H,d,J=15.2Hz), 7.14(1H,d,J=7.0Hz), 7.51(1H,t,J=8.0Hz), 7.6-8.0(8H,m), 10.61(1H,s)

Example 81

[0325] To a suspension of 3-(2,3-dimethyl-3H-imidazol-4-yl)phenylamine (78mg) and 3-(2,3-dichlorophenyl)acrylic acid (90mg) in dichloromethane (4ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (120mg) and N,N-dimethylaminopyridine (25mg) and the mixture was stirred for 24 hours. The mixture was diluted with 15% methanol in dichloromethane and washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give (2E)-3-(2,3-dichlorophenyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-propenamide (44mg).

APCI-mass;m/z386,388(M+H⁺)

NMR(DMSO, δ): 2.36(3H,s), 3.56(3H,s), 6.87(1H,s), 6.91(1H,d,J=15.6Hz), 7.15(1H,d,J=7.6Hz), 7.4-7.6(2H,m), 7.6-7.9(5H,m), 7.89(1H,d,J=15.6Hz), 10.46(1H,s)

Example 82

[0326] To a suspension of 3-(2-chlorophenyl)acrylic acid (92mg) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphonate (286mg) in N,N-dimethylformamide (5ml) was added 3-(4,5-dimethylimidazol-1-yl)aniline (94mg) and the mixture was stirred for 6 hours. The mixture was diluted with ethyl acetate and washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with ethyl acetate, collected by filtration and dried to give (2E)-3-(2-chlorophenyl)-N-[3-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-2-propenamide (138mg).

APCI-mass;m/z352,254(M+H⁺)

NMR(DMSO, δ): 2.11(3H,s), 2.12(3H,s), 6.89(1H,d,J=15.6Hz), 7.12(1H,d,J=8.7Hz), 7.4-7.9(8H,m), 7.90(1H,d,J=15.6Hz), 10.57(1H,s)

Example 83

[0327] To a mixture of 4-chlorocinnamic acid (142mg) and oxalyl chloride (0.136ml) in dichloromethane (3ml) was added small amount of N,N-dimethylformamide. The mixture was stirred for 2 hours under nitrogen atmosphere and concentrated in vacuo, and diluted with dichloromethane (3ml) to give an acid chloride solution. To a solution of 5-(4,5-dimethyl-1H-imidazol-1-yl)-2-fluoroaniline (160mg) in dichloromethane (2ml) was added the acid chloride solution and 4-(dimethylamino)pyridine (one portion). The mixture was stirred for 2 hours under nitrogen atmosphere. The mixture was diluted with dichloromethane. The separated organic layer was washed with water and brine, and concentrated in vacuo. The crude solid was triturated with dichloromethane to give (2E)-3-(2-chlorophenyl)-N-[5-(4,5-dimethyl-1H-imidazol-1-yl)-2-fluorophenyl]-2-propenamide (137mg).

APCI-mass;m/z370(M+1)

NMR(DMSO, δ): 2.15(3H,s), 2.37(3H,s), 7.23(1H,d,J=15.5Hz), 7.40-7.67(5H,m), 7.76-7.81(1H,m), 7.92(1H,d,J=15.5Hz), 8.43(1H,dd,J=6.8Hz,2.5Hz), 9.27(1H,s), 10.5 (1H,s)

EP 1 264 820 A1

Example 84

[0328] N-[5-chloro-6-[(2-pyridylmethyl)amino]-3-pyridyl]-2,3-dimethyl-1H-indole-7-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z406(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.18(3H,s), 2.35(3H,s), 4.68(2H,d,J=5.7Hz), 6.9-7.1(2H,m), 7.2-7.4(2H,m), 7.5-7.8(3H,m), 8.21(1H,d,J=2.2Hz), 8.28(1H,d,J=2.2Hz), 8.52(1H,d,J=4.0Hz), 10.15(1H,s), 10.73(1H,s)

Example 85

[0329] N-[5-chloro-6-[(2-pyridylmethyl)amino]-3-pyridyl]-4'-fluoro[1,1'-biphenyl]-3-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z433(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.68(2H,d,J=5.7Hz), 7.0-7.5(5H,m), 7.6-8.0(6H,m), 8.11(1H,d,J=2.4Hz), 8.19(1H,s), 8.26(1H,d,J=2.4Hz), 8.52(1H,d,J=4.8Hz), 10.27(1H,s)

Example 86

[0330] N-[5-chloro-6-[(2-pyridylmethyl)amino]-3-pyridyl]-3-(2-thienyl)benzamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z421.40(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.68(2H,d,J=5.7Hz), 7.08(1H,t,J=5.7Hz), 7.1-7.3(3H,m), 7.5-7.9(5H,m), 8.10(1H,d,J=2.2Hz), 8.17(1H,s), 8.26(1H,d,J=2.2Hz), 8.52(1H,d,J=4.8Hz), 10.28(1H,s)

Example 87

[0331] N-[5-chloro-6-[(2-pyridylmethyl)amino]-3-pyridyl]-5-phenyl-2-thiophenecarboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z420.93(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.68(2H,d,J=5.7Hz), 7.09(1H,t,J=5.7Hz), 7.2-7.6(5H,m), 7.62(1H,d,J=3.9Hz), 7.7-7.8(3H,m), 7.93(1H,d,J=3.9Hz), 8.05(1H,d,J=2.2Hz), 8.21(1H,d,J=2.2Hz), 8.52(1H,d,J=4.4Hz), 10.21(1H,s)

Example 88

[0332] N-[5-chloro-6-[(2-pyridylmethyl)amino]-3-pyridyl]-5-(4-fluorophenyl)-2-thiophenecarboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z439(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.68(2H,d,J=5.7Hz), 7.09(1H,t,J=5.7Hz), 7.2-7.4(4H,m), 7.58(1H,d,J=4.0Hz), 7.7-7.9(3H,m), 7.92(1H,d,J=4.0Hz), 8.04(1H,d,J=2.3Hz), 8.20(1H,d,J=2.3Hz), 8.52(1H,d,J=4.0Hz), 10.21(1H,s)

Example 89

[0333] N-[5-chloro-6-[(2-pyridylmethyl)amino]-3-pyridyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z428(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.70(2H,d,J=5.7Hz), 7.08(1H,t,J=5.7Hz), 7.2-7.5(5H,m), 7.6-7.8(2H,m), 8.06(1H,d,J=7.7Hz), 8.16(1H,d,J=7.7Hz), 8.2-8.6(4H,m), 10.33(1H,s)

Example 90

[0334] N-[5-chloro-6-[(2-pyridylmethyl)amino]-3-pyridyl]-6-fluoro-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

EP 1 264 820 A1

APCI-mass;m/z446(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.70(2H,d,J=5.7Hz), 7.08(2H,d,J=5.7Hz), 7.2-7.4(4H,m), 7.6-7.8(2H,m), 8.0-8.1(1H,m), 8.08(1H,d,J=7.6Hz), 8.25(1H,d,J=2.2Hz), 8.31(1H,d, J=2.1Hz), 8.38(1H,d,J=7.6Hz), 8.53(1H,d,J=4.9Hz), 10.34(1H,s), 11.54(1H,s)

Example 91

[0335] To a suspension of 9H-fluorene-1-carboxylic acid (147mg) in dichloromethane (3ml) was added oxalyl chloride (0.2ml) and N,N-dimethylformamide (0.01ml). The mixture was stirred for 2 hours and evaporated to give crude 9H-fluorene-1-carboxylic acid chloride. To a suspension of 4-(pyridine-2-ylmethoxy)aniline dihydrochloride (191mg) and pyridine (0.283ml) in dichloromethane (3ml) was added a solution of crude 9H-fluorene-1-carboxylic acid chloride (obtained above) in dichloromethane (3ml) and stirred for 6 hours. The mixture was diluted with dichloromethane and washed with water and brine. The separated organic layer was dried over potassium carbonate and evaporated. The residue was triturated with methanol, collected by filtration, washed with methanol and isopropyl ether and dried to give N-[4-(2-pyridylmethoxy)phenyl]-9H-fluorene-1-carboxamide (151mg).

APCI-mass;m/z393(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.18(2H,s), 5.19(2H,s), 7.04(2H,d,J=9.1Hz), 7.3-7.8(9H,m), 7.85(1H,t,J=7.8Hz), 7.97(1H,d,J=6.7Hz), 8.09(1H,dd,J=7.5,0.9Hz), 8.59(1H,d, J=7.5Hz), 10.22(1H,s)

Example 92

[0336] To a suspension of N-(4-aminophenyl)-9H-fluorene-1-carboxamide (150mg) and 2-formylpyridine (54mg) and acetic acid (0.03ml) in 1,2-dichloroethane (5ml) was added sodium tri(acetoxyl)borohydride (148mg) and the mixture was stirred for 2 hours. The mixture was diluted with dichloromethane and washed with aqueous sodium hydrogen-carbonate (saturated), water and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was purified with column chromatography (silica gel, 25g, 2% methanol in dichloromethane) to give N-[4-[(2-pyridylmethyl)amino]phenyl]-9H-fluorene-1-carboxamide (61mg).

APCI-mass;m/z392(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.16(2H,s), 4.37(1H,d,J=6.1Hz), 6.25(1H,t,J=6.1Hz), 6.58 (2H,d,J=8.8Hz), 7.2-7.8(10H,m), 7.95(1H,d,J=6.7Hz), 8.06(1H,d,J=6.7Hz), 8.53(1H,d, J=4.0Hz), 9.95(1H,s)

Example 93

[0337] N-[6-(2-pyridylmethoxy)-3-pyridyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 91.

APCI-mass;m/z394(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.20(2H,s), 5.43(2H,s), 7.00(2H,d,J=8.9Hz), 7.3-7.9(8H,m), 7.98(1H,d,J=6.6Hz), 8.1-8.2(2H,m), 8.53(1H,d,J=2.5Hz), 8.57(1H,d,J=4.4Hz), 10.39 (1H,s)

Example 94

[0338] N-[6-(2-pyridylmethoxy)-3-pyridyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z395(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;5.44(2H,s), 7.03(1H,d,J=8.9Hz), 7.2-7.6(5H,m), 7.69(1H,t, J=7.2Hz), 7.83(1H,t,J=7.2Hz), 8.09(1H,d,J=7.5Hz), 8.2-8.3(2H,m), 8.38(1H,d, J=7.5Hz), 8.5-8.7(2H,m)10.45(1H,s), 11.49(1H,s)

Example 95

[0339] N-[6-[(2-pyridylmethyl)amino]-3-pyridyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z393(M+H⁺)

EP 1 264 820 A1

¹H-NMR(DMSO-d₆): δ ;4.18(2H,s), 4.57(2H,d,J=6.0Hz), 6.61(1H,d,J=8.9Hz), 7.08 (1H,t,J=6.1Hz), 7.2-7.8(9H,m), 7.96(1H,d,J=6.5Hz), 8.09(1H,d,J=7.4Hz), 8.28(1H,d, J=2.4Hz), 8.51(1H,d,J=4.7Hz), 10.06(1H,s)

Example 96

5

[0340] N-[6-[(2-pyridylmethyl)amino]-3-pyridyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z394(M+H⁺)

10

¹H-NMR(DMSO-d₆): δ ;4.58(2H,d,J=6.0Hz), 6.63(1H,d,J=8.9Hz), 7.08(1H,t,J=6.0Hz), 7.1-7.5(5H,m), 7.6-7.9(3H,m), 8.05(1H,d,J=7.6Hz), 8.16(1H,d,J=7.6Hz), 8.2-8.3 (2H,m), 8.52(1H,d,J=4.8Hz), 10.16(1H,s), 11.44(1H,s)

Example 97

15

[0341] N-[6-[(2-methyl-3-pyridyl)oxy]-3-pyridyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z395(M+H⁺)

20

¹H-NMR(DMSO-d₆): δ ;2.34(3H,s), 7.1-7.3(4H,m), 7.42(1H,t,J=7.6Hz), 7.53(1H,d, J=8.0Hz), 7.71(1H,d,J=8.0Hz), 8.10(1H,d,J=7.5Hz), 8.17(1H,d,J=7.7Hz), 8.3-8.5 (3H,m), 8.56(1H,s), 10.55(1H,s), 11.49(1H,s)

Example 98

25

[0342] 3-methyl-N-[6-[(2-pyridylmethyl)amino]-3-pyridyl]-2-(trifluoromethyl)-1H-indole-7-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z426(M+H⁺)

30

¹H-NMR(DMSO-d₆):δ;2.43(3H,s), 4.57(2H,d,J=6.0Hz), 6.61(1H,d,J=8.9Hz), 7.07 (1H,t,J=6.0Hz), 7.2-7.4(3H,m), 7.7-8.0(4H,m), 8.28(1H,d,J=2.4Hz), 8.51(1H,dt, J=4.9,0.8Hz), 10.18(1H,s) 11.33(1H,s)

Example 99

35

[0343] A suspension of N-(2-chloro-4-pyridyl)-9H-fluorene-1-carboxamide (160mg) in 1-benzylpiperazine (2ml) was stirred at 140°C for 4 hours and 160°C for 6 hours. After cooling, the mixture was poured into water and the mixture was stirred for 10 minutes. The precipitate was collected by filtration, washed with water and dried to give N-[2-(4-benzyl-1-piperazinyl)-4-pyridyl]-9H-fluorene-1-carboxamide.

APCI-mass;m/z461(M+H⁺)

40

¹H-NMR(DMSO-d₆):δ;3.5-3.7(10H,m), 4.19(2H,s), 7.09(1H,dd,J=1.7,5.7Hz), 7.2-7.8 (11H,m), 7.97(1H,d, J=6.4Hz), 8.04(1H,d,J=5.6Hz), 8.13(1H,d,J=6.7Hz), 10.43(1H,s)

Example 100

45

[0344] To a solution of N-[2-(4-benzyl-1-piperazinyl)-4-pyridyl]-9H-fluorene-1-carboxamide (100mg) in methanol (2ml) and tetrahydrofuran was added hydrochloric acid (6N, 0.1ml) and the mixture was hydrogenated over 10 % palladium hydroxide on carbon (100mg, 50%wet) under hydrogen atmosphere for 8 hours. The catalyst was filtered off and the filtrate was evaporated. To the residue was added hydrochloric acid (1N, 0.5ml) and evaporated. The residue was triturated with ethanol, collected by filtration, washed with ethanol and dried to give N-[2-(1-piperazinyl)-4-pyridyl]-9H-fluorene-1-carboxamide dihydrochloride (64mg).

50

APCI-mass;m/z371(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.29(4H,s), 3.89(4H,s), 4.23(2H,s), 7.3-7.7(5H,m), 7.8-7.9 (2H,m), 8.00(1H,d,J=6.4Hz), 8.10(1H,d,J=6.7Hz), 8.19(1H,d,J=7.5Hz), 9.4-9.8(2H,m), 11.22(1H,s)

55

Example 101

[0345] To a suspension of 2-(3-pyridylmethyl)-5-isoindolylamine (248mg) and pyridine (0.242ml) in dichloromethane (5ml) was added a solution of 9H-fluorene-1-carbonyl chloride (229mg) in dichloromethane (5ml) and stirred for 1 hour.

EP 1 264 820 A1

The mixture was diluted with dichloromethane and washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol and isopropyl ether, collected by filtration, washed with isopropyl ether and dried to give N-[2-(3-pyridylmethyl)-2,3-dihydro-1H-isindol-5-yl]-9H-fluorene-1-carboxamide (151mg).

APCI-mass;m/z418(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 3.83(2H,s), 3.89(2H,s), 3.91(2H,s), 4.18(2H,s), 7.20(1H,d, J=8.0Hz), 7.3-7.5(3H,m), 7.5-7.7(5H,m), 7.80(1H,d,J=7.8Hz), 7.97(1H,d,J=6.7Hz), 8.10(1H,d,J=7.2Hz), 8.50(1H,d,J=3.6Hz), 8.59(1H,s), 10.30(1H,s)

Example 102

[0346] N-benzyl-5-[(9H-fluorene-1-ylcarbonyl)amino]nicotinamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z420(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.23(2H,s), 4.53(1H,d,J=5.9Hz), 7.2-7.5(7H,m), 7.5-7.7 (2H,m), 7.81(1H,d,J=7.6Hz), 7.99 (1H,d,J=6.4Hz), 8.15(1H,d,J=7.3Hz), 8.71(1H,s), 8.82(1H,d,J=1.8Hz), 9.08(1H,d,J=2.4Hz), 9.30(1H,t,J=5.9Hz), 10.70(1H,s)

Example 103

[0347] N-(4-fluorobenzyl)-5-[(9H-fluorene-1-ylcarbonyl)amino]nicotinamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z438(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.23(2H,s), 4.53(1H,d,J=5.9Hz), 7.2-7.5(7H,m), 7.5-7.7 (2H,m), 7.81(1H,d,J=7.6Hz), 7.99 (1H,d,J=6.4Hz), 8.15(1H,d,J=7.3Hz), 8.71(1H,s), 8.82(1H,d,J=1.8Hz), 9.08(1H,d,J=2.4Hz), 9.30(1H,t,J=5.9Hz), 10.70(1H,s)

Example 104

[0348] N-[6-[(2-pyridylmethyl)amino]-3-pyridyl]-3-(2-thienyl)benzamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z426(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.57(2H,d,J=6.0Hz), 6.61(1H,d,J=8.9Hz), 7.1-7.5(5H,m), 7.6-7.9(6H,m), 8.17(1H,s), 8.26 (1H,d,J=2.5Hz), 8.51(1H,d,J=4.8Hz), 10.12(1H,s)

Example 105

[0349] 3-(2-thienyl)-N-[3-(1H-1,2,4-triazol-1-yl)phenyl]benzamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z347(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 7.20(1H,dd,J=3.7,5.0Hz), 7.5-7.7(5H,m), 7.8-8.0(3H,m), 8.22 (1H,s), 8.26(1H,s), 8.39(1H,s), 9.29(1H,s), 10.62(1H,s)

Example 106

[0350] N-[3-(5-pyrimidinyl)phenyl]-3-(2-thienyl)benzamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z358(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 7.20(1H,dd,J=3.8,4.8Hz), 7.5-7.7(5H,m), 7.8-8.0(3H,m), 8.17 (1H,s), 8.22(1H,s), 9.12(2H,s), 9.23(1H,s), 10.53(1H,s)

EP 1 264 820 A1

Example 107

[0351] N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2-[4-(1-methyl-1-phenylethyl) phenyl]acetamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z424(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 1.62(6H,s), 2.34(3H,s), 3.51(3H,s), 3.60(2H,s), 6.83(1H,s), 7.0-7.5(10H,m), 7.55(1H,d, J=8.7Hz), 7.68(1H,s), 10.25(1H,s)

Example 108

[0352] A suspension of (2E)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-3-(1-naphthyl)-2-propenamide (81mg) in methanol (2ml) was hydrogenated over 10 % palladium on carbon (50%wet) under hydrogen atmosphere for 10 hours. The catalyst was filtered off. The filtrate was concentrated, purified with column chromatography (silica gel, 20g, 3% methanol in dichloromethane) to give N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-3-(1-naphthyl)propanamide (57mg).

APCI-mass;m/z370(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.34(3H,s), 2.75(2H,t,J=7.7Hz), 3.44(2H,t,J=7.7Hz), 3.52 (3H,s), 6.83(1H,s), 7.08(1H,d, J=7.7Hz), 7.34(1H,d,J=8.0Hz), 7.4-8.0(8H,m), 8.14(1H, d,J=8.0Hz), 10.05(1H,s)

Example 109

[0353] N-[2-[(2-pyridylmethyl)amino]-5-pyrimidinyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z395(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.62(2H,d,J=6.2Hz), 7.1-7.4(4H,m), 7.41(1H,t,J=7.6Hz), 7.6-7.8(3H,m), 8.07(1H,d, J=7.6Hz), 8.17(1H,d,J=7.7Hz), 8.51(1H,d,J=4.8Hz), 8.67(2H,s), 10.29(1H,s), 11.47(1H,s)

Example 110

[0354] N-[2-[(2-pyridylmethyl)amino]-5-pyrimidinyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z394(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.20(2H,s), 4.61(2H,d,J=6.3Hz), 7.2-7.5(4H,m), 7.5-7.9 (5H,m), 7.97(1H,d,J=6.7Hz), 8.11 (1H,d,J=7.4Hz), 8.50(1H,d,J=4.8Hz), 8.61(1H,s), 10.18(1H,s)

Example 111

[0355] To a suspension of 3-chloro-5-nitro-N-(2-pyridylmethyl)-2-pyridylamine (132mg) and iron powder (139mg) in ethanol (2ml) was added hydrochloric acid (1N, 1ml) and the mixture was refluxed for 3 hours. After cooling, the mixture was filtered and the filtrate was evaporated. To the residue was added 9H-fluorene-1-carboxylic acid (105mg) and dichloromethane (5ml). To a suspension was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (144mg) and N,N-dimethylaminopyridine (183mg) and the mixture was stirred for 16 hours. To the mixture was added aqueous sodium hydroxide (1N, 5ml) and dichloromethane and stirred for 15 minutes and filtered through celite. The organic layer was separated and washed with water and brine, dried over magnesium sulfate and evaporated. The residue was purified with column chromatography (silica gel, 25g, 2% methanol in dichloromethane) to give N-[5-chloro-6-[(2-pyridylmethyl)amino]-3-pyridyl]-9H-fluorene-1-carboxamide (55mg).

APCI-mass;m/z427(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 4.19(2H,s), 4.68(2H,d,J=5.7Hz), 7.08(1H,t,J=5.7Hz), 7.2-7.8 (8H,m), 7.97(1H,d,J=6.5Hz), 8.10(1H,d,J=6.9Hz), 8.16(1H,dd,J=2.2Hz), 8.26(1H,d, J=2.2Hz), 8.52(1H,d,J=4.8Hz), 10.24(1H,s)

Example 112

[0356] N-[5-chloro-6-[(2-pyrazinylmethyl)amino]-3-pyridyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 161.

EP 1 264 820 A1

APCI-mass;m/z428(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;4.18(2H,s), 4.73(2H,d,J=5.8Hz), 7.16(1H,t,J=5.8Hz) 7.3-7.7 (4H,m), 7.72(1H,d,J=6.9Hz), 7.97(1H,d,J=6.3Hz), 8.11(1H,d,J=6.8Hz) 8.16(1H,d, J=2.2Hz), 8.26(1H,d,J=2.2Hz), 8.5-8.7(3H,m), 10.25(1H,s)

5 Example 113

[0357] N-[3-(4-methoxy-3-pyridyl)phenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

10 APCI-mass;m/z394(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.88(3H,s), 7.1-7.7(7H,m), 7.70(1H,d,J=8.0Hz), 7.80(1H,d, J=8.1Hz), 8.08(1H,s), 8.1-8.3 (2H,m), 8.3-8.5(2H,m), 8.48(1H,d,J=5.7Hz), 10.45(1H,s), 11.51(1H,s)

Example 114

15

[0358] N-[3-(1-ethyl-2-methyl-1H-imidazol-5-yl)phenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z395(M+H⁺)

20 ¹H-NMR(DMSO-d₆): δ ;1.19(3H,t,J=7.1Hz), 2.39(3H,s), 4.01(2H,q,J=7.1Hz), 6.85 (1H,s), 7.1-7.5(5H,m), 7.71(1H, d,J=8.1Hz), 7.88(1H,d,J=8.1Hz), 7.96(1H,s), 8.11(1H, d,J=7.7Hz), 8.18(1H,J=7.7Hz), 8.38(1H,d,J=7.5Hz), 10.48 (1H,s), 11.48(1H,s)

Example 115

25

[0359] N-[3-(1-ethyl-2-methyl-1H-imidazol-5-yl)phenyl]-3-(2-thienyl)benzamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z388(M+H⁺)

30 ¹H-NMR(DMSO-d₆): δ ;1.18(3H,t,J=7.2Hz), 3.99(2H,q,J=7.2Hz), 6.84(1H,s), 7.1-7.3 (2H,m), 7.45(1H,t,J=7.9Hz), 7.5-7.7(3H,m), 7.78(1H,d,J=8.1Hz), 7.8-8.0(3H,m), 8.19 (1H,s), 10.46(1H,s)

Example 116

35

[0360] 3-(5-chloro-2-thienyl)-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl] benzamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z408(M+H⁺)

40 ¹H-NMR(DMSO-d₆): δ ;2.36(3H,s), 3.55(3H,s), 6.88(1H,s), 7.1-7.3(2H,m), 7.45(1H,t, J=7.9Hz), 7.5-7.7(2H,m), 7.7-8.0(4H,m), 8.13(1H,s), 10.44(1H,s)

Example 117

45

[0361] N-[3-[2-(difluoromethyl)-1-methyl-1H-imidazol-5-yl]phenyl]-3-(2-thienyl) benzamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z410(M+H⁺)

50 ¹H-NMR(DMSO-d₆): δ ;3.77(3H,s), 7.0-7.3(3H,m), 7.28(1H,d,J=7.8Hz), 7.5-7.7 (4H,m), 7.9-8.1(4H,m), 8.19(1H, s), 10.51(1H,s)

Example 118

55

[0362] N-[3-[2-(difluoromethyl)-1-methyl-1H-imidazol-5-yl]phenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z417(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;3.79(3H,s), 7.2-7.5(6H,m), 7.56(1H,d,J=7.8Hz), 7.71(1H,d, J=8.0Hz), 7.96(1H,d, J=8.1Hz), 8.06(1H,s), 8.12(1H,d,J=7.5Hz), 8.18(1H,d,J=7.7Hz), 8.39(1H,d,J=7.7Hz), 10.53(1H,s), 11.50(1H,s)

EP 1 264 820 A1

Example 119

[0363] N-[6-[(2-pyrazinylmethyl)amino]-3-pyridyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass; m/z 394($M+H^+$)

1H -NMR(DMSO- d_6): δ ;4.18(2H,s), 4.63(2H,d,J=6.0Hz), 6.65(1H,d,J=8.9Hz), 7.17 (1H,t,J=6.0Hz), 7.3-7.6(4H,m), 7.63(1H,d,J=6.5Hz), 7.71(1H,d,J=6.9Hz), 7.82(1H,dd, J=8.9Hz,2.6Hz), 7.96(1H,dd,J=8.0Hz,1.5Hz), 8.09(1H,d, J=6.7Hz), 8.28(1H,d, J=2.4Hz), 8.51(1H,d,J=2.3Hz), 8.5-8.6(2H,m), 10.08(1H,s)

Example 120

[0364] N-[3-(3-methyl-4H-1,2,4-triazol-4-yl)phenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass; m/z 368.47($M+H^+$)

1H -NMR(DMSO- d_6): δ ;2.40(3H,s), 7.2-7.5(4H,m), 7.61(1H,t,J=8.0Hz), 7.71(1H,d, J=8.0Hz), 7.98(1H,d,J=8.0Hz), 8.0-8.3(3H,m),8.40(1H,d,J=7.1Hz), 8.73(1H,s), 10.65 (1H,s), 11.51(1H,s)

Example 121

[0365] N-[4-methoxy-3-(5-pyrimidinyl)phenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass; m/z 395($M+H^+$)

1H -NMR(DMSO- d_6): δ ;3.84(3H,s), 7.2-7.5(4H,m), 7.71(1H,d,J=8.0Hz), 7.93(1H,dd, J=8.9Hz,2.6Hz), 8.03(1H,d, J=2.4Hz), 8.13(1H,d,J=8.0Hz), 8.17(1H,d,J=8.0Hz), 8.37 (1H,d,J=7.5Hz), 8.98(2H,s), 9.18(1H,s), 10.41(1H,s), 11.51(1H,s)

Example 122

[0366] To a mixture of N-(3-formylphenyl)-9H-fluorene-1-carboxamide (94mg), 4-aminopyrimidine (57mg), and N,N-dimethylformamide (1ml) was added titanium (IV) isopropoxide (146mg) at ambient temperature. After stirring for 1 hour, to the reaction mixture was added sodium triacetoxyborohydride (254mg) and stirred for 14 hours. The reaction mixture was diluted with ethyl acetate (30ml) and washed with water (3 times, 30ml) and brine (10ml). The organic layer was dried over magnesium sulfate and filtered. Evaporation gave a residue which was purified by silica gel chromatography (ethyl acetate) to give N-[3-[(4-pyrimidinylamino)methyl]phenyl]-9H-fluorene-1-carboxamide (42mg) as white crystals.

MS:393($M+1$)

NMR(DMSO, δ);4.18(2H,br s), 4.54(2H,d,J=5.7Hz), 6.4-6.6(1H,m), 7.07(1H,d, J=7.5Hz), 7.2-8.2(12H,m), 8.41 (1H,s), 10.35(1H,br s)

Example 123

[0367] This was prepared in a manner similar to Example 122 to give N-[3-[(4-pyridylamino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:392($M+1$)

NMR(DMSO, δ);4.18(2H,br s), 4.49(2H,d,J=5.7Hz), 6.6-7.0(2H,m), 7.10(1H,d, J=8.1Hz), 7.3-8.2(12H,m), 8.61 (1H, s), 10.39(1H,br s)

Example 124

[0368] This was prepared in a manner similar to Example 122 to give N-[3-[(5-bromo-1,3-thiazol-2-yl)amino]methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:476,478(1:1,Br isotopes, $M+1$)

EP 1 264 820 A1

NMR(DMSO, δ): 4.18(2H, br s), 4.44(2H, d, J=5.8Hz), 7.0-7.2(2H, m), 7.2-7.9(8H, m), 7.97(1H, d, J=6.6Hz), 8.10(1H, d, J=7.2Hz), 8.37(1H, t, J=5.8Hz), 10.37(1H, br s)

Example 125

5

[0369] This was prepared in a manner similar to Example 122 to give N-[3-[[[3-methyl-5-isoxazolyl)amino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:396(M+1)

10 NMR(DMSO, δ): 2.00(3H, s), 4.18(2H, br s), 4.26(2H, d, J=6.2Hz), 7.08(1H, d, J=7.6Hz), 7.2-8.2(12H, m), 10.36(1H, br s)

Example 126

15 [0370] This was prepared in a manner similar to Example 122 to give N-[3-[[[4,6-dimethyl-2-pyridyl)amino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:420(M+1)

20 NMR(DMSO, δ): 2.14(3H, s), 2.28(3H, s), 4.20(2H, br s), 4.52(2H, d, J=5.9Hz), 6.2-6.4 (2H, m), 7.09(1H, d, J=7.6Hz), 7.2-7.8(8H, m), 7.84(1H, br s), 7.97(1H, d, J=6.5Hz), 8.10(1H, d, J=7.3Hz), 10.36(1H, br s)

Example 127

25 [0371] This was prepared in a manner similar to Example 122 to give N-[3-[[[5,6-dimethyl-1,2,4-triazin-3-yl)amino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:422(M+1)

30 NMR(DMSO, δ): 2.31(3H, s), 2.38(3H, s), 4.17(2H, br s), 4.55(2H, d, J=6.5Hz), 7.07(1H, d, J=7.3Hz), 7.2-7.9(9H, m), 7.97(1H, d, J=7.7Hz), 8.10(1H, d, J=7.3Hz), 10.32(1H, br s)

Example 128

35 [0372] This was prepared in a manner similar to Example 122 to give N-[3-[[[6-chloro-3-pyridazinyl)amino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:427(M+1)

NMR(DMSO, δ): 4.18(2H, br s), 4.56(2H, d, J=5.8Hz), 6.97(1H, d, J=9.3Hz), 7.10(1H, d, J=7.6Hz), 7.2-7.8(9H, m), 7.83(1H, br s), 7.97(1H, d, J=6.6Hz), 8.10(1H, d, J=7.2Hz), 10.35 (1H, br s)

Example 129

[0373] This was prepared in a manner similar to Example 122 to give N-[3-[[[5-pyridine-3-yl-4H-1,2,4-triazol-3-yl)amino)methyl]phenyl]-9H-fluorene-1-carboxamide (11.2mg).

45 MS:459(M+1)

NMR(DMSO, δ): 4.18(2H, br s), 4.45(2H, d, J=6.6Hz), 7.0-8.4(15H, m), 8.54(1H, d, J=4.5Hz), 9.08(1H, br s), 10.37 (1H, br s)

Example 130

50

[0374] This was prepared in a manner similar to Example 122 to give N-[3-[(1,3,4-thiadiazol-2-ylamino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:399(M+1)

55 NMR(DMSO, δ): 4.19(2H, br s), 4.51(2H, d, J=5.7Hz), 7.11(1H, d, J=7.8Hz), 7.2-7.8 (7H, m), 7.86(1H, br s), 7.97(1H, d, J=6.5Hz), 8.11(1H, d, J=7.0Hz), 8.33(1H, t, J=5.7Hz), 8.64(1H, s), 10.36(1H, br s)

EP 1 264 820 A1

Example 131

[0375] This was prepared in a manner similar to Example 122 to give N-[3-[(1H-1,2,4-triazol-3-ylamino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:382(M+1)

NMR(DMSO, δ): 4.18(2H, br s), 4.31(2H, d, J=5.8Hz), 6.77(1H, t, J=5.8Hz), 6.9-7.8 (10H, m), 7.85(1H, br s), 7.97(1H, d, J=6.6Hz), 8.10(1H, d, J=7.0Hz), 10.35(1H, br s)

Example 132

[0376] This was prepared in a manner similar to Example 122 to give N-[3-[(2-chloro-4-pyridyl)amino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:426(M+1)

NMR(DMSO, δ): 4.18(2H, br s), 4.36(2H, d, J=5.8Hz), 6.4-6.6(2H, m), 7.08(1H, d, J=7.5Hz), 7.3-7.9(10H, m), 7.97(1H, d, J=6.6Hz), 8.10(1H, d, J=7.4Hz), 10.37(1H, br s)

Example 133

[0377] This was prepared in a manner similar to Example 158 to give N-[3-[(2-chloro-4-pyridyl)amino)methyl]phenyl]-9H-carbazol-1-carboxamide.

MS:427(M+1)

NMR(DMSO, δ): 4.37(2H, d, J=5.8Hz), 6.5-6.6(2H, m), 7.0-7.5(5H, m), 7.53(1H, t, J=5.8Hz), 7.6-8.0(4H, m), 8.0-8.3(2H, m), 8.37(1H, d, J=7.1Hz), 10.41(1H, br s), 11.49 (1H, br s)

Example 134

[0378] This was prepared in a manner similar to Example 158 to give N-[3-[(4-pyridylamino)methyl]phenyl]-9H-carbazol-1-carboxamide.

MS:393(M+1)

NMR(DMSO, δ): 4.34(2H, d, J=5.8Hz), 6.4-6.6(2H, m), 7.0-7.5(6H, m), 7.6-8.3(7H, m), 8.36(1H, d, J=7.5Hz), 10.40(1H, br s), 11.50(1H, br s)

Example 135

[0379] This was prepared in a manner similar to Example 156 to give N-[3-[(5-fluoro-1H-benzimidazol-2-yl)amino)methyl]phenyl]-9H-fluorene-1-carboxamide.

MS:449(M+1)

NMR(DMSO, δ): 4.18(2H, br s), 4.54(2H, d, J=6.0Hz), 6.5-6.8(1H, m), 6.8-7.8(11H, m), 7.86(1H, br s), 7.96(1H, d, J=6.6Hz), 8.10(1H, d, J=7.2Hz), 10.36(1H, br s)

Example 136

[0380] This was prepared in a manner similar to Example 158 to give N-[3-[(5-methoxy-1H-benzimidazol-2-yl)amino)methyl]phenyl]-9H-carbazol-1-carboxamide.

MS:462(M+1)

NMR(DMSO, δ): 3.70(3H, s), 4.54(2H, d, J=5.8Hz), 6.48(1H, dd, J=2.3Hz, 8.4Hz), 6.75 (1H, d, J=2.3Hz), 6.9-7.5(7H, m), 7.6-7.8(2H, m), 7.95(1H, br s), 8.0-8.3(2H, m), 8.36(1H, d, J=7.6Hz), 10.40(1H, br s), 10.7(1H, br s), 11.51(1H, br s)

Example 137

[0381] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-fluoro-5-(iminobenzylamino)phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

EP 1 264 820 A1

mp:103-105°C

MS:428(M+1)

NMR(DMSO, δ):6.37(1H,d,J=10.0Hz), 6.53(2H,s), 6.81-6.93(2H,m), 7.31-7.49 (4H,m), 7.64(1H,dd,J=7.5Hz, 7.5Hz), 7.73-7.95(6H,m), 10.44(1H,s)

5

Example 138

[0382] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-(iminobenzylamino)phenyl]-3-(2-fluorophenyl)-2-propenamide.

10

mp:186-187°C

MS:394(M+1)

NMR(DMSO, δ):6.57(3H,s), 6.92(1H,d,J=15.8Hz), 7.04(1H,s), 7.24-7.37(2H,m), 7.39-7.56(4H,m), 7.55-7.78(3H,m), 7.94(2H,s), 10.37(1H,s)

15

Example 139

[0383] This was prepared in a manner similar to Example 14 to give (2E)-N-[5-(iminobenzylamino)-2-methylphenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

20

mp:220-222°C

MS:424(M+1)

NMR(DMSO, δ):2.24(3H,s), 6.54(2H,s), 6.67(1H,d,J=7.6Hz), 7.07-7.21(2H,m), 7.30 (1H,s), 7.39-7.56(3H,m), 7.63 (1H,dd,J=7.5Hz,7.5Hz), 7.75-8.03(6H,m), 9.52 (1H,s)

25

Example 140

[0384] This was prepared in a manner similar to Example 14 to give (2E)-N-[5-(iminobenzylamino)-2-methoxyphenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

30

mp:208-210°C

MS:440(M+1)

NMR(DMSO, δ):3.87(3H,s), 6.33(2H,s), 6.62(1H,d,J=7.0Hz), 7.04(1H,d,J=8.7Hz), 7.34(1H,d,J=15.6Hz), 7.40-7.50(3H,m), 7.62(1H,dd,J=7.6Hz,7.6Hz), 7.71-8.00(7H,m), 9.48(1H,s)

35

Example 141

[0385] This was prepared in a manner similar to Example 14 to give (2E)-N-[2-chloro-5-(iminobenzylamino)phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

40

mp:198-199°C

MS:444(M+1)

NMR(DMSO, δ):6.47(2H,s), 6.68(1H,d,J=8.3Hz), 7.26(1H,d,J=15.4Hz), 7.35-7.69 (6H,m), 7.73-8.03(6H,m), 9.68 (1H,s)

45

Example 142

[0386] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-(iminobenzylamino)phenyl]-3-(2-bromophenyl)-2-propenamide.

50

mp:99-101°C

MS:454,456(M+1,Br isomer)

NMR(DMSO, δ):6.58(3H,br s), 6.81(1H,d,J=15.5Hz), 7.02(1H,s), 7.31-7.62(6H,m), 7.70-7.80(2H,m), 7.85(1H,d,J=15.5Hz), 7.97(2H,m), 10.37(1H,s)

55

Example 143

[0387] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)-4-methylphenyl]-

EP 1 264 820 A1

3-(2-trifluoromethylphenyl)-2-propenamide.

mp:112-116°C

MS:424(M+1)

5 NMR(DMSO, δ):2.04(3H,s), 6.16(2H,s), 6.90(1H,d,J=15.3Hz), 7.11-7.19(2H,m), 7.29(1H,d,J=8.3Hz), 7.40-7.51(3H,m), 7.62(1H,dd,J=7.4Hz,7.4Hz), 7.71-8.03(6H,m), 10.19(1H,s)

Example 144

10 **[0388]** This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)-4-methoxyphenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

mp:213-214°C

MS:440(M+1)

15 NMR(DMSO, δ):3.71(3H,s), 6.28(2H,s), 6.88(1H,d,J=15.3Hz), 6.97(1H,d,J=8.9Hz), 7.17(1H,s), 7.33-7.50(4H,m), 7.62(1H,dd,J=7.5Hz,7.5Hz), 7.71-8.00(6H,m), 10.16(1H,s)

Example 145

20 **[0389]** This was prepared in a manner similar to Example 14 to give (2E)-N-[4-chloro-3-(iminobenzylamino)phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

mp:188-189°C

MS:444(M+1)

25 NMR(DMSO, δ):6.49(2H,s), 6.88(1H,d,J=15.4Hz), 7.27-7.50(6H,m), 7.63(1H,dd, J=7.5Hz,7.5Hz), 7.72-7.97(6H,m), 10.37(1H,s)

Example 146

30 **[0390]** This was prepared in a manner similar to Example 14 to give (2E)-N-[3-(iminobenzylamino)-5-(methylsulfonylamino)phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

mp:150-155°C

MS:503(M+1)

35 NMR(DMSO, δ):3.02(3H,s), 6.47(3H,br s), 6.92(1H,d,J=15.4Hz), 7.10(1H,s), 7.28(1H,s), 7.40-7.51(3H,m), 7.63(1H,dd,J=7.4Hz,7.4Hz), 7.70-7.99(6H,m), 9.68(1H,s), 10.34(1H,s)

Example 147

40 **[0391]** This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[imino(4-methylsulfonylamino)benzyl]amino]phenyl]-3-(2-chlorophenyl)-2-propenamide.

mp: 158-160°C

MS:503(M+1)

45 NMR(DMSO, δ):6.50(2H,br s), 6.57(1H,s), 6.86(1H,d,J=15.6Hz), 7.01(1H,s), 7.23(2H,d,J=8.7Hz), 7.41-7.50(2H,m), 7.50-7.59(2H,m), 7.73-7.95(4H,m), 10.01(1H,s) 10.37(1H,s)

Example 148

50 **[0392]** This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[imino(2-fluorobenzyl)amino]phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

mp:209-210°C

MS:462(M+1)

55 NMR(CDCl₃, δ):5.29(2H,br s), 6.49(1H,d,J=15.3Hz), 6.80(1H,s), 7.08-7.31(3H,m), 7.41-7.76(7H,m), 8.04-8.18(2H,m)

EP 1 264 820 A1

Example 149

[0393] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-[imino(2-fluorobenzyl)amino]phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide hydrochloride.

MS:428(free+1)

NMR(DMSO, δ): 7.05(1H,d,J=15.4Hz), 7.37-7.74(7H,m), 7.77-8.03(5H,m), 8.48(1H,s), 9.23(1H,s), 10.07(1H,s), 11.05(1H,s), 11.61(1H,s)

Example 150

[0394] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-(iminobenzylamino)-2-methoxyphenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

MS:474(M+1)

NMR(DMSO, δ): 3.80(3H,s), 6.50(2H,s), 6.64(1H,s), 7.30-7.55(4H,m), 7.63(1H,t,J=7.4Hz), 7.75-8.05(7H,m), 9.71(1H,s)

Example 151

[0395] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-(iminobenzylamino)-4-methoxyphenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

MS:474(M+1)

NMR(DMSO, δ): 3.68(3H,s), 6.53(2H,br s), 6.84(1H,d,J=15.3Hz), 7.00(1H,s), 7.40-7.46(3H,m), 7.55-7.69(2H,m), 7.71-8.06(6H,m), 10.23(1H,s)

Example 152

[0396] This was prepared in a manner similar to Example 14 to give (2E)-N-[2,4-difluoro-5-[imino(4-acetylaminobenzyl)amino]phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

mp:180-185°C

MS:503(M+1)

NMR(DMSO, δ): 2.07(3H,s), 6.54(2H,s), 7.14(1H,d,J=15.3Hz), 7.29(1H,t,J=10.8Hz), 7.60-7.95(10H,m), 10.03(1H,s), 10.12(1H,s)

Example 153

[0397] This was prepared in a manner similar to Example 14 to give 1:1 complex of phosphoric acid with (2E)-N-[3-chloro-5-[imino(4-methylsulfonylaminobenzyl)amino]phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

mp:180-185°C

MS:537(M+1)

NMR(DMSO, δ): 3.17(3H,s), 6.89(1H,d,J=15.4Hz), 7.29(1H,s), 7.36-7.43(2H,m), 7.60-7.96(9H,m), 9.40(2H,br s), 10.51(1H,s), 10.76(1H,s), 11.36(1H,s)

Example 154

[0398] This was prepared in a manner similar to Example 14 to give (2E)-N-[2,3-dichloro-5-(iminobenzylamino)phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide.

mp:213-214°C

MS:478(M+1)

NMR(DMSO, δ): 6.67(2H,s), 6.89(1H,s), 7.25(1H,d,J=15.3Hz), 7.40-7.50(4H,m), 7.64(1H,t,J=7.5Hz), 7.75-7.98(6H,m), 9.82(1H,s)

EP 1 264 820 A1

Example 155

[0399] To (2E)-N-[2,3-dichloro-5-(iminobenzylamino)phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide (50mg) in ethyl acetate (1ml) was added 4N hydrochloric acid (1ml) in ethyl acetate. After one hour at room temperature, evaporated, slurried in hexane to give (2E)-N-[2,3-dichloro-5-(iminobenzylamino)phenyl]-3-(2-trifluoromethylphenyl)-2-propenamide hydrochloride (14mg) as a brown amorphous solid.

MS:478(free+1)

NMR(DMSO, δ): 7.12-8.22(13H,m), 9.24(1H,s), 9.98(1H,s), 10.21(1H,s), 11.68(1H,s)

Example 156

[0400] To a mixture of 3-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluoroaniline (62mg) and triethylamine (73mg) in dichloromethane (1ml) was added fluorene-1-carboxylic acid chloride (145mg) at ambient temperature. After stirring for 6 hours, the reaction mixture was diluted with ethyl acetate (5ml) and washed with water (3 times, 30ml). The organic layer was dried over magnesium sulfate and filtered. Evaporation gave a residue which was purified by silica gel chromatography (dichloromethane-methyl alcohol=10/1) and triturated with a mixture of ethyl acetate-isopropyl ether to give N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-fluorophenyl]-9H-fluorene-1-carboxamide (55mg) as pale yellow crystals.

MS:398(M+1)

NMR(DMSO, δ): 2.37(3H,s), 3.60(3H,s), 4.21(2H, br s), 6.97(1H,s), 6.9-7.2(1H,m), 7.3-7.5(2H,m), 7.5-7.9(5H,m), 7.99(1H,d,J=6.5Hz), 8.14(1H,d,J=7.2Hz), 10.62(1H,s)

Example 157

[0401] This was prepared in a manner similar to Example 156 to give N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-9H-fluorene-1-carboxamide.

MS:414(M+1)

NMR(DMSO, δ): 2.37(3H,s), 3.59(3H,s), 4.21(2H, br s), 6.98(1H,s), 7.2-7.9(7H,m), 7.9-8.1(2H,m), 8.14(1H,d,J=7.3Hz), 10.60(1H,s)

Example 158

[0402] To a mixture of 3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyaniline (1.07g), 1-fluorene-1-carboxylic acid (1.24g), 1-hydroxybenzotriazole (799mg), 4-dimethylaminopyridine (722mg), and dichloromethane (50ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.13g) at ambient temperature under stirring. After stirring for 2 days, the reaction mixture was poured into 1N-hydrochloric acid (200ml). The separated aqueous layer was washed with dichloromethane (200ml), neutralized with 1N-sodium hydroxide, and extracted with dichloromethane (3 times, 200ml). The combined organic extracts were dried over magnesium sulfate and filtered. Evaporation gave a residue which was purified by silica gel chromatography (dichloromethane-methyl alcohol; 1 \rightarrow 2 \rightarrow 3%) and triturated with ethyl acetate-n-hexane (1:2) to give N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyphenyl]-9H-fluorene-1-carboxamide (1.16g) as pale yellow crystals.

MS:410(M+1)

NMR(DMSO, δ): 2.36(3H,s), 3.57(3H,s), 3.81(3H,s), 4.20(2H, br s), 6.7-6.8(1H,m), 6.89(1H,s), 7.3-7.5(3H,m), 7.5-7.7(3H,m), 7.74(1H,d,J=7.7Hz), 7.9-8.1(1H,m), 8.13(1H,d,J=7.5Hz), 10.40(1H, br s)

Example 159

[0403] This was prepared in a manner similar to Example 156 to give N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-(4-morpholinyl)phenyl]-9H-fluorene-1-carboxamide.

MS:465(M+1)

NMR(DMSO, δ): 2.35(3H,s), 3.0-3.3(4H,m), 3.56(3H,s), 3.6-3.9(4H,m), 4.20(2H, br s), 6.72(1H,s), 6.86(1H,s), 7.2-7.8(7H,m), 7.9-8.1(1H,m), 8.11(1H,d,J=7.2Hz), 10.29(1H,s)

EP 1 264 820 A1

Example 160

[0404] This was prepared in a manner similar to Example 158 to give (2E)-N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-3-(2-(trifluoromethyl)phenyl)-2-propenamide.

MS:420(M+1)

NMR(DMSO, δ): 2.36(3H,s), 3.57(3H,s), 6.87(1H,d,J=15.3Hz), 6.97(1H,s), 7.2-7.3(1H,m), 7.5-8.0(7H,m), 10.65(1H,br s)

Example 161

[0405] To a suspension of 3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyaniline (52mg) and 6-fluoro-9H-carbazol-1-carboxylic acid (55mg) in dichloromethane (2ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (69mg) and N,N-dimethylaminopyridine (15mg) and the mixture was stirred for 18 hours. The mixture was diluted with dichloromethane and washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyphenyl]-6-fluoro-9H-carbazol-1-carboxamide (40mg).

APCI-mass;m/z429.40(M+H⁺)

¹H-NMR(DMSO-d₆): δ : 2.37(3H,s), 3.59(3H,s), 3.83(3H,s), 6.74(1H,s), 6.91(1H,s), 7.2-7.4(2H,m), 7.53(1H,t, J=1.4Hz), 7.62(1H,t,J=2.0Hz), 7.71(1H,dd,J=4.6Hz,8.9Hz), 8.03(1H,dd,J=2.5Hz,9.3Hz), 8.13(1H,d,J=7.2Hz), 8.40(1H,d,J=7.6Hz), 10.44(1H,s), 11.56(1H,s)

Example 162

[0406] N-[3-(1,2-dimethyl-1H-imidazol-5-yl)-5-methoxyphenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z411.40(M+H⁺)

¹H-NMR(DMSO-d₆): δ : 2.37(3H,s), 3.59(3H,s), 3.83(3H,s), 6.74(1H,t,J=1.8Hz), 6.91(1H,s), 7.21(1H,t,J=7.5Hz), 7.31(1H,t,J=7.7Hz), 7.42(1H,t,J=7.6Hz), 7.54(1H,s), 7.63(1H,t,J=2.0Hz), 8.10(1H,d,J=7.7Hz), 8.18(1H,d,J=7.7Hz), 8.38(1H,d,J=7.6Hz), 10.43(1H,s), 11.50(1H,s)

Example 163

[0407] N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z415.27(M+H⁺)

¹H-NMR(DMSO-d₆): δ : 2.38(3H,s), 3.61(3H,s), 6.99(1H,s), 7.2-7.5(4H,m), 7.72(1H,d, J=8.0Hz), 7.84(1H,t, J=1.6Hz), 8.1-8.3(3H,m), 8.40(1H,d,J=7.5Hz), 10.61(1H,s), 11.53(1H,s)

Example 164

[0408] N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-6-fluoro-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z433.20(M+H⁺)

¹H-NMR(DMSO-d₆): δ : 2.37(3H,s), 3.61(3H,s), 6.98(1H,s), 7.2-7.4(3H,m), 7.70(1H,dd,J=9.3Hz,4.6Hz), 7.83(1H,s), 8.04(1H,dd,J=9.3Hz,2.5Hz), 8.1-8.3(2H,m), 8.42(1H,d,J=7.6Hz), 10.61(1H,s), 11.50(1H,s)

Example 165

[0409] N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-2,3-dimethyl-1H-indole-7-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z393.33(M+H⁺)

¹H-NMR(DMSO-d₆): δ : 2.18(3H,s), 2.37(6H,s), 3.59(3H,s), 6.96(1H,s), 7.09(1H,t, J=7.7Hz), 7.23(1H,t,J=1.7Hz),

EP 1 264 820 A1

7.63(1H,d,J=7.7Hz), 7.71(1H,d,J=7.7Hz), 7.81(1H,s), 8.11(1H,t,J=1.9Hz), 10.44(1H,s) 10.80(1H,s)

Example 166

5 [0410] N-[3-chloro-5-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z414.33(M+H⁺)

10 ¹H-NMR(DMSO-d₆): δ ;2.12(3H,s), 2.15(3H,s), 4.21(2H,s), 7.3-7.5(3H,m), 7.5-7.9 (5H,m), 7.98(1H,d,J=6.4Hz), 8.05(1H,t,J=1.8Hz), 8.15(1H,d,J=6.8Hz), 10.70(1H,s)

Example 167

15 [0411] N-[3-chloro-5-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z415.20(M+H⁺)

20 ¹H-NMR(DMSO-d₆): δ ;2.14(3H,s), 2.17(3H,s), 7.21(1H,t,J=7.5Hz), 7.3-7.5(3H,m), 7.6-7.8(2H,m), 7.87(1H,t,J=1.9Hz), 8.1-8.3(3H,m), 8.41(1H,d,J=7.5Hz), 10.71(1H,s), 11.54 z(1H,s)

Example 168

25 [0412] N-[3-chloro-5-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-2,3-dimethyl-1H-indole-7-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z393.33(M+H⁺)

30 ¹H-NMR(DMSO-d₆): δ ;2.12(3H,s), 2.15(3H,s), 2.19(3H,s), 2.36(3H,s), 7.10(1H,t, J=7.7Hz), 7.30(1H,t,J=1.9Hz), 7.64(1H,d,J=7.7Hz), 7.7-7.9(2H,m), 7.84(1H,t, J=1.7Hz), 8.15(1H,t,J=1.9Hz) 10.55(1H,s), 10.82(1H,s)

Example 169

35 [0413] N-[3-(4,5-dimethyl-1H-imidazol-1-yl)-5-methoxyphenyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z410.47(M+H⁺)

40 ¹H-NMR(DMSO-d₆): δ ;2.12(3H,s), 2.14(3H,s), 3.82(3H,s), 4.20(2H,s), 6.75(1H,t, J=2.0Hz), 7.3-7.5(3H,m), 7.5-7.7(4H,m), 7.74(1H,d,J=7.7Hz), 7.98(1H,d,J=6.2Hz), 8.13(1H,d,J=6.6Hz) 10.52(1H,s)

Example 170

45 [0414] N-[3-(4,5-dimethyl-1H-imidazol-1-yl)-5-methoxyphenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z411.33(M+H⁺)

50 ¹H-NMR(DMSO-d₆): δ ;2.13(3H,s), 2.16(3H,s), 3.85(3H,s), 6.76(1H,t,J=2.0Hz), 7.20 (1H,t,J=7.1Hz), 7.31(1H,t,J=7.7Hz 7.42(1H,t,J=7.1Hz), 7.56(1H,t,J=1.7Hz), 7.6-7.8 (3H,m), 8.10(1H,d,J=7.7Hz), 8.17(1H,d,J=7.6Hz), 8.39 (1H,d,J=7.7Hz), 10.53(1H,s), 11.50(1H,s)

Example 171

55 [0415] N-[3-(4,5-dimethyl-1H-imidazol-1-yl)-5-methoxyphenyl]-2,3-dimethyl-1H-indole-7-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z389.27(M+H⁺)

¹H-NMR(DMSO-d₆): δ ;2.12(3H,s), 2.13(3H,s), 2.18(3H,s), 2.36(3H,s), 3.83(3H,s), 6.73(1H,t,J=2.0Hz), 7.09(1H,t,J=7.6Hz), 7.53(1H,s), 7.6-7.7(2H,s), 7.71(1H,d, J=7.1Hz), 10.36(1H,s), 10.77(1H,s)

EP 1 264 820 A1

Example 172

[0416] N-[3-cyano-5-(4,5-dimethyl-1H-imidazol-1-yl)phenyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z405.40(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.13(3H,s), 2.16(3H,s), 4.22(2H,s), 7.3-7.9(7H,m), 7.99(1H,d, J=6.7Hz), 8.11(1H,t, J=2.0Hz), 8.16(1H,d,J=6.8Hz), 8.31(1H,t,J=1.6Hz), 10.85(1H,s)

Example 173

[0417] N-[3-(5-chloro-4-methyl-1H-imidazol-1-yl)phenyl]-9H-carbazol-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z401(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.19(3H,s), 7.22(1H,d,J=8.0Hz), 7.32(1H,t,J=7.7Hz), 7.42(1H,t,J=7.6Hz), 7.59(1H,t, J=8.0Hz), 7.70(1H,d,J=8.0Hz), 7.9-8.3(5H,m), 8.39(1H, d,J=7.8Hz), 10.65(1H,s), 11.51(1H,s)

Example 174

[0418] N-[3-(5-chloro-4-methyl-1H-imidazol-1-yl)phenyl]-9H-fluorene-1-carboxamide was obtained according to the similar manner to that of Example 161.

APCI-mass;m/z400.27(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.17(3H,s), 4.20(2H,s), 7.21(1H,d,J=7.7Hz), 7.3-7.7(5H,m), 7.75(1H,d,J=6.7Hz), 7.9-8.1 (4H,m), 8.14(1H,d,J=6.7Hz) 10.63(1H,s)

Example 175

[0419] To a suspension of 9H-fluorene-1-carboxylic acid (835mg) and 3-methyl-N²-(2-pyridylmethyl)-2,5-pyridyldi-amine (845mg) in dichloromethane (30ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.14g) and 4-dimethylaminopyridine (242mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (silica gel 150g, eluting with 1-4% methanol/dichloromethane) to give N-[5-methyl-6-[methyl(2-pyridylmethyl)amino]-3-pyridyl]-9H-fluorene-1-carboxamide (1.14g).

APCI-mass;m/z407(M+1)

NMR(200MHz,DMSO-d₆): δ; 2.20(3H,s), 4.17(2H,s), 4.66(2H,d,J=5.8Hz), 6.55(1H,t, J=5.8Hz), 7.19-7.74(9H,m), 7.96(1H,d,J=7.1Hz), 8.08(1H,d,J=7.1Hz), 8.12(1H,d, J=2.3Hz), 8.50(1H,d,J=4.5Hz), 10.02(1H,s)

Example 176

[0420] To a suspension of 9H-fluorene-1-carboxylic acid (178mg) and N²-(2-pyridylmethyl)-3-(trifluoromethyl)-2,5-pyridyldiamine (230mg) in dichloromethane (5.0ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (244mg) and 4-dimethylaminopyridine (52mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol, collected by filtration and dried to give N-[6-[(2-pyridylmethyl)amino]-5-(trifluoromethyl)-3-pyridyl]-9H-fluorene-1-carboxamide (143mg).

APCI-mass;m/z461(M+1)

NMR(200MHz,DMSO-d₆): δ; 4.20(2H,s), 4.73(2H,d,J=5.4Hz), 7.11(1H,t,J=5.4Hz), 7.22-7.78(8H,m), 7.97(1H,d, J=6.5Hz), 8.12(1H,d,J=7.0Hz), 8.36(1H,d,J=2.3Hz), 8.52(2H,d,J=4.2Hz), 10.33(1H,s)

Example 177

[0421] To a suspension of 9H-fluorene-1-carboxylic acid (167mg) and N²-methyl-N²-(2-pyridylmethyl)-2,5-pyridyldi-amine (170mg) in dichloromethane (6.0ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (228mg) and 4-dimethylaminopyridine (48mg) and stirred for 18 hours. The mixture was diluted with dichloromethane,

EP 1 264 820 A1

washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol, collected by filtration and dried to give N-[6-[methyl(2-pyridylmethyl)amino]-3-pyridyl]-9H-fluorene-1-carboxamide (121mg).

5 APCI-mass;m/z407(M+1)
NMR(200MHz,DMSO-d6): δ ;3.13(3H,s), 4.19(2H,s), 4.86(2H,s), 6.71(1H,d,J=9.1Hz), 7.12(1H,d,J=7.8Hz), 7.25-7.76(7H,m), 7.91(1H,dd,J=9.1Hz,2.6Hz), 7.96(1H,d, J=7.5Hz), 8.09(1H,d,J=6.7Hz), 8.41(1H,d,J=2.4Hz), 8.52(1H,d,J=4.8Hz), 10.13(1H,s)

10 Example 178

[0422] To a suspension of 9H-fluorene-1-carboxylic acid (151mg) and 3-chloro-N²-methyl-N²-(2-pyridylmethyl)-2,5-pyridyldiamine (185mg) in dichloromethane (6.0ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (207mg) and 4-dimethylaminopyridine (44mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (silica gel 20g, eluting with 3-5% methanol/dichloromethane) to give N-[5-chloro-6-[methyl(2-pyridylmethyl)amino]-3-pyridyl]-9H-fluorene-1-carboxamide (129mg).

20 APCI-mass;m/z441(M+1)
NMR(200MHz,DMSO-d6): δ ;2.91(3H,s), 4.21(2H,s), 4.60(2H,s), 7.24-7.45(4H,m), 7.59(1H,d,J=7.6Hz), 7.63(1H,d,J=7.6Hz), 7.74-7.79(2H,m), 7.98(1H,d,J=6.9Hz), 8.13 (1H,d,J=6.9Hz), 8.31(1H,d,J=2.3Hz), 8.50(1H,s), 8.52 (1H,d,J=2.3Hz), 10.47(1H,s)

25 Example 179

[0423] To a suspension of 9H-fluorene-1-carboxylic acid (128mg) and N²-[(4-methyl-2-pyridyl)methyl]-2,5-pyridyldiamine (133mg) in dichloromethane (4.0ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (174mg) and 4-dimethylaminopyridine (37mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol, collected by filtration and dried to give N-[6-[[[4-methyl-2-pyridyl)methyl] amino]-3-pyridyl]-9H-fluorene-1-carboxamide (95mg).

35 APCI-mass;m/z407(M+1)
NMR(200MHz,DMSO-d6): δ ;2.28(3H,s), 4.18(2H,s), 4.52(2H,d,J=6.0Hz), 6.60(1H,d, J=8.9Hz), 7.00-7.73(7H,m), 7.79(1H,dd,J=8.9Hz,2.5Hz), 7.92(1H,d,J=6.8Hz), 8.09(1H, d,J=6.8Hz), 8.29(1H,d,J=2.5Hz), 8.36(1H,d,J=5.0Hz), 10.06(1H,s)

Example 180

40 [0424] To a suspension of 9H-fluorene-1-carboxylic acid (160mg) and N²-[(3-methyl-2-pyridyl)methyl]-2,5-pyridyldiamine (164mg) in dichloromethane (6.0ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (220mg) and 4-dimethylaminopyridine (47mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol, collected by filtration and dried to give N-[6-[[[3-methyl-2-pyridyl)methyl] amino]-3-pyridyl]-9H-fluorene-1-carboxamide (161mg).

50 APCI-mass;m/z407(M+1)
NMR(200MHz,DMSO-d6): δ ;2.35(3H,s), 4.19(2H,s), 4.54(2H,d,J=5.0Hz), 6.72(1H,d, J=8.9Hz), 6.80(1H,t,J=5.0H), 7.23(1H,dd,J=7.5Hz,4.8Hz), 7.32-7.82(7H,m), 7.97(1H, d,J=6.9Hz), 8.09(1H,d,J=6.9Hz), 8.35(1H,s), 8.38(1H,d, J=8.9Hz), 10.06(1H,s)

Example 181

55 [0425] To a suspension of 9H-fluorene-1-carboxylic acid (190mg) and N²-[[3-chloro-(5-trifluoromethyl)-2-pyridyl]methyl]-2,5-pyridyldiamine (320mg) in dichloromethane (5.5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (259mg) and 4-dimethylaminopyridine (55mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (silica gel 35g, eluting with 3-5% methanol/dichloromethane)

EP 1 264 820 A1

ane) to give N-[6-[[[3-chloro-5-(trifluoromethyl)-2-pyridyl]methyl]amino]-3-pyridyl]-9H-fluorene-1-carboxamide (98mg).

APCI-mass;m/z495(M+1)

NMR(200MHz,DMSO-d6): δ ;4.17(2H,s), 4.66(2H,d,J=5.8Hz), 6.64(1H,d,J=8.9Hz), 7.24(1H,t,J=6.1Hz), 7.31-7.72 (6H,m), 7.82(1H,dd,J=8.9Hz,2.5Hz), 7.96(1H,d, J=6.5Hz), 8.07-8.16(2H,m), 8.26(1H,d,J=2.4Hz), 8.90(1H,s), 10.06(1H,s)

Example 182

[0426] To a suspension of 9H-fluorene-1-carboxylic acid (365mg) and N²-(3-pyridylmethyl)-2,5-pyridyldiamine (388mg) in dichloromethane (8.0ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (500mg) and 4-dimethylaminopyridine (105mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with diisopropyl ether and methanol, collected by filtration and dried to give N-[6-[(3-pyridylmethyl)amino]-3-pyridyl]-9H-fluorene-1-carboxamide (215mg).

APCI-mass;m/z393(M+1)

NMR(200MHz,DMSO-d6): δ ;4.18(2H,s), 4.50(2H,d,J=6.0Hz), 6.58(1H,d,J=8.9Hz), 7.06(1H,t,J=6.0Hz), 7.30-7.82 (8H,m), 7.96(1H,d,J=6.5Hz), 8.09(1H,d,J=7.1Hz), 8.32 (1H,d,J=2.4Hz), 8.43(1H,dd,J=1.5Hz,4.7Hz), 8.56(1H,d, J=1.7Hz), 10.06(1H,s)

Example 183

[0427] To a suspension of 9H-fluorene-1-carboxylic acid (172mg) and N²-[2-(2-pyridyl)ethyl]-2,5-pyridyldiamine (180mg) in dichloromethane (4.0ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (235mg) and 4-dimethylaminopyridine (50mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol, collected by filtration and dried to give N-[6-[[2-(2-pyridyl)ethyl]amino]-3-pyridyl]-9H-fluorene-1-carboxamide (45mg).

APCI-mass;m/z407(M+1)

NMR(200MHz,DMSO-d6): δ ;3.00(1H,t,J=6.7Hz), 3.59(2H,td,J=6.7Hz,6.2Hz), 4.19 (2H,s), 6.48-6.52(2H,m), 7.19-7.75(9H,m), 7.97(1H,d,J=6.5Hz), 8.09(1H,d,J=7.3Hz), 8.33(1H,d,J=2.3Hz), 8.51(1H,d,J=4.0Hz), 10.05(1H,s)

Example 184

[0428] To a suspension of 9H-fluorene-1-carboxylic acid (366mg) and N²-benzyl-2,5-pyridyldiamine (440mg) in dichloromethane (8.0ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (500mg) and 4-dimethylaminopyridine (106mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with diisopropyl ether and methanol, collected by filtration and dried to give N-[6-(benzylamino)-2-pyridyl]-9H-fluorene-1-carboxamide (205mg).

APCI-mass;m/z392(M+1)

NMR(200MHz,DMSO-d6): δ ;4.18(2H,s), 4.48(2H,d,J=6.1Hz), 6.55(1H,d,J=8.9Hz), 6.98(1H,t,J=6.1Hz), 7.20-7.80 (11H,m), 7.96(1H,d,J=6.6Hz), 8.08(1H,d,J=7.1Hz), 8.30 (1H,d,J=2.4Hz), 10.05(1H,s)

Example 185

[0429] To a suspension of 9H-fluorene-1-carboxylic acid (73mg) and 3-(4-pyridylmethyl)aniline (64mg) in dichloromethane (3.5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (100mg) and 4-dimethylaminopyridine (21mg) and stirred for 18 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (silica gel 15g, eluting with 1-4% methanol/dichloromethane) to give N-[3-(4-pyridylmethyl)phenyl]-9H-fluorene-1-carboxamide (96mg).

APCI-mass;m/z377(M+1)

EP 1 264 820 A1

NMR(200MHz,DMSO-d₆): δ;3.99(2H,s), 4.17(2H,s), 7.02(1H,d,J=7.5Hz), 7.25-7.72 (10H,m), 7.97(1H,d,J=7.9Hz), 8.10(1H,d,J=7.2Hz), 8.48(2H,dd,J=1.4Hz,4.5Hz), 10.30 (1H,s)

Example 186

[0430] This was prepared in a manner similar to Example 14 to give N-[3-(1,2-benzisoxazol-3-ylamino)-5-chlorophenyl]-2-chlorocinnamamide.

mp:133-135°C

MS:424(M+1)

NMR(DMSO, δ):6.93(1H,d,J=15.6Hz), 7.35-7.67(8H,m), 7.76-7.85(1H,m), 7.92(1H,d, J=15.6Hz), 8.05(1H,s), 8.17(1H,d,J=7.9Hz), 9.88(1H,s), 10.59(1H,s)

Elemental analysis:

Calculated+(H₂O)_{1.0}:C;59.74,H;3.87,N;9.50

Found:C;59.69,H;3.89,N;9.51

Example 187

[0431] To a suspension of 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (146mg) in dichloromethane (3ml) was added oxalyl chloride (0.15ml) and N,N-dimethylformamide (1 drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (111mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol to give 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (105mg).

APCI-mass;m/z350(M+H⁺)

¹H-NMR(DMSO-d₆): δ;2.98(2H,t,J=4.5Hz), 4.25(2H,t,J=4.7Hz), 7.07(1H,dd, J=15.4Hz,5.1Hz), 7.1-7.3(3H,m), 7.3-7.4(2H,m), 7.49(1H,t,J=8.0Hz), 7.6-7.7(2H,m), 7.97(1H,t,J=1.9Hz), 8.16(1H,s), 10.19(1H,s)

Example 188

[0432] To a suspension of 9-methanesulfonyl-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (188mg) in dichloromethane (2ml) was added oxalyl chloride (0.2ml) and N,N-dimethylformamide (1 drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (111mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 3 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol to give 9-methanesulfonyl-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (248mg).

APCI-mass;m/z410(M+H⁺)

¹H-NMR(DMSO-d₆): δ;3.01(2H,t,J=4.4Hz), 3.32(3H,s), 4.45(2H,t,J=4.6Hz), 7.14 (1H,s), 7.2-7.4(3H,m), 7.50(1H,t,J=8.0H 7.6-8.0(4H,m), 7.98(1H,s), 8.17(1H,s) 10.26(1H,s)

Example 189

[0433] To a suspension of 9-chloro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (157mg) in dichloromethane (3ml) was added oxalyl chloride (0.16ml) and N,N-dimethylformamide (1 drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (111mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol to give 9-chloro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (195mg).

EP 1 264 820 A1

APCI-mass;m/z366(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 3.02(2H,t,J=4.3Hz), 4.37(2H,t,J=4.7Hz), 7.07(1H,d,J=7.8Hz), 7.12(1H,s), 7.27(1H,s), 7.3-7.6(4H,m), 7.6-7.8(2H,m), 7.97(1H,t,J=2.0Hz), 8.17(1H,d, J=1.0Hz), 10.22(1H,s)

5 Example 190

[0434] To a suspension of 8-methoxy-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (154mg) in dichloromethane (3ml) was added oxalyl chloride (0.15ml) and N,N-dimethylformamide (1 drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (111mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was triturated with methanol to give 8-methoxy-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (222mg).

15

APCI-mass;m/z362(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.94(2H,t,J=4.7Hz), 3.77(3H,s), 4.26(2H,t,J=4.7Hz), 6.56(1H, d,J=2.4Hz), 6.68(1H,d, J=8.6Hz), 7.12(1H,s), 7.25(1H,s), 7.3-7.4(2H,m), 7.46(1H,d, J=8.0Hz), 7.6-7.7(2H,m), 7.96(1H,s), 8.16(1H,s), 10.07(1H,s)

20

Example 191

[0435] To a suspension of 7-methoxy-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (154mg) in dichloromethane (3ml) was added oxalyl chloride (0.15ml) and N,N-dimethylformamide (1 drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (111mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was purified with column chromatography (silica gel 25g, 2% methanol in dichloromethane) to give 7-methoxy-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (189mg).

30

APCI-mass;m/z362(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.96(2H,t,J=4.7Hz), 3.74(3H,s), 4.20(2H,t,J=4.7Hz), 6.8-7.0 (2H,m), 7.02(1H,d,J=2.7Hz), 7.13(1H,s), 7.24(1H,s), 7.34(1H,d,J=8.4Hz), 7.48(1H,d, J=8.0Hz), 7.6-7.8(2H,m), 7.97(1H,s), 8.17(1H,s), 10.17 (1H,s)

35

Example 192

[0436] To a suspension of 7-chloro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (157mg) in dichloromethane (3ml) was added oxalyl chloride (0.16ml) and N,N-dimethylformamide (1 drop) and the mixture stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (111mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was crystallized from methanol and collected by filtration to give 7-chloro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (197mg).

45

APCI-mass;m/z366(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.98(2H,t,J=4.6Hz), 4.27(2H,t,J=4.6Hz), 7.01(1H,d,J=8.7Hz), 7.13(1H,s), 7.23(1H,s), 7.3-7.7(6H,m), 7.96(1H,t,J=1.9Hz), 8.16(1H,s), 10.17(1H,s)

50

Example 193

55

[0437] To a suspension of 2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (154mg) and 1-hydroxybenzotriazole (131mg) in dichloromethane (10ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (233mg) and the mixture was stirred for 1 hour. To the mixture 3-(imidazol-1-yl)aniline (129mg) and N,N-dimethylaminopyridine

EP 1 264 820 A1

(109mg) was added and the mixture was stirred for 24 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over potassium carbonate and evaporated. The residue was purified with column chromatography (silica gel, 25g, 3% methanol in dichloromethane) to give 2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (196mg).

ESI-mass;m/z332(M+H⁺)

¹H-NMR(DMSO-d₆): δ;2.98(2H,t,J=4.3Hz), 4.27(2H,t,J=4.3Hz), 7.0-7.6(8H,m), 7.6-7.8(2H,m), 7.98(1H,t,J=2.0Hz), 8.16(1H,s), 10.17(1H,s)

Example 194

[0438] A suspension of 2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (110mg) in ethanol (5ml) was hydrogenated over palladium on carbon (10% w/w, 50% wet, 50mg) under hydrogen atmosphere for 10 hours. The catalyst was filtered off, the filtrate was evaporated under reduced pressure. The residue was triturated with dichloromethane and isopropyl ether to give 2,3,4,5-tetrahydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (59mg).

APCI-mass;m/z334(M+H⁺)

NMR(DMSO-d₆): δ;2.0-2.3(2H,m), 2.6-3.2(3H,m), 3.6-3.8(1H,m), 4.3-4.5(1H,m), 6.9-7.6(8H,m), 7.63(1H,s), 7.92(1H,s), 8.14(1H,s), 10.23(1H,s)

Example 195

[0439] To a suspension of 8-chloro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (106mg) and 1-hydroxybenzotriazole (77mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (136mg) and the mixture was stirred for 30 minutes. To the mixture 3-(imidazol-1-yl)aniline (75mg) and N,N-dimethylaminopyridine (63mg) was added and the mixture was stirred for 24 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over potassium carbonate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give 8-chloro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (102mg).

ESI-mass;m/z366(M+H⁺)

¹H-NMR(DMSO-d₆): δ;2.98(2H,t,J=4.6Hz), 4.29(2H,t,J=4.6Hz), 7.09(1H,d,J=2.1Hz), 7.13(1H,d,J=2.1Hz), 7.16(1H,d,J=2.2Hz), 7.26(1H,s), 7.34(1H,d,J=9.0Hz), 7.46(1H,d,J=6.3Hz), 7.50(1H,d,J=6.8Hz), 7.6-7.8(2H,m), 7.96(1H,t,J=2.0Hz), 8.16(1H,s), 10.19(1H,s)

Example 196

[0440] To a suspension of 1,1-dioxo-2,3-dihydro-1H-benzo[b]thiepin-4-carboxylic acid (135mg) and 1-hydroxybenzotriazole (92mg) in dichloromethane (3ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (163mg) and the mixture was stirred for 30 minutes. To the mixture 3-(imidazol-1-yl)aniline (90mg) and N,N-dimethylaminopyridine (83mg) was added and the mixture was stirred for 24 hours. The mixture was diluted with dichloromethane, washed with water and brine, dried over potassium carbonate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give 1,1-dioxo-2,3-dihydro-benzo[b]thiepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (50mg).

ESI-mass;m/z380(M+H⁺)

¹H-NMR(DMSO-d₆): δ;3.05(2H,t,J=6.6Hz), 3.80(2H,t,J=6.6Hz), 7.13(1H,s), 7.37(1H,d,J=9.0Hz), 7.4-7.8(7H,m), 7.99(1H,s), 8.06(1H,d,J=7.4Hz), 8.18(1H,s), 10.42(1H,s)

Example 197

[0441] To a suspension of 7-methyl-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (143mg) in dichloromethane (3ml) was added oxalyl chloride (0.15ml) and N,N-dimethylformamide (1 drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (111mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried

EP 1 264 820 A1

over magnesium sulfate and evaporated under reduced pressure. The residue was crystalized from 2-propanol and collected by filtration to give 7-methyl-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (3-imidazol-1-yl-phenyl)-amide (178mg).

5 APCI-mass;m/z346(M+H⁺)
¹H-NMR(DMSO-d₆): δ ;2.27(3H,s), 2.96(2H,t,J=4.4Hz), 4.23(2H,t,J=4.7Hz), 6.88(1H, d,J=8.2Hz), 7.0-7.2(2H,m), 7.2-7.3(2H,m), 7.34(1H,d,J=9.0Hz), 7.48(1H,d,J=8.0Hz), 7.6-7.8(2H,m), 7.98(1H,t,J=1.9Hz), 8.17(1H,s), 10.14(1H,s)

10 Example 198

[0442] To a suspension of 8,9-dihydro-7H-benzocycloheptene-6-carboxylic acid (132mg) in dichloromethane (3ml) was added oxalyl chloride (0.15ml) and N,N-dimethylformamide (1 drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (111mg) in dichloromethane (3ml) and pyridine (0.17ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was crystalized from methanol and collected by filtration to give 8,9-dihydro-7H-benzocycloheptene-6-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (195mg).

20 APCI-mass;m/z330(M+H⁺)
¹H-NMR(DMSO-d₆): δ ;2.0-2.2(2H,m), 2.60(2H,t,J=6.3Hz), 2.7-2.9(2H,m), 7.13 (1H,s), 7.2-7.5(6H,m), 7.47(1H,t,J=8.0Hz), 7.6-7.8(2H,m), 7.99(1H,t,J=2.0Hz), 8.17 (1H,s), 10.19(1H,s)

25 Example 199

[0443] To a suspension of 7-iodo-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (142mg) in dichloromethane (3ml) was added oxalyl chloride (0.15ml) and N,N-dimethylformamide (1drop) and the mixture was stirred at ambient temperature for 2 hours. The solvents were evaporated under reduced pressure to give crude acid chloride. To a suspension of 3-(imidazol-1-yl)aniline (72mg) in dichloromethane (3ml) and pyridine (0.11ml) was added a solution of acid chloride (obtained above) in dichloromethane (3ml) dropwise and the mixture was stirred at ambient temperature for 2 hours. The mixture was diluted with dichloromethane, washed with water and brine. The separated organic layer was dried over magnesium sulfate and evaporated under reduced pressure. The residue was crystalized from methanol and collected by filtration to give 7-iodo-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid(3-imidazol-1-yl-phenyl)-amide (162mg).

40 APCI-mass;m/z458(M+H⁺)
¹H-NMR(DMSO-d₆): δ ;2.97(2H,t,J=4.2Hz), 4.26(2H,t,J=4.5Hz), 6.81(1H,d,J=8.5Hz), 7.13(1H,s), 7.22(1H,s), 7.34(1H,d,J=8.0Hz), 7.46(1H,d,J=8.0Hz), 7.56(1H,dd,J=2.2Hz, 8.5=Hz), 7.7-7.8(2H,m), 7.82(1H,d,J=2.0Hz), 7.96(1H,s), 8.16(1H,s), 10.15(1H,s)

Example 200

45 [0444] To a suspension of 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (83mg) and 5-amino-3-chloro-2-(pyridine-2-ylmethyl)aminopyridine (97mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (115mg) and N,N-dimethylaminopyridine (24mg) and the mixture was stirred for 24 hours and diluted with dichloromethane-methanol (10:1). The solution was washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid[5-chloro-6-[(pyridine-2-ylmethyl)amino]pyridine-3-yl]amide (139mg).

55 APCI-mass;m/z425(M+H⁺)
¹H-NMR(DMSO-d₆): δ ;2.94(2H,t,J=4.5Hz), 4.22(2H,t,J=4.7Hz), 4.66(2H,d,J=5.7Hz), 6.9-7.4(7H,m), 7.71(1H,dt,J=1.8Hz,7.7Hz), 8.01(1H,d,J=2.2Hz), 8.18(1H,d,J=2.2Hz), 8.50(1H,d,J=3.6Hz), 9.88(1H,s)

EP 1 264 820 A1

Example 201

5 [0445] To a suspension of 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (104mg) and 3-[1,2,4]triazol-1-yl-phenylamine (80mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (134mg) and N,N-dimethylaminopyridine (31mg) and the mixture was stirred for 24 hours and diluted with dichloromethane. The solution was washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (3-[1,2,4]triazol-1-yl-phenyl)-amide (74mg).

10 APCI-mass;m/z351 (M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.99(2H,t,J=4.4Hz), 4.25(2H,t,J=4.7Hz), 7.00(1H,dd,J=5.2Hz, 8.9Hz), 7.12(1H,dt, J=3.0Hz,8.3Hz), 7.22(1H,s), 7.33(1H,dd,J=3.0Hz,10.0Hz), 7.5-7.9 (3H,m), 8.2-8.3(2H,m), 9.27(1H,s), 10.25(1H,s)

Example 202

15 [0446] To a suspension of 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (104mg) and 3-pyrimidin-5-yl-phenylamine (86mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (134mg) and N,N-dimethylaminopyridine (31mg) and the mixture was stirred for 24 hours and diluted with dichloromethane. The solution was washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (3-pyrimidin-5-yl-phenyl)-amide (133mg)

20 APCI-mass;m/z362(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.99(2H,t,J=4.4Hz), 4.25(2H,t,J=4.7Hz), 7.01(1H,dd,J=5.2Hz, 9.0Hz), 7.12(1H,dt, J=3.0Hz,8.3Hz), 7.22(1H,s), 7.33(1H,dd,J=3.0Hz,9.8Hz), 7.5-7.6 (2H,m), 7.8-7.9(1H,m), 8.08(1H,s), 9.09(2H,s), 9.21(1H,s), 10.16(1H,s)

Example 203

30 [0447] To a suspension of 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (104mg) and 3-(2,3-dimethyl-3H-imidazol-4-yl)-phenylamine (99mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (134mg) and N,N-dimethylaminopyridine (31mg) and the mixture was stirred for 24 hours and diluted with dichloromethane. The solution was washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid [3-(2,3-dimethyl-3H-imidazol-4-yl)-phenyl]-amide (108mg).

35 APCI-mass;m/z378(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.36(3H,s), 2.98(2H,t,J=5.0Hz), 3.55(3H,s), 4.25(2H,t, J=4.7Hz), 6.86(1H,s), 7.00(1H,dd, J=5.2Hz,8.9Hz), 7.0-7.2(4H,m), 7.3-7.5(2H,m), 7.69(1H,d,J=8.2Hz), 7.77(1H,s), 10.08(1H,s)

Example 204

45 [0448] To a suspension of 3-(2,3-dimethyl-3H-imidazol-4-yl)-aniline (94mg) and 3-naphthalen-1-yl-acrylic acid (99mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (144mg) and N,N-dimethylaminopyridine (31mg) and the mixture was stirred for 24 hours and evaporated. The residue was purified with column chromatography (silica gel 20g, 3% methanol in dichloromethane) to give N-[3-(2,3-dimethyl-3H-imidazol-4-yl)-phenyl]-3-naphthalen-1-yl-acrylamide (64mg).

50 APCI-mass;m/z368(M+H⁺)

¹H-NMR(DMSO-d₆): δ; 2.37(3H,s), 3.57(3H,s), 6.9-7.0(2H,m), 7.15(1H,d,J=7.7Hz), 7.44(1H,t,J=7.9Hz), 7.6-7.8 (4H,m), 7.9-8.1(4H,m), 8.26(1H,d,J=7.6Hz), 8.39(1H,d, J=15.5Hz), 10.42(1H,s)

Example 205

55 [0449] This was prepared in a manner similar to Example 14 to give (2E)-N-[3-chloro-5-[[imino(phenyl)methyl]amino]phenyl]-3-(1H-indole-3-yl)-2-propenamide.

EP 1 264 820 A1

mp:184-187°C

MS:415(M+1)

NMR(DMSO, δ): 6.60(3H, br s), 6.78(1H, d, J=15.8Hz), 6.97-7.28(2H, m), 7.30-7.69 (5H, m), 7.78(1H, d, J=15.8Hz), 7.83-8.05(5H, m), 10.09(1H, s), 11.68(1H, s)

5

Example 206

[0450] To a suspension of 3-(4,5-dimethylimidazol-1-yl)aniline (94mg) and 6-chloro-2H-chromenyl-3-carboxylic acid (106mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (144mg) and N,N-dimethylaminopyridine (31mg) and the mixture was stirred for 24 hours. The mixture was diluted with dichloromethane and washed with water, aqueous sodium hydroxide (1N) and brine. The separated organic layer was dried over magnesium sulfate and evaporated. The residue was triturated with methanol, collected by filtration and dried to give 6-chloro-2H-chromenyl-3-carboxylic acid[3-(4,5-dimethylimidazol-1-yl)-phenyl]-amide (73mg).

15

APCI-mass;m/z380,382(M+H⁺)

¹H-NMR(DMSO-d₆): δ : 2.10(3H, s), 2.11(3H, s), 5.02(2H, s), 6.92(1H, d, J=8.6Hz), 7.12(1H, d, J=8.3Hz), 7.31(1H, dd, J=8.3Hz, 2.6Hz), 7.4-7.5(2H, m), 7.50(1H, t, J=8.0Hz), 7.63(1H, s), 7.7-7.9(2H, m), 10.33(1H, s)

Example 207

20

[0451] To a suspension of 2-(pyridine-2-ylmethylamino)-5-aminopyridine (100mg) and 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid (104mg) in dichloromethane (5ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (144mg) and N,N-dimethylaminopyridine (31mg) and the mixture was stirred for 24 hours and evaporated. The residue was purified with column chromatography (silica gel 20g, 2-3% methanol in dichloromethane) to give 7-fluoro-2,3-dihydro-benzo[b]oxepin-4-carboxylic acid[6-[(pyridine-2-ylmethyl)amino]-pyridine-3-yl]-amide (109mg).

25

APCI-mass;m/z391(M+H⁺)

30

¹H-NMR(DMSO-d₆): δ : 2.94(2H, t, J=4.7Hz), 4.22(2H, t, J=4.7Hz), 4.54(2H, d, J=6.0Hz), 6.9-7.4(7H, m), 7.6-7.8(2H, m), 8.18(1H, d, J=2.4Hz), 8.50(1H, d, J=4.1Hz) 9.71(1H, s)

Example 208

[0452] To a suspension of 3-amino-5-(pyridine-3-yl)pyridine dihydrochloride (80mg) and pyridine (0.27ml) in dichloromethane (5ml) was added a solution of the fluorene-1-carbonyl chloride (75mg) in dichloromethane (2ml) dropwise and stirred for 6 hours. The mixture was diluted with dichloromethane and washed with a aqueous solution of sodium hydrogen carbonate and brine. The separated organic layer was dried over sodium sulfate and evaporated. The residue was purified with column chromatography (silica gel 25g, 3% methanol in dichloromethane) to give 9H-fluorene-1-carboxylic acid [3,3'-bipyridyl-5-ylamide] (103mg).

40

ESI-mass;m/z386(M+Na⁺)

¹H-NMR(DMSO-d₆): δ : 4.24(2H, s), 7.3-7.5(2H, m), 7.5-7.7(2H, m), 7.83(1H, d, J=6.8Hz), 7.99(1H, d, J=6.5Hz), 8.1-8.2(2H, m), 8.57(1H, t, J=3.8Hz), 8.66(1H, dd, J=4.8Hz, 1.5Hz), 8.72(1H, d, J=2.0Hz), 8.95(1H, d, J=2.0Hz), 9.03(1H, d, J=2.2Hz), 10.69 (1H, s)

45

Example 209

[0453] To a solution of 9H-fluorene-1-carboxylic acid(5-hydrazinocarbonyl-pyridine-3-yl)-amide (0.37g) in n-butanol (15ml) were added methyl isocyanate (79mg) and 1,8-diazabicyclo[5.4.0]undec-7-ene (80 μ l), and the mixture was heated to 120°C for 5 hours. Evaporation gave a residue which was taken up into water. The resultant precipitate was collected by filtration, washed with water, and dried in vacuo to give 9H-fluorene-1-carboxylic acid[5-(4-methyl-5-thio-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-pyridine-3-yl]-amide (203mg).

50

APCI-mass;400(m/z,[M+H]⁺)

55

NMR(DMSO-d₆, d): 3.62(3H, s), 4.23(2H, s), 7.36-7.44(2H, m), 7.55-7.66(2H, m), 7.82 (1H, d, J=7.0Hz), 8.00(1H, d, J=6.3Hz), 8.17(1H, d, J=7.0Hz), 8.61(1H, d, J=2.1Hz), 8.70 (1H, d, J=1.9Hz), 9.13(1H, d, J=2.4Hz) 10.79(1H, s), 14.03 (1H, brs)

EP 1 264 820 A1

Example 210

[0454] To a solution of 9H-fluorene-1-carboxylic acid[5-(4-methyl-5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-pyridine-3-yl]-amide (120mg) in acetic acid (5ml) was added a solution of sodium nitrite (83mg) in water(0.4ml), and the mixture was heated to 100°C for 1 hour. After cooling to ambient temperature the resultant precipitate was collected by filtration, washed with water, and dried in vacuo to give 9H-fluorene-1-carboxylic acid[5-(4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine-3-yl]-amide (112mg).

APCI-mass;368(m/z,[M+H]⁺)

NMR(DMSO-d₆,d);3.88(3H,s), 4.24(2H,s), 7.36-7.44(2H,m), 7.57-7.66(2H,m), 7.82(1H,d,J=7.1Hz) 8.00(1H,d,J=6.3Hz), 8.17(1H,d,J=7.1Hz), 8.71(1H,d,J=2.2Hz), 8.76(1H,d,J=1.9Hz) 8.95(1H,s), 9.16(1H,d,J=2.3Hz) 10.83(1H,s)

Example 211

[0455] To a solution of 3-methyl-2-trifluoromethyl-1H-indole-7-carboxylic acid (60mg), 6-(2-methyl-pyridine-3-yloxy) pyridine-3-ylamine (50mg), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (66mg) in dichloromethane (3ml) was added 4-dimethylaminopyridine (15mg) at ambient temperature. After stirring at ambient temperature for 48 hours, the reaction mixture was diluted with ethyl acetate, washed in turn with water, aqueous potassium carbonate and brine, and dried over potassium carbonate. Evaporation under reduced pressure gave a residue which was triturated with methanol to give 3-methyl-2-trifluoromethyl-1H-indole-7-carboxylic acid[6-(2-methyl-pyridine-3-yloxy)-pyridine-3-yl]amide (43mg).

APCI-mass;427(m/z,[M+H]⁺)

NMR(DMSO-d₆,d);2.32(3H,s), 2.43(3H,d,J=2.0Hz), 7.17(1H,d,J=8.8Hz), 7.23-7.40 (2H,m), 7.51(1H,d,J=8.1Hz), 7.85-8.05(2H,m), 8.23-8.40(2H,m), 8.48(1H,d,J=2.5Hz), 10.58 (1H,s), 11.46(1H,s)


Claims

1. A compound of the formula (I):




wherein

R¹ is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents, R² is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents, or thienyl which may have suitable substituents, A is a group of the formula:



or



in which R³ and R⁴ are each hydrogen or linked together to form imino,

R⁵ is hydrogen or lower alkyl,
t is 0, 1 or 2,

EP 1 264 820 A1

p, m and n are each 0 or 1,

X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents,

Y is bond, lower alkylene, or lower alkenylene,

and a salt thereof.

2. The compound of claim 1, wherein

R¹ is imidazolyl;

imidazolyl which have 1 to 3 lower alkyl;

imidazolyl which have 1 to 3 lower alkanoyl;

imidazolyl which have 1 to 3 halogen and/or lower alkyl;

pyridyl;

pyridyl which have 1 to 3 lower alkyl;

pyridyl which have 1 to 3 lower alkoxy;

pyridyl which have 1 to 3 halogen;

pyridyl which have 1 to 3 halogen and/or trihalo(lower)alkyl;

phenyl;

phenyl which have 1 to 3 lower alkyl;

phenyl which have 1 to 3 lower alkylamino;

phenyl which have 1 to 3 lower alkanoylamino;

phenyl which have 1 to 3 lower alkylsulfonylamino;

phenyl which have 1 to 3 halogen;

phenyl which have 1 to 3 lower alkoxy;

phenyl which have 1 to 3 halogen and/or lower alkoxy;

phenyl which have unsaturated heteromonocyclic group containing 1 to 4 nitrogen atom(s);

phenyl which have unsaturated heteromonocyclic group containing 1 or 2

sulfur atom(s) and 1 to 3 nitrogen atom(s);

phenyl which have unsaturated heteromonocyclic group containing 1 or 2

oxygen atom(s) and 1 to 3 nitrogen atom(s);

phenyl which have oxidopyridyloxy;

oxochromenyl;

piperazinyl;

triazolyl ;

triazolyl which have 1 to 3 lower alkyl;

triazolyl which have 1 to 3 thioxo and/or lower alkyl;

triazolyl which have unsaturated heteromonocyclic group containing 1 to 4 nitrogen atom(s);

pyrimidinyl;

pyrazinyl;

quinolinyl;

isoquinolinyl;

thienyl;

thiazolyl which have 1 to 3 halogen;

benzothiazolyl;

isoxazolyl which have 1 to 3 lower alkyl;

triazinyl which have 1 to 3 lower alkyl;

pyridazinyl which have 1 to 3 halogen;

thiadiazolyl;

benzimidazolyl which have 1 to 3 lower alkyl;

benzimidazolyl which have 1 to 3 halogen;

benzimidazolyl which have 1 to 3 lower alkoxy;

benzisoaxazolyl;

indolyl which have 1 to 3 lower alkyl,


R² is fluorenyl;

indolyl which have 1 to 3 lower alkyl;


EP 1 264 820 A1

phenyl;
 phenyl which have 1 to 3 halogen;
 phenyl which have 1 to 3 lower alkyl;
 phenyl which have 1 to 3 lower alkoxy;
 5 phenyl which have 1 to 3 trihalo(lower)alkyl;
 phenyl which have 1 to 3 cyano;
 phenyl which have halophenyl;
 phenyl which have phenyl;
 phenylsulfanyl;
 10 phenyl which have lower alkylphenyl;
 phenyl which have thienyl;
 phenyl which have halothienyl;
 pyridyl;
 thienyl which have phenyl;
 15 carbazolyl;
 carbazolyl which have 1 to 3 halogen;
 carbazolyl which have 1 to 3 trihalo(lower)alkyl and/or lower alkyl;
 naphthyl;
 2,3-dihydrobenzo[b]oxepinyl;
 20 2,3-dihydrobenzo[b]oxepinyl which have 1 to 3 lower alkyl;
 2,3-dihydrobenzo[b]oxepinyl which have 1 to 3 halogen;
 2,3-dihydro-benzo[b]oxepinyl which have 1 to 3 lower alkanesulfonyl;
 2,3-dihydro-benzo[b]oxepinyl which have 1 to 3 lower alkoxy;
 2,3-dihydro-benzo[b]thiepinyl which have dioxo;
 25 8,9-dihydro-benzocycloheptyl;
 chromenyl which have 1 to 3 halogen;
 indolyl;
 indolyl which have 1 to 3 trihalo(lower)alkyl and/or lower alkyl,

A is a group of the formula:



or



In which R³ and R⁴ are each hydrogen or linked together to form imino,

R⁵ is hydrogen or lower alkyl,

t is 0, 1 or 2,

p, m and n are each 0 or 1, X is phenylene;

phenylene which have 1 to 3 halogen;

50 phenylene which have 1 to 3 cyano;

phenylene which have 1 to 3 lower alkyl;

phenylene which have 1 to 3 lower alkoxy;

phenylene which have 1 to 3 lower alkylsulfonylamino;

phenylene which have 1 to 3 halogen and/or lower alkoxy;

55 phenylene which have saturated heteromonocyclic group containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s);

pyridinylene;

pyridinylene which have 1 to 3 halogen;

EP 1 264 820 A1


pyridinylene which have 1 to 3 trihalo(lower)alkyl;
 pyridinylene which have 1 to 3 lower alkyl;
 pyridinylene which have saturated heteromonocyclic group containing 1 to 4 nitrogen atom(s);
 piperadinylene which have unsaturated heteromonocyclic group containing 1 to 4 nitrogen atom(s);
 pyrimidinylene;
 isoindolinylene, Y is vinylene;
 1-propenylene;
 methylene;
 ethylene.

3. A compound of the formula (I):



wherein

R¹ is phenyl,
 R² is phenyl which have trihalo(lower)alkyl,
 A is a group of the formula:



in which R³ and R⁴ are linked together to form imino,

R⁵ is hydrogen,
 p is 1,
 n is 0,

X is phenylene which have halogen and lower alkoxy,
 Y is vinylene,

and a salt thereof.

4. A compound of the formula (I):



wherein

R¹ is unsaturated heteromonocyclic group containing 1 to 4 nitrogen atom(s) which have 1 to 3 lower alkyl,
 R² is indolyl which have 1 to 3 lower alkyl,
 A is bond,
 X is phenylene which have 1 to 3 halogen,
 Y is bond,

and a salt thereof.

5. The compound of claim 4, wherein

R¹ is 4,5-di(lower alkyl)imidazolyl,

EP 1 264 820 A1

R² is 2,3-di(lower alkyl)indolyl,
X is phenylene which have 1 halogen.

6. A compound of the formula (I):



wherein

R¹ is unsaturated heteromonocyclic group containing 1 to 4 nitrogen atom(s) which have 1 to 3 lower alkyl,
R² is carbazolyl,
A is bond,
X is phenylene which have 1 to 3 lower alkoxy,
Y is bond,

and a salt thereof.


7. The compound of claim 6, wherein

R¹ is 4,5-di(lower alkyl)imidazolyl,
X is phenylene which have 1 lower alkoxy.

8. A process for preparing a compound of the formula:



or a salt thereof,
subjecting a compound of the formula:




or a salt thereof,
to amidation reaction with a compound of the formula:




or a salt thereof,
wherein

R¹ is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents,
R² is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents,
or thienyl which may have suitable substituents,
A is a group of the formula:



or



in which R³ and R⁴ are each hydrogen or linked together to form imino,

R⁵ is hydrogen or lower alkyl,


t is 0, 1 or 2,

p, m and n are each 0 or 1,

X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents,


Y is bond, lower alkylene, or lower alkenylene.

9. A process for preparing a compound of the formula:



or a salt thereof,

subjecting a compound of the formula:



or a salt thereof,

to condensation reaction with a compound of the formula:



or a salt thereof,

wherein


R¹ is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents, R² is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents, or thienyl which may have suitable substituents,

X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which may have suitable substituents,

Y is bond, lower alkylene, or lower alkenylene,

R⁶ is lower alkyl.


10. A process for preparing a compound of the formula:



or a salt thereof,
subjecting a compound of the formula:




or a salt thereof,
to amidation reaction with a compound of the formula:



or a salt thereof,
wherein

R¹ is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents,
R² is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents,
or thienyl which may have suitable substituents,
X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which
may have suitable substituents,
Y is bond, lower alkylene, or lower alkenylene,
R⁶ is lower alkyl.


11. A process for preparing a compound of the formula:



or a salt thereof,
subjecting a compound of the formula:



or a salt thereof,
to reaction with a compound of the formula:



or a salt thereof,
wherein

EP 1 264 820 A1

R¹ is heterocyclic group which may have suitable substituents, or phenyl which may have suitable substituents,
R² is condensed phenyl which may have suitable substituents, phenyl which may have suitable substituents,
or thienyl which may have suitable substituents,

5 X is phenylene which may have suitable substituents, or bivalent heterocyclic group containing nitrogen which
may have suitable substituents,

Y is bond, lower alkylene, or lower alkenylene.

12. A pharmaceutical composition, which has a compound of claim 1 and a pharmaceutically acceptable carriers or
10 excipients.

13. A process for preparing a pharmaceutical composition, which comprises a compound of claim 1 in admixture with
a pharmaceutically acceptable carriers or excipients.

14. A use of a compound of claim 1 as a medicament.

15

15. A use of a compound of claim 1 as a 5-HT antagonist.

16. A use of a compound of claim 1 as a 5-HT_{2C} antagonist.

20 17. A use of a compound of claim 1 for preparing a medicament for treating 5-HT-mediated diseases.

18. A method for treating 5-HT-mediated diseases which comprises administering a compound of claim 1 to human
or animals.

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/01993

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁷ C07C233/75, C07C233/80, C07C233/81, C07C257/14, C07C257/18, C07C257/20, C07D233/64, C07D249/08, C07D239/26, C07D213/75, C07D231/12, C07D217/22, C07D333/20, C07D277/28, C07D263/32, C07D233/36, C07D215/12, C07D209/08, C07D405/12, C07D403/12, According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. Cl. ⁷ C07C233/75, C07C233/80, C07C233/81, C07C257/14, C07C257/18, C07C257/20, C07D233/64, C07D249/08, C07D239/26, C07D213/75, C07D231/12, C07D217/22, C07D333/20, C07D277/28, C07D263/32, C07D233/36, C07D215/12, C07D209/08, C07D405/12, C07D403/12, Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), CAOLD (STN), REGISTRY (STN)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	JP, 11-130750, A (Fujisawa Pharmaceutical Co., Ltd.), 18 May, 1999 (18.05.99) (Family: none)	1-2,8,12-17 3-7,9-11
X A	KALKMAN, Hans O. "Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat", Eur. J. Pharmacol., 1998, Vol.343 No.2/3, p.201-207	1,12-17 2-11
X A	WO, 96/23783, A1 (SMITHKLINE BEECHAM PLC), 08 August, 1996 (08.08.96) & JP, 10-513442, A & EP, 808312, A1	1 2-17
X A	WO, 96/23769, A2 (SMITHKLINE BEECHAM PLC), 08 August, 1996 (08.08.96) & JP, 10-513443, A & EP, 807104, A2	1,12-17 2-11
X A	WO, 95/30675, A1 (SMITHKLINE BEECHAM PLC), 16 November, 1995 (16.11.95) & JP, 9-512804, A & EP, 758330, A1	1,8,12-15,17 2-7,9-11,16
X A	MANUEL, N. A., "Ketanserin-sensitive depressant actions of 5-HT receptor agonists in the neonatal rat spinal cord", Br. J. Pharmacol., 1995, Vol.116 No.6, p.2647-2654	1,12-17 2-11
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 09 July, 2001 (09.07.01)		Date of mailing of the international search report 17 July, 2001 (17.07.01)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/01993

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	WO, 95/06044, A1 (SMITHKLINE BEECHAM PLC), 02 March, 1995 (02.03.95) & JP, 9-504004, A & EP, 714389, A1	1-2, 8, 12-15, 17 3-7, 9-11, 16
X A	WO, 95/04729, A1 (SMITHKLINE BEECHAM PLC), 16 February, 1995 (16.02.95) & JP, 9-501171, A & EP, 712397, A1	1, 8, 12-15, 17 2-7, 9-11, 16
X A	WO, 98/42696, A1 (SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES), 01 October, 1998 (01.10.98) & EP, 973763, A1	1-2, 8-9, 12-14 3-7, 10-11, 15-17
X A	WO, 95/05363, A1 (FISONS CORPORATION), 23 February, 1995 (23.02.95) & JP, 9-501918, A & EP, 713483, A1	1, 9, 12-14 2-8, 10-11, 15-17
X A	WO, 94/21621, A1 (FISONS CORPORATION), 29 September, 1994 (29.09.94) & EP, 690851, A1	1, 8, 12-14 2-7, 9-11, 15-17
X A	JP, 4-76530, A (Konica Corporation), 11 March, 1992 (11.03.92) (Family: none)	1 2-11
X A	JP, 3-282536, A (Konica Corporation), 12 December, 1991 (12.12.91) (Family: none)	1 2-11
A	GB, 1007334, A1 (DR. A. WANDER S.A.), 13 October, 1965 (13.10.65) (Family: none)	1-11
X A	KORBONITS, Dezso et al., "Synthesis of 4-aminopyrimidines from 1,2,4-oxadiazoles. I. New general method for the preparation of 4-aminoquinazolines and their hetero analogs", Chem. Ber., 1984, Vol.117, No.11, pp.3183-3193	1 2-11
X A	WO, 00/06550, A1 (Nippon Soda Co., Ltd.), 10 February, 2000 (10.02.00) & EP, 1101759, A1	1, 8, 12-14 2-7, 9-11, 15-17
X A	JP, 11-349572, A (Fujisawa Pharmaceutical Co., Ltd.), 21 December, 1999 (21.12.99) (Family: none)	1, 8, 12-15, 17 2-7, 9-11, 16

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/01993

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18
because they relate to subject matter not required to be searched by this Authority, namely:
Claim 18 pertains to a method for treatment of the human body by therapy and thus relates to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

With respect to the reasons advanced in the payment order notice sent earlier concerning a fee to be additionally paid, an opposition was raised by the applicant and, as a result, a decision of opposition was made to the effect that the order is groundless.

(See extra sheet.)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☒ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP01/01993

A. Continuation of A. CLASSIFICATION OF SUBJECT MATTER (IPC)

A61K31/167, A61K31/4164, A61K31/41, A61K31/505, A61K31/44, A61K31/4436, A61K31/472, A61K31/47, A61K31/381, A61K31/428, A61K31/421, A61K31/4178, A61K31/55, C07D311/22, A61K31/352, A61P43/00, A61P25/22, A61P25/24, A61P25/06, A61P1/14, A61P25/28, A61P25/20, A61P3/04, A61P25/30, A61P25/00, A61K31/415, C07D277/82, C07D277/28, C07D277/42, A61K31/426, A61K31/428, C07D285/12, A61K31/433, A61K31/404, C07D401/14, A61K31/4439, C07D409/14, C07D401/04, A61K31/506, C07D409/12, C07D401/12, A61K31/497, A61K31/4196, C07D405/14, A61K31/4427, C07D209/18, A61K31/405

B. Continuation of B. FIELD SEARCHED (IPC)

A61K31/167, A61K31/4164, A61K31/41, A61K31/505, A61K31/44, A61K31/4436, A61K31/472, A61K31/47, A61K31/381, A61K31/428, A61K31/421, A61K31/4178, A61K31/55, C07D311/22, A61K31/352, A61P43/00, A61P25/22, A61P25/24, A61P25/06, A61P1/14, A61P25/28, A61P25/20, A61P3/04, A61P25/30, A61P25/00, A61K31/415, C07D277/82, C07D277/28, C07D277/42, A61K31/426, A61K31/428, C07D285/12, A61K31/433, A61K31/404, C07D401/14, A61K31/4439, C07D409/14, C07D401/04, A61K31/506, C07D409/12, C07D401/12, A61K31/497, A61K31/4196, C07D405/14, A61K31/4427, C07D209/18, A61K31/405

Continuation of Box No.II of continuation of first sheet(1)

However, as a result of a search through prior art documents, the subject matter of claim 1 was found to involve many known compounds which deny novelty. Because of this, the common technical feature, i.e., "a compound represented by the general formula (I)," is not considered to be a technical feature which enables the subject matter of each claim to contribute to the prior art, and cannot be a special technical feature in the sense of the second sentence of Rule 13.2 of the Regulations under the PCT.

Consequently, the subject matter of claim 1 has no technical relationship involving one or more identical or corresponding special technical features and is hence not considered to be so linked as to form a single general inventive concept. Therefore, this application does not comply with the requirement of unity of invention.